{"4e0385374b925fedb26a2cb19595549d04827718": [["All rights reserved Coagulopathy in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) infection has been reported, 1 and there is evidence that the extent of coagulopathy correlates with severity of respiratory illness.", [["respiratory", "ANATOMY", 225, 236], ["Coagulopathy", "DISEASE", 20, 32], ["acute respiratory syndrome coronavirus", "DISEASE", 57, 95], ["SARS-CoV- 2) infection", "DISEASE", 99, 121], ["coagulopathy", "DISEASE", 184, 196], ["respiratory illness", "DISEASE", 225, 244], ["patients", "ORGANISM", 36, 44], ["SARS-CoV- 2", "ORGANISM", 99, 110], ["patients", "SPECIES", 36, 44], ["severe acute respiratory syndrome coronavirus", "SPECIES", 50, 95], ["SARS-CoV- 2", "SPECIES", 99, 110], ["Coagulopathy", "PROBLEM", 20, 32], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 50, 95], ["SARS", "PROBLEM", 99, 103], ["CoV", "TEST", 104, 107], ["infection", "PROBLEM", 112, 121], ["coagulopathy", "PROBLEM", 184, 196], ["respiratory illness", "PROBLEM", 225, 244], ["Coagulopathy", "OBSERVATION", 20, 32], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["respiratory syndrome", "OBSERVATION", 63, 83], ["infection", "OBSERVATION", 112, 121], ["coagulopathy", "OBSERVATION", 184, 196], ["respiratory illness", "OBSERVATION", 225, 244]]], ["2 The predominant clinical sequelae of this coagulopathy have been venous thromboembolic events, 3 as well as end-organ failure secondary to a microangiopathy believed to be similar to disseminated intravascular coagulation.", [["venous", "ANATOMY", 67, 73], ["organ", "ANATOMY", 114, 119], ["intravascular", "ANATOMY", 198, 211], ["coagulopathy", "DISEASE", 44, 56], ["venous thromboembolic", "DISEASE", 67, 88], ["end-organ failure", "DISEASE", 110, 127], ["microangiopathy", "DISEASE", 143, 158], ["intravascular coagulation", "DISEASE", 198, 223], ["venous", "ANATOMICAL_SYSTEM", 67, 73], ["organ", "ORGAN", 114, 119], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 198, 211], ["this coagulopathy", "PROBLEM", 39, 56], ["venous thromboembolic events", "PROBLEM", 67, 95], ["end-organ failure", "PROBLEM", 110, 127], ["a microangiopathy", "PROBLEM", 141, 158], ["disseminated intravascular coagulation", "PROBLEM", 185, 223], ["predominant", "OBSERVATION_MODIFIER", 6, 17], ["sequelae", "OBSERVATION_MODIFIER", 27, 35], ["coagulopathy", "OBSERVATION", 44, 56], ["venous", "ANATOMY", 67, 73], ["thromboembolic", "OBSERVATION", 74, 88], ["organ", "ANATOMY", 114, 119], ["failure", "OBSERVATION", 120, 127], ["microangiopathy", "OBSERVATION", 143, 158], ["disseminated", "OBSERVATION_MODIFIER", 185, 197], ["intravascular coagulation", "OBSERVATION", 198, 223]]], ["4 Stroke is also recognized, and in the largest series to date, was seen in 5.7% of those with critical illness in comparison to 0.8% of those with milder COVID-19 disease.", [["Stroke", "DISEASE", 2, 8], ["critical illness", "DISEASE", 95, 111], ["Stroke", "PROBLEM", 2, 8], ["critical illness", "PROBLEM", 95, 111], ["milder COVID-19 disease", "PROBLEM", 148, 171], ["Stroke", "OBSERVATION", 2, 8], ["illness", "OBSERVATION", 104, 111], ["19 disease", "OBSERVATION", 161, 171]]], ["5 As severity of COVID-19 illness correlates with both large artery ischemia and coagulopathy, it would seem plausible to associate the two phenomena.", [["artery", "ANATOMY", 61, 67], ["illness", "DISEASE", 26, 33], ["artery ischemia", "DISEASE", 61, 76], ["coagulopathy", "DISEASE", 81, 93], ["artery", "MULTI-TISSUE_STRUCTURE", 61, 67], ["COVID", "TEST", 17, 22], ["both large artery ischemia", "PROBLEM", 50, 76], ["coagulopathy", "PROBLEM", 81, 93], ["the two phenomena", "PROBLEM", 132, 149], ["large artery", "ANATOMY", 55, 67], ["ischemia", "OBSERVATION", 68, 76], ["coagulopathy", "OBSERVATION", 81, 93], ["two", "OBSERVATION_MODIFIER", 136, 139], ["phenomena", "OBSERVATION", 140, 149]]], ["Herein, we describe three SARS-CoV-2 infected individuals with large artery stroke as their presenting illness in the absence of advanced COVID-19, and describe the details of their work up for coagulopathy.", [["artery", "ANATOMY", 69, 75], ["SARS-CoV-2 infected", "DISEASE", 26, 45], ["artery stroke", "DISEASE", 69, 82], ["coagulopathy", "DISEASE", 194, 206], ["individuals", "ORGANISM", 46, 57], ["artery", "MULTI-TISSUE_STRUCTURE", 69, 75], ["large artery stroke", "PROBLEM", 63, 82], ["coagulopathy", "PROBLEM", 194, 206], ["large", "OBSERVATION_MODIFIER", 63, 68], ["artery", "ANATOMY", 69, 75], ["stroke", "OBSERVATION", 76, 82], ["coagulopathy", "OBSERVATION", 194, 206]]]], "PMC4616012": [["INTRODUCTIONKorea recently experienced an unprecedented outbreak of Middle East Respiratory Syndrome (MERS), in which it became the country with the second most confirmed patients worldwide, after Saudi Arabia.", [["Middle East Respiratory Syndrome", "DISEASE", 68, 100], ["MERS", "DISEASE", 102, 106], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["Middle East Respiratory Syndrome", "PROBLEM", 68, 100], ["unprecedented", "OBSERVATION_MODIFIER", 42, 55], ["outbreak", "OBSERVATION_MODIFIER", 56, 64], ["Middle", "ANATOMY_MODIFIER", 68, 74], ["Respiratory Syndrome", "OBSERVATION", 80, 100]]], ["During this outbreak, which caused massive economic damage and social disruption throughout the country, the importance of preventive measures against the spread of infectious diseases from abroad, such as quarantine and epidemiologic investigations, became increasingly clear.", [["infectious diseases", "DISEASE", 165, 184], ["massive economic damage", "PROBLEM", 35, 58], ["social disruption", "PROBLEM", 63, 80], ["preventive measures", "TREATMENT", 123, 142], ["infectious diseases", "PROBLEM", 165, 184], ["epidemiologic investigations", "TEST", 221, 249], ["massive", "OBSERVATION_MODIFIER", 35, 42], ["economic", "OBSERVATION_MODIFIER", 43, 51], ["damage", "OBSERVATION", 52, 58], ["social disruption", "OBSERVATION", 63, 80], ["infectious", "OBSERVATION", 165, 175], ["clear", "OBSERVATION", 271, 276]]], ["The purpose of conducting epidemiologic investigations when an outbreak of an infectious disease such as MERS occurs is to promptly confirm the outbreak and to identify the causes and sources of infection.", [["MERS", "DISEASE", 105, 109], ["infection", "DISEASE", 195, 204], ["conducting epidemiologic investigations", "TEST", 15, 54], ["an infectious disease", "PROBLEM", 75, 96], ["MERS", "PROBLEM", 105, 109], ["infection", "PROBLEM", 195, 204], ["infectious", "OBSERVATION", 78, 88], ["infection", "OBSERVATION", 195, 204]]], ["Ultimately, the goal is to prevent the spread of the infectious disease.", [["infectious disease", "DISEASE", 53, 71], ["the infectious disease", "PROBLEM", 49, 71], ["infectious", "OBSERVATION", 53, 63]]], ["The importance of epidemiologic investigations lies not only in the fact that they effectively prevent the spread of the ongoing infectious disease, but also in the fact that they provide information allowing the prediction and prevention of potential outbreaks in the future.", [["infectious disease", "DISEASE", 129, 147], ["epidemiologic investigations", "TEST", 18, 46], ["the ongoing infectious disease", "PROBLEM", 117, 147], ["infectious", "OBSERVATION", 129, 139]]], ["The effective implementation of epidemiologic investigations requires the presence of a solid infrastructure including a national response system for infectious diseases, sufficient investment in public health institutions, high-quality operational management, and, above all, policies that support the training and retention of highly qualified personnel.INTRODUCTIONModern epidemiologic investigations of infectious diseases have more than 150 years of history, dating from the epidemiologic investigation of cholera that was performed by John Snow (1813-1853), known as the father of epidemiology.", [["infectious diseases", "DISEASE", 150, 169], ["infectious diseases", "DISEASE", 407, 426], ["cholera", "DISEASE", 511, 518], ["epidemiologic investigations", "TEST", 32, 60], ["a solid infrastructure", "PROBLEM", 86, 108], ["infectious diseases", "PROBLEM", 150, 169], ["the training", "TREATMENT", 299, 311], ["infectious diseases", "PROBLEM", 407, 426], ["effective", "OBSERVATION_MODIFIER", 4, 13], ["infectious", "OBSERVATION", 407, 417]]], ["Epidemiologic investigations employ a rational and scientific methodology that integrates logical reasoning to identify the cause of an outbreak.", [["Epidemiologic investigations", "TEST", 0, 28], ["an outbreak", "PROBLEM", 133, 144], ["outbreak", "OBSERVATION", 136, 144]]], ["Although epidemiologic investigations can be conducted in different ways depending on the situation, the principles are the same.", [["epidemiologic investigations", "TEST", 9, 37]]], ["The first step is verifying that an outbreak has taken place and measuring its size, the second step involves conducting descriptive epidemiological analyses of the epidemic, the third step is formulating hypotheses based on those analyses, the fourth step involves examining those hypotheses using analytical epidemiologic methodologies, and the fifth step comprises evaluation and communication [1].INTRODUCTIONKorea suffered a large-scale MERS outbreak in 2015, and critics have suggested that the epidemiologic investigation was not properly carried out.", [["an outbreak", "PROBLEM", 33, 44], ["those analyses", "TEST", 225, 239], ["the fifth step comprises evaluation", "TEST", 343, 378], ["the epidemiologic investigation", "TEST", 497, 528], ["size", "OBSERVATION_MODIFIER", 79, 83], ["large", "OBSERVATION_MODIFIER", 430, 435]]], ["In this study, we provide a chronological review of the epidemiologic investigation of the MERS outbreak as well as suggestions about how to strengthen epidemiologic investigations in the future.CRISIS LEVELS IN THE MANAGEMENT OF INFECTIOUS DISEASESThe official Korean manual for the management of infectious diseases establishes four crisis levels: attention, caution, alert, and severe.", [["infectious diseases", "DISEASE", 298, 317], ["this study", "TEST", 3, 13], ["the epidemiologic investigation", "TEST", 52, 83], ["epidemiologic investigations", "TEST", 152, 180], ["infectious diseases", "PROBLEM", 298, 317], ["INFECTIOUS", "OBSERVATION", 230, 240], ["infectious", "OBSERVATION", 298, 308], ["severe", "OBSERVATION_MODIFIER", 381, 387]]], ["\u2018Attention\u2019 refers to situations where no patients of a given disease have been confirmed in Korea, but it is possible for the disease to be imported into Korea, since some patients have been identified in other countries.", [["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 173, 181], ["disease", "PROBLEM", 62, 69], ["the disease", "PROBLEM", 123, 134]]], ["This level involves preparing for an outbreak in the case of an influx of patients to Korea by establishing preparedness and response plans, specifying the roles of the relevant institutions, and providing education programs for the personnel who would be involved.", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["education programs", "TREATMENT", 206, 224]]], ["In 2014, the Public Health Emergency Response Group held a symposium on MERS, and the Korea Centers for Disease Control and Prevention (KCDC) prepared a testing system, published the 2014 MERS management guidelines, and trained public health personnel to handle MERS cases.", [["Disease Control", "TREATMENT", 104, 119]]], ["The 2014 management guidelines stated that \u201cthese guidelines can be applied in situations where the national infectious disease crisis level is \u2018attention\u2019 or \u2018caution\u2019, and can be continuously revised as the situation changes\u201d [2].CRISIS LEVELS IN THE MANAGEMENT OF INFECTIOUS DISEASESIn the case of the recent MERS outbreak, the most important element of the \u2018attention\u2019 crisis level was the early detection of MERS cases with the goal of treating them in isolation.", [["INFECTIOUS", "OBSERVATION", 267, 277]]], ["However, the early clinical identification of MERS cases is difficult because the symptoms of MERS are non-specific [3].", [["MERS", "DISEASE", 94, 98], ["MERS", "CANCER", 46, 50], ["the symptoms of MERS", "PROBLEM", 78, 98]]], ["Therefore, the most important factor in the early diagnosis of MERS is implementing a surveillance program to check the travel histories of patients with respiratory symptoms.", [["respiratory", "ANATOMY", 154, 165], ["MERS", "DISEASE", 63, 67], ["respiratory symptoms", "DISEASE", 154, 174], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["respiratory symptoms", "PROBLEM", 154, 174]]], ["When suspected MERS cases are identified, they should be promptly isolated, the medical staff should wear protective equipment, and clinical specimens should be examined in the early stage of the illness.", [["specimens", "ANATOMY", 141, 150], ["protective equipment", "TREATMENT", 106, 126], ["clinical specimens", "TEST", 132, 150]]], ["The guidelines specify that when the first confirmed case is identified, the KCDC should elevate the infectious disease crisis level from \u2018attention\u2019 to \u2018caution\u2019.", [["the infectious disease crisis level", "PROBLEM", 97, 132], ["infectious", "OBSERVATION", 101, 111]]], ["When the crisis level is raised to \u2018caution\u2019, a task force reporting to the director of the KCDC should be established and put in charge of managing the response to MERS.", [["MERS", "PROTEIN", 165, 169], ["the crisis level", "PROBLEM", 5, 21], ["the KCDC", "TREATMENT", 88, 96]]], ["These actions were taken on May 20, 2015, when the first confirmed MERS case was identified [4].THE PRINCIPLES OF EARLY EPIDEMIOLOGIC INVESTIGATIONWhen a confirmed case is identified, an epidemiologic investigation is carried out by the Epidemic Intelligence Service (EIS) officers of the KCDC.", [["an epidemiologic investigation", "TEST", 184, 214]]], ["At this time, a very careful and thorough epidemiologic investigation should be carried out and proper preventive measures should be put in place.", [["thorough epidemiologic investigation", "TEST", 33, 69], ["proper preventive measures", "TREATMENT", 96, 122]]], ["When dealing with emerging infectious diseases whose characteristics are not yet well understood, it is safest to implement maximal precautionary measures.THE PRINCIPLES OF EARLY EPIDEMIOLOGIC INVESTIGATIONThe first step of an epidemiologic investigation is verifying that an outbreak has taken place and measuring its size of the outbreak, following these steps:THE PRINCIPLES OF EARLY EPIDEMIOLOGIC INVESTIGATIONAfter verifying the presence of an outbreak and estimating its size in the first stage of the epidemiologic investigation, it is necessary to determine what would constitute an appropriate response.", [["infectious diseases", "DISEASE", 27, 46], ["emerging infectious diseases", "PROBLEM", 18, 46], ["maximal precautionary measures", "TREATMENT", 124, 154], ["an epidemiologic investigation", "TEST", 224, 254], ["an outbreak", "PROBLEM", 273, 284], ["an outbreak", "PROBLEM", 446, 457], ["the epidemiologic investigation", "TEST", 504, 535], ["infectious", "OBSERVATION", 27, 37], ["outbreak", "OBSERVATION", 276, 284], ["size", "OBSERVATION_MODIFIER", 319, 323], ["outbreak", "OBSERVATION", 331, 339], ["outbreak", "OBSERVATION", 449, 457], ["size", "OBSERVATION_MODIFIER", 477, 481]]], ["It is also important to collect, analyze, and store all possible specimens in order to identify the cause of the outbreak.ACTIONS TO BE TAKEN WHEN AN OUTBREAK IS IDENTIFIEDIf it is determined that an outbreak has taken place, preventive measures should be implemented.", [["specimens", "ANATOMY", 65, 74], ["the outbreak", "PROBLEM", 109, 121], ["preventive measures", "TREATMENT", 226, 245], ["outbreak", "OBSERVATION", 113, 121]]], ["Depending on the type of the infectious disease and the timing of the outbreak, the prioritization and the specific details of the preventive measures will vary.", [["infectious disease", "DISEASE", 29, 47], ["the infectious disease", "PROBLEM", 25, 47], ["infectious", "OBSERVATION", 29, 39]]], ["In instances of single exposures, as in cases of food poisoning, the mode of transmission should be identified by preserving suspected foods or ensuring that the site of transmission remains intact.", [["food poisoning", "DISEASE", 49, 63], ["food poisoning", "PROBLEM", 49, 63], ["intact", "OBSERVATION", 191, 197]]], ["However, if the disease spreads through person-to-person transmission, prompt and active preventive measures need to be taken.", [["person", "SPECIES", 40, 46], ["person", "SPECIES", 50, 56], ["active preventive measures", "TREATMENT", 82, 108]]], ["For infectious diseases spread by person-to-person transmission, each patient is a source of infection, and it is therefore important to identify suspected cases as soon as possible and to treat them in isolation.", [["infectious diseases", "DISEASE", 4, 23], ["infection", "DISEASE", 93, 102], ["patient", "ORGANISM", 70, 77], ["person", "SPECIES", 34, 40], ["person", "SPECIES", 44, 50], ["patient", "SPECIES", 70, 77], ["infectious diseases", "PROBLEM", 4, 23], ["infection", "PROBLEM", 93, 102], ["infection", "OBSERVATION", 93, 102]]], ["Some diseases are transmitted during the incubation period, while other diseases are transmitted only after the onset of symptoms.", [["Some diseases", "PROBLEM", 0, 13], ["other diseases", "PROBLEM", 66, 80], ["symptoms", "PROBLEM", 121, 129], ["diseases", "OBSERVATION", 5, 13], ["diseases", "OBSERVATION", 72, 80]]], ["The period of infectiousness as well as the natural history of a disease should be taken into consideration when implementing preventive measures.", [["infectiousness", "PROBLEM", 14, 28], ["a disease", "PROBLEM", 63, 72], ["preventive measures", "TREATMENT", 126, 145], ["infectiousness", "OBSERVATION", 14, 28]]], ["Infectious diseases such as the common cold and influenza are transmitted before the onset of symptoms, making it difficult and inefficient to identify and quarantine people who have been exposed.", [["Infectious diseases", "DISEASE", 0, 19], ["influenza", "DISEASE", 48, 57], ["people", "ORGANISM", 167, 173], ["people", "SPECIES", 167, 173], ["Infectious diseases", "PROBLEM", 0, 19], ["the common cold", "PROBLEM", 28, 43], ["influenza", "PROBLEM", 48, 57], ["symptoms", "PROBLEM", 94, 102], ["influenza", "OBSERVATION", 48, 57]]], ["However, severe acute respiratory syndrome, and MERS are known to be infectious only after the onset of symptoms, not during the incubation period; therefore, actively identifying contacts to be monitored and close contacts to be quarantined can be an effective measure for preventing the spread of this disease [6,7].", [["acute respiratory syndrome", "DISEASE", 16, 42], ["severe acute respiratory syndrome", "PROBLEM", 9, 42], ["MERS", "PROBLEM", 48, 52], ["infectious", "PROBLEM", 69, 79], ["symptoms", "PROBLEM", 104, 112], ["this disease", "PROBLEM", 299, 311], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["acute", "OBSERVATION_MODIFIER", 16, 21], ["respiratory syndrome", "OBSERVATION", 22, 42], ["infectious", "OBSERVATION", 69, 79]]], ["It is also important to properly disinfect areas where confirmed cases have been present in order to eliminate the possibility of further infection [6].ACTIONS TO BE TAKEN WHEN AN OUTBREAK IS IDENTIFIEDThis article focuses on the process of epidemiologic investigations, and therefore does not describe preventive measures.", [["infection", "DISEASE", 138, 147], ["further infection", "PROBLEM", 130, 147], ["epidemiologic investigations", "TEST", 241, 269], ["preventive measures", "TREATMENT", 303, 322], ["infection", "OBSERVATION", 138, 147]]], ["The following items must be carried out during an epidemiologic investigation: 1) determining the period of infectiousness (for MERS, after the onset of symptoms); 2) tracing the movement of the cases during the period of infectiousness; 3) identifying contacts of the cases before quarantine; 4) if the confirmed cases visited any hospitals, blocking the spread of the infection in those hospitals by urging them to implement prompt preventive measures; 5) after identifying the major paths of cases, directly interviewing the cases if possible to verify their movements, supplementing their list of contacts, and, if necessary, obtaining consent for checking credit card details; 6) further confirming that the records of their movement are complete by checking credit card details; 7) checking whether contacts of the case show the symptoms of the disease and, if so, performing the same investigation that was performed for the first case; 8) when necessary, identifying any missing contacts by checking surveillance cameras; 9) when necessary, collecting environmental specimens and performing laboratory examinations; and 10) when necessary, inspecting hospital facilities to ensure that preventive measures are taken against the outbreak.May 20-May 25, 2015: investigation carried out according to the 2014 MERS management guidelines ::: BRIEF DESCRIPTION OF THE MERS EPIDEMIOLOGIC INVESTIGATION, KOREA, 2015On May 20, the first MERS case (Patient zero) was confirmed, and the KCDC followed the 2014 MERS management guidelines [2] regarding the definition of close contacts and the assignment of investigative roles to hospitals.", [["specimens", "ANATOMY", 1074, 1083], ["infection", "DISEASE", 370, 379], ["infectiousness", "PROBLEM", 108, 122], ["symptoms", "PROBLEM", 153, 161], ["infectiousness", "PROBLEM", 222, 236], ["the infection", "PROBLEM", 366, 379], ["the symptoms", "PROBLEM", 831, 843], ["the disease", "PROBLEM", 847, 858], ["the same investigation", "TEST", 882, 904], ["surveillance cameras", "TEST", 1008, 1028], ["collecting environmental specimens", "TEST", 1049, 1083], ["laboratory examinations", "TEST", 1099, 1122], ["preventive measures", "TREATMENT", 1194, 1213], ["infection", "OBSERVATION", 370, 379]]], ["A close contact was defined as a person who had physical contact with either a confirmed case or a suspected case, or a person who stayed within a two-meter radius of a case for more than one hour in the same space.", [["person", "SPECIES", 33, 39], ["person", "SPECIES", 120, 126]]], ["Although suspected cases were defined as anyone who had clinical, radiological, histological, or pathological pulmonary parenchymal disease, such as pneumonia or acute respiratory distress syndrome, in practice, the presence of a fever over 38\u00b0C was used to identify suspected cases.", [["pulmonary parenchymal", "ANATOMY", 110, 131], ["respiratory", "ANATOMY", 168, 179], ["pulmonary parenchymal disease", "DISEASE", 110, 139], ["pneumonia", "DISEASE", 149, 158], ["acute respiratory distress syndrome", "DISEASE", 162, 197], ["fever", "DISEASE", 230, 235], ["pulmonary parenchymal", "MULTI-TISSUE_STRUCTURE", 110, 131], ["pathological pulmonary parenchymal disease", "PROBLEM", 97, 139], ["pneumonia", "PROBLEM", 149, 158], ["acute respiratory distress syndrome", "PROBLEM", 162, 197], ["a fever", "PROBLEM", 228, 235], ["pulmonary", "ANATOMY", 110, 119], ["parenchymal", "ANATOMY_MODIFIER", 120, 131], ["disease", "OBSERVATION", 132, 139], ["pneumonia", "OBSERVATION", 149, 158], ["acute", "OBSERVATION_MODIFIER", 162, 167], ["respiratory distress syndrome", "OBSERVATION", 168, 197], ["fever", "OBSERVATION", 230, 235]]], ["Closed-circuit television (CCTV) records were analyzed to objectively determine the level of exposure in the affected hospitals during the epidemiologic field investigation.", [["the epidemiologic field investigation", "TEST", 135, 172]]], ["CCTV analysis is commonly employed in forensic science, but this was the first time that this method was applied to the epidemiologic investigation of an infectious disease in Korea.May 25-June 3: investigation carried out according to the third edition of the MERS management guidelines ::: BRIEF DESCRIPTION OF THE MERS EPIDEMIOLOGIC INVESTIGATION, KOREA, 2015On May 23rd, the fourth case (the daughter of the third confirmed case) asked the health authorities for a MERS confirmatory test and quarantine after observing that her body temperature was 37.9\u00b0C, but the health authorities did not accept this request.", [["body", "ANATOMY", 532, 536], ["infectious disease", "DISEASE", 154, 172], ["body", "ORGANISM_SUBDIVISION", 532, 536], ["CCTV analysis", "TEST", 0, 13], ["this method", "TREATMENT", 89, 100], ["an infectious disease", "PROBLEM", 151, 172], ["a MERS confirmatory test", "TEST", 467, 491], ["her body temperature", "TEST", 528, 548], ["infectious", "OBSERVATION", 154, 164]]], ["Also, on the same day, a physician who treated the Patient zero (#1) for less than five minutes was confirmed to have MERS.", [["MERS", "PROTEIN", 118, 122], ["MERS", "PROBLEM", 118, 122]]], ["Thus, the criterion for the temperature of a suspected case was lowered to 37.5\u00b0C, and myalgia, chills, and diarrhea were also included as suspicious symptoms in the new guidelines.", [["myalgia", "DISEASE", 87, 94], ["chills", "DISEASE", 96, 102], ["diarrhea", "DISEASE", 108, 116], ["the temperature", "TEST", 24, 39], ["myalgia", "PROBLEM", 87, 94], ["chills", "PROBLEM", 96, 102], ["diarrhea", "PROBLEM", 108, 116], ["suspicious symptoms", "PROBLEM", 139, 158]]], ["Furthermore, on May 31, the joint public-private Expert Committee on the MERS-Coronavirus Outbreak Investigation was established.", [["joint", "ANATOMY", 28, 33]]], ["The reinvestigation included analyzing CCTV footage in the hospitals, determining the spatial distribution of all cases who were eventually diagnosed with MERS using hospital maps, obtaining a list of all medical staff, hospitalized patients, and caregivers reevaluating exposure and reclassifying close contacts, investigating the hospital ventilation system, and collecting and examining environmental specimens.", [["specimens", "ANATOMY", 404, 413], ["patients", "ORGANISM", 233, 241], ["patients", "SPECIES", 233, 241], ["The reinvestigation", "TEST", 0, 19]]], ["Despite this comprehensive reinvestigation, it was difficult to adequately identify close contacts, and MERS cases continuously occurred.", [["this comprehensive reinvestigation", "TEST", 8, 42]]], ["It became clear that considering only droplets as a mode of transmission, as was initially thought, was not enough to account for the observed patterns of MERS occurrence.", [["MERS occurrence", "PROBLEM", 155, 170], ["clear", "OBSERVATION", 10, 15]]], ["Consequently, the diffusion of air currents within the wards of the Pyeongtaek St.Mary\u2019s Hospital was studied and an in-depth investigation of medical staff members was carried out in order to identify the mode of transmission of the disease.", [["the disease", "PROBLEM", 230, 241], ["disease", "OBSERVATION", 234, 241]]], ["These considerations were also reflected in the evolving MERS management guidelines; thus, the definition of suspected cases was expanded to include employees, patients, caregivers or visitors with symptoms such as fever or shortness of breath who were in a hospital where cases of MERS occurred within 14 days of the onset of symptoms of the suspected case.", [["fever", "DISEASE", 215, 220], ["shortness of breath", "DISEASE", 224, 243], ["MERS", "DISEASE", 282, 286], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 160, 168], ["symptoms", "PROBLEM", 198, 206], ["fever", "PROBLEM", 215, 220], ["shortness of breath", "PROBLEM", 224, 243], ["MERS", "PROBLEM", 282, 286], ["symptoms", "PROBLEM", 327, 335]]], ["Also, after the public was informed on June 5 that Pyeongtaek St. Mary\u2019s Hospital was the locus of the outbreak, personnel from the Health Insurance Review and Assessment Service started to support the epidemiologic investigation.", [["the epidemiologic investigation", "TEST", 198, 229]]], ["Their role was to help check the hospital visit histories of cases who had been hospitalized anywhere in Korea and to obtain hospital visit histories as required for the epidemiologic investigation.", [["the epidemiologic investigation", "TEST", 166, 197]]], ["This step was taken because relying only on case statements during the epidemiologic investigation resulted in missing hospitals that cases had actually visited.", [["the epidemiologic investigation", "TEST", 67, 98]]], ["Therefore, in order to ensure that no hospitals were missed, Drug Utilization Review information was utilized to obtain hospital and pharmacy visit histories for use in the epidemiological investigation.", [["the epidemiological investigation", "TEST", 169, 202]]], ["This was also a method that was not used in the initial epidemiologic investigation.June 7-present: investigation carried out according to edition 3.3 of the MERS management guidelines ::: BRIEF DESCRIPTION OF THE MERS EPIDEMIOLOGIC INVESTIGATION, KOREA, 2015On June 7, all information about the hospitals where MERS cases had occurred or MERS cases had visited was disclosed, and people who had visited those hospitals during the period when MERS cases were present were contacted and informed that they should notify the call center if they had any symptoms of MERS.", [["MERS", "DISEASE", 563, 567], ["people", "ORGANISM", 381, 387], ["people", "SPECIES", 381, 387], ["any symptoms of MERS", "PROBLEM", 547, 567]]], ["Edition 3.3 of the MERS management guidelines was also published [8].", [["the MERS management", "TREATMENT", 15, 34]]], ["The contents of edition 3.2 of the MERS management guidelines were preserved regarding the definitions of cases and close contacts.", [["the MERS management guidelines", "TREATMENT", 31, 61]]], ["Since the outbreak had already lasted for some time, the revised edition included considerable information about secondary issues, such as treatment protocols, criteria for determining when confirmed cases have completely recovered, protocols for lifting the quarantine of those who had been isolated in their homes, and procedures for dealing with the death of MERS cases.", [["death", "DISEASE", 353, 358], ["MERS", "DISEASE", 362, 366], ["secondary issues", "PROBLEM", 113, 129], ["treatment protocols", "TREATMENT", 139, 158]]], ["At this time, it was possible to implement a cohort isolation in Daechung Hospital and Konyang University Hospital, based on lessons from the outbreak in Pyeongtaek St. Mary\u2019s Hospital.June 7-present: investigation carried out according to edition 3.3 of the MERS management guidelines ::: BRIEF DESCRIPTION OF THE MERS EPIDEMIOLOGIC INVESTIGATION, KOREA, 2015In the early phase of the outbreak, the concept of cohort isolation was very unfamiliar and the ethical and legal grounds for cohort isolation were not robust.", [["cohort isolation", "TREATMENT", 411, 427], ["cohort isolation", "TREATMENT", 486, 502], ["early phase", "OBSERVATION_MODIFIER", 367, 378]]], ["However, as the outbreak caused economic losses and social disruption, the general public reached a consensus that made it easier to implement drastic measures to prevent the further transmission of MERS.", [["MERS", "DISEASE", 199, 203], ["economic losses", "PROBLEM", 32, 47], ["social disruption", "PROBLEM", 52, 69], ["drastic measures", "TREATMENT", 143, 159], ["social disruption", "OBSERVATION", 52, 69]]], ["A probable MERS case traveled to Jeju Island while symptomatic.", [["symptomatic", "PROBLEM", 51, 62], ["probable", "UNCERTAINTY", 2, 10], ["MERS", "OBSERVATION", 11, 15]]], ["Additional measures were taken due to these inconsistencies, including location tracking using the base stations of mobile phones and checking credit card bills.", [["Additional measures", "TREATMENT", 0, 19], ["mobile phones", "TREATMENT", 116, 129]]], ["These were new methods that had not been used in previous epidemiological investigations.The role of Epidemic Intelligence Service officers ::: CHALLENGES IN THE EPIDEMIOLOGICAL INVESTIGATIONEIS officers check the contacts of a confirmed case during an investigation and establish the standards used to designate persons subject to epidemic prevention measures based on the level of contact.", [["persons", "ORGANISM", 313, 320], ["persons", "SPECIES", 313, 320], ["previous epidemiological investigations", "TEST", 49, 88], ["an investigation", "TEST", 250, 266], ["epidemic prevention measures", "TREATMENT", 332, 360], ["new", "OBSERVATION_MODIFIER", 11, 14]]], ["It is also the role of the health department and public health centers in a given city or province to take preventative measures against epidemics, such as locating persons subject to preventive measures, calling them individually, checking if they have any symptoms, performing tests if necessary, and implementing tracking and management procedures such as quarantine and active monitoring.", [["persons", "SPECIES", 165, 172], ["preventative measures", "TREATMENT", 107, 128], ["epidemics", "PROBLEM", 137, 146], ["preventive measures", "TREATMENT", 184, 203], ["any symptoms", "PROBLEM", 254, 266], ["performing tests", "TEST", 268, 284], ["management procedures", "TREATMENT", 329, 350], ["quarantine", "TREATMENT", 359, 369], ["active monitoring", "TEST", 374, 391]]], ["However, many situations exist in which these roles are not clearly distinguishable.", [["not clearly distinguishable", "UNCERTAINTY", 56, 83]]], ["If an outbreak occurs in a hospital, as occurred in this MERS outbreak, it is very difficult for public health centers to implement quarantines or to track and manage contacts who are hospitalzed patients without the cooperation of hospitals and clinics, even though EIS officers officially determine the criteria used to designate persons subject to preventative measures based on the extent of their contact with the infected case.The role of Epidemic Intelligence Service officers ::: CHALLENGES IN THE EPIDEMIOLOGICAL INVESTIGATIONIn addition, it is extremely difficult for EIS officers to make decisions alone in this context, since EIS officers have no legal power to order the temporary suspension of services in a hospital where cases occurred, even when it is necessary to take urgent measures to prevent an epidemic.", [["patients", "ORGANISM", 196, 204], ["persons", "ORGANISM", 332, 339], ["patients", "SPECIES", 196, 204], ["persons", "SPECIES", 332, 339], ["preventative measures", "TREATMENT", 351, 372], ["urgent measures", "TREATMENT", 787, 802], ["an epidemic", "PROBLEM", 814, 825], ["outbreak", "OBSERVATION", 6, 14], ["infected", "OBSERVATION", 419, 427], ["epidemic", "OBSERVATION", 817, 825]]], ["Moreover, the suspension of services in a large hospital can cause serious violations of the rights of other patients, who have no connection with the epidemic, to be treated.", [["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117]]], ["These issues were continuously raised during the MERS outbreak.", [["These issues", "PROBLEM", 0, 12]]], ["During the MERS outbreak, the epidemiological investigation encountered many difficulties due to the absence of regulations enabling the investigators to carry out the investigation without coming into conflict with the Personal Information Protection Act.", [["the epidemiological investigation", "TEST", 26, 59], ["the investigation", "TEST", 164, 181]]], ["Additionally, many cases continued their daily lives as usual while symptomatic until they were confirmed to be infected; this interval ranged from as short as one to two days to as long as over one week.", [["symptomatic", "PROBLEM", 68, 79], ["infected", "OBSERVATION", 112, 120]]], ["During the MERS outbreak, contacts were missed for these reasons, and some of those who were missed eventually became infected, resulting in the risk of a large epidemic.", [["infected", "PROBLEM", 118, 126], ["a large epidemic", "PROBLEM", 153, 169], ["infected", "OBSERVATION", 118, 126], ["large", "OBSERVATION_MODIFIER", 155, 160], ["epidemic", "OBSERVATION", 161, 169]]], ["Checking CCTV records currently requires assistance from technical specialists, as well as consent from the person concerned.", [["person", "SPECIES", 108, 114]]], ["Tracking the location of mobile phones and obtaining information about their credit card use require the agreement of the case, guardian of the case, and/or the person living with the case.", [["person", "SPECIES", 161, 167]]], ["A set of measures should be established to ensure that the goals of an epidemiological investigation are accomplished rapidly while protecting civil rights and personal information.Protection of epidemiological investigators, including Epidemic Intelligence Service officers ::: CHALLENGES IN THE EPIDEMIOLOGICAL INVESTIGATIONAs observed in this MERS outbreak, when a case occurs in a hospital, the hospitals and clinics must be considered to be contaminated.", [["an epidemiological investigation", "TEST", 68, 100]]], ["Therefore, epidemiological investigators should be fully prepared to take infection prevention measures before they participate in the investigation.", [["infection", "DISEASE", 74, 83], ["infection prevention measures", "TREATMENT", 74, 103], ["the investigation", "TEST", 131, 148]]], ["However, in the beginning of the epidemiological investigation of MERS, level D protective gear was not provided to epidemiological investigators, and the epidemiological investigation team was set up inside the affected hospital.", [["level D protective gear", "TREATMENT", 72, 95]]], ["This would lead to a major crisis and a vacuum in the epidemiological investigation.", [["a major crisis", "PROBLEM", 19, 33], ["a vacuum", "TREATMENT", 38, 46], ["the epidemiological investigation", "TEST", 50, 83], ["major", "OBSERVATION_MODIFIER", 21, 26], ["crisis", "OBSERVATION", 27, 33], ["vacuum", "OBSERVATION", 40, 46]]], ["It is therefore extremely important to ensure that the investigation personnel do not become infected.Inadequacies in the system of compensation for quarantine measures ::: CHALLENGES IN THE EPIDEMIOLOGICAL INVESTIGATIONWhen the epidemiological investigation confirms that a person has been in close contact with an infected case, that person is subject to quarantine measures, such as home quarantine or active monitoring.", [["person", "SPECIES", 275, 281], ["person", "SPECIES", 336, 342], ["infected", "PROBLEM", 93, 101], ["the epidemiological investigation", "TEST", 225, 258], ["quarantine measures", "TREATMENT", 357, 376], ["home quarantine", "TREATMENT", 386, 401], ["active monitoring", "TREATMENT", 405, 422], ["infected", "OBSERVATION", 93, 101]]], ["Facilities including hospitals and clinics are subject to measures such as temporary shutdown according to the quarantine guidelines.", [["temporary shutdown", "TREATMENT", 75, 93]]], ["However, no guidelines existed regarding adequate compensation for the losses incurred by affected persons and facilities following quarantine measures.", [["persons", "SPECIES", 99, 106], ["the losses", "PROBLEM", 67, 77], ["quarantine measures", "TREATMENT", 132, 151]]], ["This led to noncooperation from the persons and facilities in question, damaging the effectiveness of the quarantine measures.Close cooperation among public health departments in central and local government and public health centers ::: CHALLENGES IN THE EPIDEMIOLOGICAL INVESTIGATIONIn this outbreak of MERS, the disease spread to several regions in a short time, making close cooperation between the affected municipalities and the central government very important.", [["MERS", "DISEASE", 305, 309], ["persons", "SPECIES", 36, 43], ["the quarantine measures", "TREATMENT", 102, 125], ["the disease spread", "PROBLEM", 311, 329], ["disease", "OBSERVATION", 315, 322], ["central", "ANATOMY_MODIFIER", 435, 442]]], ["However, disclosure of information from the central government was delayed and confirmatory test methods were not quickly transferred to the Research Institute of Public Health and Environment of each municipality, resulting in a late and discordant response from the municipalities.Measures to strengthen epidemiological investigations ::: DISCUSSIONSeveral problems mentioned above should be solved in order to ensure that future epidemiological investigations will be implemented successfully.", [["confirmatory test methods", "TEST", 79, 104], ["epidemiological investigations", "TEST", 432, 462]]], ["This section contains some suggestions for improving subsequent epidemiological investigations in Korea.Review and amendment of related laws ::: DISCUSSIONAccording to Article 2, No. 17 of the Infectious Disease Control and Prevention Act, the term \u201cepidemiological investigation\u201d refers to the activity of investigating cases involving patients infected by an infectious disease, patients suspected of an infectious disease, and carriers of the pathogen, as well as tracing the sources of their infection, in order to quarantine such infectious diseases and to prevent their spread, and the investigation of adverse events to vaccinations, if any such cases occur.Review and amendment of related laws ::: DISCUSSIONIn Article 12, No. 1 of the Enforcement Decree of the Infectious Disease Control and Prevention Act, the contents of an epidemiological investigation are clearly stipulated to involve the followings: (1) the personal information of patients infected by an infectious disease; (2) the date and place of their infection; (3) the origin and route of infection; (4) the medical records of the patients infected by the infectious disease; (5) other factors related to examining the causes of the infectious disease.Review and amendment of related laws ::: DISCUSSIONIn the Article 14 of the Enforcement Decree of the Infectious Disease Control and Prevention Act, the method of an epidemiological investigation is stipulated to involve the following steps: (1) questionnaires and interviews; (2) collecting and testing clinical specimens; (3) collecting and testing specimens from the environment; (4) collecting and testing specimens from vectors of infectious diseases, such as insects and animals; (5) investigating medical records and interviewing doctors.Review and amendment of related laws ::: DISCUSSIONHowever, these laws and decrees do not contain any content regarding extremely urgent situations in which the epidemiological investigation is directly linked to quarantine measures, as occurred in this MERS outbreak.", [["specimens", "ANATOMY", 1539, 1548], ["specimens", "ANATOMY", 1577, 1586], ["specimens", "ANATOMY", 1636, 1645], ["Infectious Disease", "DISEASE", 193, 211], ["infectious disease", "DISEASE", 361, 379], ["infection", "DISEASE", 496, 505], ["infectious diseases", "DISEASE", 535, 554], ["Infectious Disease", "DISEASE", 770, 788], ["infectious disease", "DISEASE", 972, 990], ["infection", "DISEASE", 1024, 1033], ["infection", "DISEASE", 1063, 1072], ["infectious disease", "DISEASE", 1130, 1148], ["infectious disease", "DISEASE", 1207, 1225], ["Infectious Disease", "DISEASE", 1328, 1346], ["infectious diseases", "DISEASE", 1662, 1681], ["patients", "ORGANISM", 337, 345], ["patients", "ORGANISM", 381, 389], ["patients", "ORGANISM", 948, 956], ["patients", "ORGANISM", 1105, 1113], ["patients", "SPECIES", 337, 345], ["patients", "SPECIES", 381, 389], ["patients", "SPECIES", 948, 956], ["patients", "SPECIES", 1105, 1113], ["the Infectious Disease Control", "TREATMENT", 189, 219], ["an infectious disease", "PROBLEM", 403, 424], ["the pathogen", "PROBLEM", 442, 454], ["their infection", "PROBLEM", 490, 505], ["such infectious diseases", "PROBLEM", 530, 554], ["adverse events", "PROBLEM", 609, 623], ["vaccinations", "TREATMENT", 627, 639], ["the Infectious Disease Control", "TREATMENT", 766, 796], ["an epidemiological investigation", "TEST", 833, 865], ["their infection", "PROBLEM", 1018, 1033], ["infection", "PROBLEM", 1063, 1072], ["the infectious disease", "PROBLEM", 1126, 1148], ["the infectious disease", "PROBLEM", 1203, 1225], ["the Infectious Disease Control", "TREATMENT", 1324, 1354], ["an epidemiological investigation", "TEST", 1389, 1421], ["collecting and testing clinical specimens", "TEST", 1507, 1548], ["collecting and testing specimens", "TEST", 1554, 1586], ["collecting and testing specimens", "TEST", 1613, 1645], ["infectious diseases", "PROBLEM", 1662, 1681], ["Infectious", "OBSERVATION", 193, 203], ["infectious", "OBSERVATION", 361, 371], ["infectious", "OBSERVATION", 406, 416], ["infection", "OBSERVATION", 496, 505], ["Infectious", "OBSERVATION_MODIFIER", 770, 780], ["infectious", "OBSERVATION", 972, 982], ["infection", "OBSERVATION", 1024, 1033], ["infection", "OBSERVATION", 1063, 1072], ["infectious", "OBSERVATION", 1130, 1140], ["infectious", "OBSERVATION", 1207, 1217], ["Infectious", "OBSERVATION_MODIFIER", 1328, 1338], ["infectious", "OBSERVATION", 1662, 1672]]], ["For example, no phrase approves measures for checking personal information, including securing and analyzing CCTV records, the location tracking of mobile phones, and checking the details of credit card use.", [["no", "UNCERTAINTY", 13, 15]]], ["These measures are necessary for establishing the movements of an infected case in order to identify a case\u2019s contacts, although the Personal Information Protection Act conflicts with quarantine measures that may be required.", [["quarantine measures", "TREATMENT", 184, 203], ["infected", "OBSERVATION", 66, 74]]], ["Clear stipulations approving a flexible response are necessary, since future epidemiological investigations may vary in terms of content, scope, and method, depending on the characteristics of future outbreaks.Reinforcing professional personnel in epidemiological investigations and strengthening their role ::: DISCUSSIONConsiderable criticism was raised regarding inadequacies in the current system of epidemiological investigations during this MERS outbreak.", [["epidemiological investigations", "TEST", 77, 107], ["scope", "TEST", 138, 143], ["epidemiological investigations", "TEST", 404, 434]]], ["Accordingly, the National Assembly of Korea amended the system of epidemiological investigations and the Infectious Disease Control and Prevention Act.", [["Infectious Disease", "DISEASE", 105, 123], ["epidemiological investigations", "TEST", 66, 96], ["the Infectious Disease Control", "TREATMENT", 101, 131], ["Infectious", "OBSERVATION_MODIFIER", 105, 115]]], ["The amended law was immediately enforced when it was promulgated on July 6, 2015, and the revised system of epidemiological investigations is scheduled to be put in place in January 2016.", [["epidemiological investigations", "TEST", 108, 138]]], ["Regarding the reinforcement of the personnel of epidemiological investigations, Article 60, No. 2 of the Infectious Disease Control and Prevention Act stipulates that \u201cMore than 30 epidemiological investigation officers shall be assigned to the Ministry of Health and Welfare and more than two epidemiological investigation officers shall be assigned to each city and do (province) to carry out responsibilities concerning the epidemiological investigation of infectious diseases.", [["Infectious Disease", "DISEASE", 105, 123], ["infectious diseases", "DISEASE", 460, 479], ["epidemiological investigations", "TEST", 48, 78], ["the Infectious Disease Control", "TREATMENT", 101, 131], ["infectious diseases", "PROBLEM", 460, 479], ["Infectious", "OBSERVATION", 105, 115], ["infectious", "OBSERVATION", 460, 470]]], ["Provided, a mayor/do administrator may appoint an epidemiological investigation officer in a si/gun/gu (city, county, or district) when necessary to carry out responsibilities concerning the epidemiological investigation\u201d.", [["the epidemiological investigation", "TEST", 187, 220]]], ["Regarding the authority of epidemiological investigation officers, it stipulates that \u201cepidemiological investigation officers may temporarily take measures to implement each item in Article 47, No. 1 in an urgent situation where the infectious disease is expected to become epidemic, seriously damaging public health unless immediate measures are taken.\u201d", [["infectious disease", "DISEASE", 233, 251], ["infectious", "OBSERVATION", 233, 243]]], ["The measures in Article 47, No. 1 include \u201cto carry out the following measures in places where infected patients present or places that have been deemed to be contaminated by the infectious pathogen: a) temporary shutdown, b) making a given place off-limits to the general public, c) restriction of movement inside a given place, and d) other measures necessary to block passage\u201d [9].Reinforcing professional personnel in epidemiological investigations and strengthening their role ::: DISCUSSIONIt is appropriate that this law was amended, even though the amendments were late.", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["temporary shutdown", "TREATMENT", 203, 221]]], ["A specific framework should be established on the basis of discussions about this issue with specialists from different fields.Necessity of a research center for emerging infectious diseases ::: DISCUSSIONThis MERS outbreak made it known to the world that Korea is not ready to respond to emerging infectious diseases adequately.", [["infectious diseases", "DISEASE", 171, 190], ["infectious diseases", "DISEASE", 298, 317], ["emerging infectious diseases adequately", "PROBLEM", 289, 328], ["infectious", "OBSERVATION", 171, 181], ["infectious", "OBSERVATION", 298, 308]]], ["In contrast to Korea\u2019s fame as an information technology powerhouse in the digital age, epidemiological investigations were still being performed in an outdated way, in which official documents had to be sent to obtain cooperation, the results of the investigation were written on paper, typed, and summarized using a word processing program, which need a considerable period of time.", [["epidemiological investigations", "TEST", 88, 118], ["the investigation", "TEST", 247, 264]]], ["This system is especially inefficient in urgent cases, where epidemiological investigators immediately determine the required quarantine measures in order to control the spread of the outbreak quickly.", [["quarantine measures", "TREATMENT", 126, 145]]], ["In contrast, this system experienced no problems in cases where epidemiological investigations began at the end of an outbreak such as foodborne outbreak.", [["epidemiological investigations", "TEST", 64, 94]]], ["Moreover, excessive anxiety and fear were spread due to incorrect communication about risks at a time when the results of the epidemiological investigation should have been disclosed not only to the general public, but also to specialists.", [["anxiety", "DISEASE", 20, 27], ["excessive anxiety", "PROBLEM", 10, 27], ["fear", "PROBLEM", 32, 36], ["the epidemiological investigation", "TEST", 122, 155]]], ["In order to solve these problems, a permanent institution in which specialists from various fields can prepare for epidemics of infectious diseases should be established through the establishment of a research center for emerging infectious diseases.", [["infectious diseases", "DISEASE", 128, 147], ["infectious diseases", "DISEASE", 230, 249], ["these problems", "PROBLEM", 18, 32], ["a permanent institution", "TREATMENT", 34, 57], ["infectious diseases", "PROBLEM", 128, 147], ["emerging infectious diseases", "PROBLEM", 221, 249], ["infectious", "OBSERVATION", 230, 240]]], ["This institute should closely monitor the current status of diseases worldwide and prepare plans for a response within Korea.", [["diseases", "PROBLEM", 60, 68]]], ["In addition, a digital system for epidemiological investigations utilizing various sources of personal information, such CCTV records, the use of navigation systems, credit card use, and prior medical records (including electronic medical records) needs to be prepared, as well as a system in which the contents of epidemiological investigations can be shared in real time between specialists and policymakers.", [["epidemiological investigations", "TEST", 34, 64], ["epidemiological investigations", "TEST", 315, 345]]], ["It is also imperative for specialists in risk communication to communicate with other specialists, citizens, and educators in each stage of all epidemiological investigations.CONCLUSIONThe response to the recent MERS outbreak in Korea demonstrated inadequate preparedness for emerging infectious diseases.", [["infectious diseases", "DISEASE", 285, 304], ["all epidemiological investigations", "TEST", 140, 174], ["emerging infectious diseases", "PROBLEM", 276, 304], ["infectious", "OBSERVATION", 285, 295]]], ["Subsequent MERS outbreaks could reoccur at any point unless the problems raised by this outbreak are solved.", [["Subsequent MERS outbreaks", "PROBLEM", 0, 25], ["the problems", "PROBLEM", 60, 72]]], ["Bill Gates has warned that the greatest threat to mankind in the 21st century is emerging infectious diseases, not nuclear weapons [10].", [["nuclear", "ANATOMY", 115, 122], ["infectious diseases", "DISEASE", 90, 109], ["emerging infectious diseases", "PROBLEM", 81, 109], ["infectious", "OBSERVATION", 90, 100]]], ["Korea should be well prepared to respond to emerging infectious diseases, utilizing this crisis as a chance for future improvement before it is too late.", [["infectious diseases", "DISEASE", 53, 72], ["emerging infectious diseases", "PROBLEM", 44, 72], ["this crisis", "TREATMENT", 84, 95], ["infectious", "OBSERVATION", 53, 63]]]], "PMC7305473": [["The new coronavirus has caused negative impacts and paralyzed professional activities considered to be at high risk of contamination worldwide.", [["coronavirus", "DISEASE", 8, 19], ["coronavirus", "ORGANISM", 8, 19], ["The new coronavirus", "PROBLEM", 0, 19], ["new", "OBSERVATION_MODIFIER", 4, 7], ["coronavirus", "OBSERVATION", 8, 19], ["negative", "OBSERVATION_MODIFIER", 31, 39], ["impacts", "OBSERVATION_MODIFIER", 40, 47], ["contamination", "OBSERVATION", 119, 132]]], ["Due to the large release of aerosols from dental procedures, dentistry, in the vast majority of countries, has been restricted to urgent and emergency care, such as odontogenic infections or trauma [1].", [["odontogenic infections", "DISEASE", 165, 187], ["trauma", "DISEASE", 191, 197], ["dental procedures", "TREATMENT", 42, 59], ["urgent and emergency care", "TREATMENT", 130, 155], ["odontogenic infections", "PROBLEM", 165, 187], ["trauma", "PROBLEM", 191, 197], ["large", "OBSERVATION_MODIFIER", 11, 16], ["aerosols", "OBSERVATION", 28, 36]]]], "1b9a8bfeae39621cb535a9fb9b92098219f3417c": [["The coronavirus crisis hit at the beginning of the Complex General Surgical Oncology Fellowship (CGSO) and Breast Oncology Fellowship interview cycles.", [["coronavirus", "ORGANISM", 4, 15], ["The coronavirus crisis", "PROBLEM", 0, 22], ["coronavirus crisis", "OBSERVATION", 4, 22], ["Breast", "ANATOMY", 107, 113]]], ["Our virtual interview day schedule mimicked our traditional in person interview day, and we always had a back-up plan for completing the interview if the virtual platform became unstable.", [["person", "SPECIES", 63, 69], ["unstable", "PROBLEM", 178, 186]]], ["Published by Elsevier Inc. All rights reserved.)INTRODUCTIONThe coronavirus crisis hit at the beginning of the Complex General Surgical Oncology Fellowship (CGSO) and Breast Oncology Fellowship interview cycles.", [["coronavirus", "ORGANISM", 64, 75], ["The coronavirus crisis", "PROBLEM", 60, 82], ["coronavirus crisis", "OBSERVATION", 64, 82], ["Breast", "ANATOMY", 167, 173]]], ["Within 2 weeks, nearly all programs switched to a virtual platform for the remainder of the season.", [["a virtual platform", "TREATMENT", 48, 66]]], ["As 1 of the 33 CGSO and 59 Breast Oncology programs, we were forced to adapt to this change quickly, only having 3 weeks to prepare for our first of 2 upcoming interview days.", [["Breast", "ANATOMY", 27, 33], ["Breast", "ANATOMY", 27, 33]]], ["[2] [3] [4] Here we describe our methods and shared experience for conducting our virtual fellowship interviews with the hopes of preparing other training programs for their upcoming interview season.PLATFORMWe chose to use Zoom as our virtual meeting platform, with standard phone calls as a backup if connections became problematic.", [["other training programs", "TREATMENT", 140, 163], ["problematic", "PROBLEM", 322, 333]]], ["This will help to minimize technical issues.PROGRAM INFORMATION SHARINGCandidates were electronically sent additional information about the program, traditionally included in our No funding was received for completion of this study.", [["technical issues", "PROBLEM", 27, 43], ["this study", "TEST", 221, 231]]], ["Correspondence: Inquiries to Maureen V. Hill, Complex General Surgical Oncology Fellow, Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111; e-mail: Maureen.Hill@fccc.edu welcome packet provided prior to their interview day.", [["Cancer", "DISEASE", 131, 137]]], ["This included information on the program rotation schedule, research opportunities, institutional history, benefits, and staff.", [["the program rotation schedule", "TREATMENT", 29, 58]]], ["In addition, links to videos showcasing the campus, faculty, and facilities were distributed.", [["campus", "ANATOMY", 44, 50]]], ["Candidates had the opportunity to ask questions of the current fellows and to gather information about the culture and camaraderie of the program.", [["the culture", "TEST", 103, 114]]], ["We had varied experiences between the CGSO and Breast Programs during these sessions, with only texted questions to the fellows in our CGSO session but more free-form discussion in the Breast session likely due to the slightly smaller size of the group.INTERVIEW DAY SCHEDULEThe online virtual interview day was designed to mirror our in-person interviews from previous years.", [["Breast", "ANATOMY", 47, 53], ["Breast", "ANATOMY", 185, 191], ["Breast", "ANATOMY", 47, 53], ["Breast", "ANATOMY", 185, 191], ["slightly", "OBSERVATION_MODIFIER", 218, 226], ["smaller", "OBSERVATION_MODIFIER", 227, 234], ["size", "OBSERVATION_MODIFIER", 235, 239]]], ["Candidates had the opportunity to ask questions to the PD's via the chat function, or at the conclusion of the session.", [["PD", "DISEASE", 55, 57]]], ["For Breast, 14 candidates interviewed with 7 individual faculty members.", [["Breast", "ANATOMY", 4, 10], ["Breast", "ANATOMY", 4, 10]]], ["There was administrative staff on hand providing reminders about time remaining.", [["hand", "ANATOMY", 34, 38], ["hand", "ORGANISM_SUBDIVISION", 34, 38]]], ["This worked out quite well as applicant information was reviewed using screen-sharing on Zoom while we discussed the applicants.", [["screen", "TEST", 71, 77], ["Zoom", "TREATMENT", 89, 93]]], ["In total the interview day lasted from 7:15 am to 1:00 pm for CGSO and 7:00 am to 2:30 pm for Breast, which was the same length or slightly shorter than our standard interview day.SPECIAL CONSIDERATIONSTime Zones \u00c0 We are an east coast program and starting the interview day at 7:00 am EST proved to be challenging for candidates located on the west coast.", [["Breast", "ANATOMY", 94, 100], ["Breast", "ANATOMY", 94, 100]]], ["The faculty were provided with the cell phone of each candidate on their schedule so that a phone interview could be conducted if the video platform became unstable, to keep the schedule on time.", [["cell", "ANATOMY", 35, 39], ["cell", "CELL", 35, 39], ["unstable", "PROBLEM", 156, 164]]], ["There were a few video streaming issues that intermittently occurred.", [["a few video streaming issues", "PROBLEM", 11, 39], ["few", "OBSERVATION_MODIFIER", 13, 16]]], ["In cases where connections were severely problematic, the interview was conducted via Apple's Facetime or standard phone call.", [["severely problematic", "PROBLEM", 32, 52]]], ["It remains to be seen whether candidates will preferentially choose programs where they have interviewed in person over programs interviewing them virtually, and whether they will also preferentially choose programs located in familiar cities over unfamiliar locations that they were not able to visit.", [["person", "SPECIES", 108, 114]]]], "PMC7522008": [["Un acc\u00e8s relatif aux m\u00e9dicaments ::: L\u2019utilit\u00e9 limit\u00e9e de la vente en ligne des m\u00e9dicamentsAffirmer que vendre des m\u00e9dicaments sur internet favoriserait un recours plus rapide de la population aux soins est-il totalement pertinent ?", [["la vente en ligne des m\u00e9dicaments", "TREATMENT", 58, 91]]], ["Au lieu d\u2019avoir une r\u00e9ponse imm\u00e9diate du pharmacien \u00e0 la demande formul\u00e9e par le client dans son officine, s\u2019ajoutent dans le cas de la vente en ligne le traitement de la commande et plus encore son acheminement postal.", [["Au", "CHEMICAL", 0, 2]]], ["Les m\u00e9dicaments disponibles en ligne \u00e9tant \u00e0 prescription m\u00e9dicale facultative, ils concernent donc des petites pathologies ou des maux du quotidien comme des migraines ou des rhumes, est-il alors pertinent d\u2019attendre ne serait-ce que deux jours, au mieux, pour recevoir le traitement ?", [["ils concernent donc des petites pathologies ou des maux du quotidien comme des migraines ou des rhumes, est-il alors pertinent d\u2019attendre ne serait-ce que deux jours, au mieux", "SPECIES", 80, 255], ["migraines", "PROBLEM", 159, 168], ["pour recevoir le traitement", "TREATMENT", 257, 284]]], ["Cela n\u2019est pas certain, m\u00eame si l\u2019on peut aussi penser, si la formule nous est permise, que \u00ab c\u2019est mieux que rien \u00bb.Un acc\u00e8s relatif aux m\u00e9dicaments ::: L\u2019utilit\u00e9 limit\u00e9e de la vente en ligne des m\u00e9dicamentsAu-del\u00e0, un autre argument avanc\u00e9 en faveur de l\u2019acc\u00e8s aux soins porte sur les personnes qui peinent \u00e0 se d\u00e9placer, lesquelles ne b\u00e9n\u00e9ficient pas ou peu du r\u00e9seau officinal quelle qu\u2019en soit l\u2019\u00e9tendue.", [["Au-del\u00e0", "CHEMICAL", 208, 215], ["Au", "CHEMICAL", 208, 210], ["la vente en ligne des m\u00e9dicaments", "TREATMENT", 175, 208]]], ["Ainsi, d\u00e9velopper la vente en ligne permettrait de favoriser l\u2019acc\u00e8s aux m\u00e9dicaments de ce public, id\u00e9e assur\u00e9ment louable12.", [["Ainsi", "TEST", 0, 5]]], ["Au-del\u00e0 d\u2019\u00e9ventuelles statistiques sur le taux d\u2019\u00e9quipement informatique des s\u00e9niors, peut-on penser qu\u2019une personne \u00e2g\u00e9e d\u00e9pendante va \u00eatre volontaire et en capacit\u00e9 de se connecter \u00e0 internet, d\u2019identifier un site autoris\u00e9 de vente en ligne, de r\u00e9aliser une commande, de payer en ligne en entrant ses r\u00e9f\u00e9rences bancaires [6] ?", [["Au", "CHEMICAL", 0, 2], ["Au", "CHEMICAL", 0, 2]]], ["Justifier la vente en ligne par une volont\u00e9 d\u2019am\u00e9lioration de l\u2019acc\u00e8s aux m\u00e9dicaments ne para\u00eet donc pas le plus pertinent.Un acc\u00e8s restreint \u00e0 certains m\u00e9dicaments ::: L\u2019utilit\u00e9 limit\u00e9e de la vente en ligne des m\u00e9dicamentsInd\u00e9pendamment de ces aspects pratiques, il faut noter l\u2019existence d\u2019obstacles juridiques \u00e0 l\u2019acc\u00e8s aux m\u00e9dicaments que favoriserait la vente en ligne.Un acc\u00e8s restreint \u00e0 certains m\u00e9dicaments ::: L\u2019utilit\u00e9 limit\u00e9e de la vente en ligne des m\u00e9dicamentsLe principal obstacle se fonde sur le p\u00e9rim\u00e8tre des m\u00e9dicaments vendus.", [["la vente en ligne par une volont\u00e9", "TREATMENT", 10, 43], ["la vente en ligne des m\u00e9dicaments", "TREATMENT", 190, 223], ["la vente en ligne des m\u00e9dicaments", "TREATMENT", 441, 474]]], ["En effet, le r\u00e9gime juridique retenu par les pouvoirs publics fran\u00e7ais lors de transposition de la directive du 8 juin 2008 permet la vente en ligne des m\u00e9dicaments \u00e0 prescription m\u00e9dicale facultative uniquement.", [["la vente en ligne des m\u00e9dicaments", "TREATMENT", 131, 164]]], ["En aucun cas, la vente des m\u00e9dicaments \u00e0 prescription m\u00e9dicale obligatoire n\u2019est autoris\u00e9e m\u00eame si la directive en laissait la possibilit\u00e9 aux \u00c9tats membres.", [["la vente des m\u00e9dicaments", "TREATMENT", 14, 38]]], ["11].Un acc\u00e8s restreint \u00e0 certains m\u00e9dicaments ::: L\u2019utilit\u00e9 limit\u00e9e de la vente en ligne des m\u00e9dicamentsD\u2019ailleurs, ce p\u00e9rim\u00e8tre de vente aurait pu \u00eatre plus restreint encore puisque initialement l\u2019ordonnance du 19 d\u00e9cembre 2012 limitait cette vente non pas \u00e0 tous les m\u00e9dicaments sans prescription mais uniquement \u00e0 ceux disponibles en acc\u00e8s direct13, c\u2019est-\u00e0-dire par-del\u00e0 le comptoir.", [["la vente en ligne des m\u00e9dicaments", "TREATMENT", 71, 104], ["c\u2019est", "TEST", 353, 358]]], ["Ce n\u2019est que par l\u2019intervention du Conseil d\u2019\u00c9tat que le champ de vente en ligne n\u2019a pas \u00e9t\u00e9 plus limit\u00e9 encore, intervention qui s\u2019est r\u00e9alis\u00e9e en deux temps.", [["Ce", "CHEMICAL", 0, 2], ["que le champ de vente en ligne", "TREATMENT", 50, 80], ["temps", "TEST", 153, 158]]], ["D\u2019abord, par une suspension de cette restriction le 14 f\u00e9vrier 2013 dans le cadre d\u2019une proc\u00e9dure en r\u00e9f\u00e9r\u00e914, puis par une annulation de cette m\u00eame disposition, toujours par le Conseil d\u2019\u00c9tat, dans un arr\u00eat en date du 17 juillet 2013 [8].Un acc\u00e8s restreint \u00e0 certains m\u00e9dicaments ::: L\u2019utilit\u00e9 limit\u00e9e de la vente en ligne des m\u00e9dicamentsCette annulation correspondait \u00e0 des enjeux majeurs puisque le nombre de m\u00e9dicaments en acc\u00e8s direct est bien plus faible que celui de la cat\u00e9gorie g\u00e9n\u00e9rale des m\u00e9dicaments sans prescription m\u00e9dicale obligatoire.", [["D\u2019abord, par une suspension", "TREATMENT", 0, 27], ["puis par une annulation", "TREATMENT", 111, 134], ["la vente en ligne des m\u00e9dicaments", "TREATMENT", 306, 339], ["Cette annulation", "TREATMENT", 339, 355], ["faible que celui de la cat\u00e9gorie g\u00e9n\u00e9rale des", "TREATMENT", 454, 499]]], ["Il a m\u00eame fallu modifier le projet de loi de ratification de l\u2019ordonnance du 19 d\u00e9cembre 2012 pour que cette annulation soit prise en compte, le gouvernement voulant initialement maintenir cette restriction du domaine de vente16.Un acc\u00e8s restreint \u00e0 certains m\u00e9dicaments ::: L\u2019utilit\u00e9 limit\u00e9e de la vente en ligne des m\u00e9dicamentsIl n\u2019est donc pas certain qu\u2019il soit pleinement int\u00e9ressant d\u2019acheter des m\u00e9dicaments en ligne, m\u00eame lorsque l\u2019on n\u2019a pas d\u2019officines \u00e0 c\u00f4t\u00e9 de chez soi, si ce n\u2019est pour une cat\u00e9gorie limit\u00e9e de produits.", [["Il a m\u00eame fallu modifier le projet", "TREATMENT", 0, 34], ["pour que cette annulation", "TREATMENT", 94, 119], ["le gouvernement voulant initialement", "TREATMENT", 142, 178], ["la vente en ligne des m\u00e9dicaments", "TREATMENT", 296, 329]]], ["L\u2019on pourrait alors affirmer que c\u2019est une forme de \u00ab pis-aller \u00bb, de \u00ab faute de mieux \u00bb en cas d\u2019absence d\u2019offre pharmaceutique, mais ce pis-aller subit d\u2019autres probl\u00e8mes, cr\u00e9\u00e9s eux-m\u00eames par la vente en ligne\u2026Le difficile respect des obligations du pharmacien ::: Les risques importants de la vente en ligne des m\u00e9dicamentsLes obligations du pharmacien d\u2019officine sont nombreuses mais l\u2019une des principales est probablement constitu\u00e9e par le devoir de conseil [9].", [["cr\u00e9\u00e9s", "TEST", 174, 179], ["eux", "TEST", 180, 183], ["Les risques", "PROBLEM", 267, 278], ["la vente en ligne des", "TREATMENT", 293, 314], ["du pharmacien d\u2019officine", "TREATMENT", 342, 366], ["difficile", "OBSERVATION", 215, 224]]], ["Pourtant, force est de constater que le respect de ce devoir est mis \u00e0 mal dans le cadre de la vente en ligne des m\u00e9dicaments sur la base d\u2019une interrogation et d\u2019un constat.Le difficile respect des obligations du pharmacien ::: Les risques importants de la vente en ligne des m\u00e9dicamentsL\u2019interrogation consiste \u00e0 se demander comment le pharmacien officinal peut-il accomplir son devoir de conseil dans ces conditions ?", [["la vente en ligne des", "TREATMENT", 92, 113], ["et d\u2019un constat", "TREATMENT", 158, 173], ["L\u2019interrogation", "TEST", 288, 303], ["difficile", "OBSERVATION", 177, 186]]], ["Est-ce gr\u00e2ce au questionnaire de sant\u00e9 mis en place17?", [["Est", "TEST", 0, 3]]], ["Ce questionnaire a pour but de permettre au pharmacien de v\u00e9rifier lors la pr\u00e9paration de la commande qu\u2019aucun \u00e9l\u00e9ment n\u2019est en d\u00e9faveur de la dispensation.", [["Ce", "CHEMICAL", 0, 2]]], ["Il doit \u00eatre rempli lors de la premi\u00e8re commande et porte sur l\u2019\u00e2ge du patient, son poids, son sexe, ses traitements en cours, ses ant\u00e9c\u00e9dents allergiques et, le cas \u00e9ch\u00e9ant, son \u00e9tat de grossesse ou d\u2019allaitement, le patient devant attester de la v\u00e9racit\u00e9 de ces informations.", [["patient", "ORGANISM", 71, 78], ["patient", "ORGANISM", 218, 225], ["patient", "SPECIES", 71, 78], ["patient", "SPECIES", 218, 225], ["le", "ANATOMY", 159, 161]]], ["Pour autant, aussi utiles que soient ces informations pour traiter et valider ou non la commande, elles ne contribuent pas au devoir de conseil puisqu\u2019il n\u2019y a pas ensuite d\u2019\u00e9changes avec le patient pour l\u2019informer des modalit\u00e9s de prise du m\u00e9dicament ou des pr\u00e9cautions \u00e0 prendre en termes d\u2019interactions m\u00e9dicamenteuses par exemple.Le difficile respect des obligations du pharmacien ::: Les risques importants de la vente en ligne des m\u00e9dicamentsDans ce cas, si ce n\u2019est pas avec le questionnaire que le pharmacien peut remplir son devoir de conseil, est-ce alors par l\u2019\u00e9change interactif obligatoire qui doit avoir lieu entre le patient et le pharmacien (bo\u00eete de dialogue en ligne\u2026) qu\u2019il le fera ?", [["Dans ce cas, si ce n\u2019est", "CHEMICAL", 448, 472], ["patient", "ORGANISM", 191, 198], ["patient", "ORGANISM", 632, 639], ["patient", "SPECIES", 191, 198], ["patient", "SPECIES", 632, 639], ["Dans ce cas, si ce n\u2019est pas avec le questionnaire que le pharmacien peut remplir son devoir de conseil, est-ce alors par l\u2019\u00e9change interactif obligatoire qui doit avoir lieu entre le patient et le pharmacien", "SPECIES", 448, 656], ["la vente en ligne des m\u00e9dicaments", "TREATMENT", 415, 448], ["lieu entre le patient et le pharmacien", "TREATMENT", 618, 656], ["difficile", "OBSERVATION", 337, 346]]], ["Au contraire, cela r\u00e9v\u00e8le en fait une erreur quant aux exigences relatives au devoir de conseil : le pharmacien doit prendre l\u2019initiative de d\u00e9livrer les informations et non pas le faire uniquement en r\u00e9ponse \u00e0 la demande du client, traduisant une mauvaise appr\u00e9ciation de l\u2019origine de l\u2019impulsion en la mati\u00e8re.", [["Au", "CHEMICAL", 0, 2], ["le", "ANATOMY", 98, 100]]], ["Le pharmacien n\u2019est pas seulement \u00e0 la disposition du patient, il doit initier l\u2019\u00e9change.Le difficile respect des obligations du pharmacien ::: Les risques importants de la vente en ligne des m\u00e9dicamentsFaut-il dans ce cas avoir plus d\u2019espoir avec la mise \u00e0 disposition de notices, m\u00eame de mani\u00e8re automatique ?", [["Faut-il", "CHEMICAL", 203, 210], ["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61], ["la vente en ligne des m\u00e9dicaments", "TREATMENT", 170, 203], ["difficile", "OBSERVATION", 92, 101]]], ["Pas du tout, en r\u00e9alit\u00e9, puisque, dans le cas d\u2019une dispensation traditionnelle, le fait que le client dispose de la notice en achetant le m\u00e9dicament ne lib\u00e8re pas le pharmacien de la d\u00e9livrance de conseils.", [["Pas", "TEST", 0, 3]]], ["Il y a ici une confusion entre l\u2019information pr\u00e9vue par le producteur et le conseil que doit donner le vendeur du produit.Le difficile respect des obligations du pharmacien ::: Les risques importants de la vente en ligne des m\u00e9dicamentsLe constat mettant \u00e0 mal le devoir de conseil se fonde sur l\u2019existence d\u2019un syst\u00e8me d\u2019achat associ\u00e9 que l\u2019on retrouve sur certains sites de vente de m\u00e9dicaments.", [["confusion", "DISEASE", 15, 24], ["la vente en ligne des m\u00e9dicaments", "TREATMENT", 203, 236], ["difficile", "OBSERVATION", 125, 134]]], ["Pratiqu\u00e9 sur des sites commerciaux classiques (musique, livres\u2026), il consiste \u00e0 proposer \u00e0 celui qui a achet\u00e9 un produit d\u2019autres biens dont on pense qu\u2019ils sont susceptibles de lui plaire, les ressemblances entre eux \u00e9tant suffisamment nombreuses.", [["Pratiqu\u00e9 sur des", "TREATMENT", 0, 16]]], ["Si ce syst\u00e8me est tr\u00e8s probablement adapt\u00e9 pour des biens de consommation classique, il nous para\u00eet tout \u00e0 fait probl\u00e9matique en mati\u00e8re de m\u00e9dicaments.", [["Si", "CHEMICAL", 0, 2]]], ["Il faut effectivement r\u00e9aliser que, dans cette hypoth\u00e8se, ce n\u2019est pas un professionnel de sant\u00e9 qui va conseiller un patient sur la combinaison opportune de plusieurs m\u00e9dicaments dans un but th\u00e9rapeutique, mais un algorithme qui va permettre \u00e0 un ordinateur de proposer d\u2019acheter d\u2019autres m\u00e9dicaments.", [["patient", "ORGANISM", 118, 125], ["patient", "SPECIES", 118, 125]]], ["Certes, l\u2019\u00e9tude pratique que nous avons pu r\u00e9aliser par le pass\u00e9 ne montre pas un tr\u00e8s grand nombre de sites utilisant ce syst\u00e8me pour des m\u00e9dicaments mais le risque n\u2019est pas th\u00e9orique pour autant [10].Le difficile respect des obligations du pharmacien ::: Les risques importants de la vente en ligne des m\u00e9dicamentsLa conclusion est donc assez s\u00e9v\u00e8re : l\u2019ex\u00e9cution du devoir de conseil para\u00eet tout \u00e0 fait compromise dans le cas de la vente en ligne de m\u00e9dicaments.", [["Certes", "TEST", 0, 6], ["ce syst\u00e8me pour des", "TREATMENT", 119, 138], ["la vente en ligne des m\u00e9dicaments", "TREATMENT", 284, 317], ["difficile", "OBSERVATION", 206, 215]]], ["Sans conseil, la dispensation se r\u00e9duit \u00e0 une simple vente, comme la jurisprudence a pu le rappeler de fa\u00e7on tr\u00e8s nette dans un arr\u00eat de la Cour d\u2019appel de Caen du 15 juillet 1993 [12] retenant la responsabilit\u00e9 du pharmacien pour s\u2019\u00eatre \u00ab content\u00e9 de d\u00e9livrer les rem\u00e8des en reproduisant sur les emballages la posologie figurant sur l\u2019ordonnance, ce qui est \u00e0 la port\u00e9e de tout \u00e9picier sachant lire et \u00e9crire, mais tout \u00e0 fait insuffisant de la part d\u2019un sp\u00e9cialiste de la sant\u00e9 qui a lui aussi tout aussi gravement [que le prescripteur] manqu\u00e9 \u00e0 son devoir de conseil et \u00e0 l\u2019obligation de moyen \u00e0 laquelle auraient d\u00fb l\u2019avoir pr\u00e9par\u00e9 six ann\u00e9es d\u2019\u00e9tudes sp\u00e9cialis\u00e9es et quelques de pratique professionnelle \u00bb.Le d\u00e9veloppement probl\u00e9matique de comportements inadapt\u00e9s ::: Les risques importants de la vente en ligne des m\u00e9dicamentsSans que cela ne soit exhaustif, sur la base de l\u2019\u00e9tude pratique que nous avons pu r\u00e9aliser des diff\u00e9rents sites web proposant des m\u00e9dicaments [10], il faut ici relever deux types de comportements possibles qui laissent penser que la vente en ligne peut cr\u00e9er des probl\u00e8mes suppl\u00e9mentaires au lieu de r\u00e9gler la question des in\u00e9galit\u00e9s territoriales de sant\u00e9 en mati\u00e8re pharmaceutique.Le d\u00e9veloppement probl\u00e9matique de comportements inadapt\u00e9s ::: Les risques importants de la vente en ligne des m\u00e9dicamentsLe premier type de comportement probl\u00e9matique porte sur la dispense de frais de port.", [["retenant la responsabilit\u00e9 du pharmacien", "TREATMENT", 185, 225], ["ce qui est \u00e0 la port\u00e9e", "TREATMENT", 348, 370], ["l\u2019avoir pr\u00e9par\u00e9", "TREATMENT", 620, 635], ["la vente en ligne des m\u00e9dicaments", "TREATMENT", 799, 832], ["il faut ici", "TREATMENT", 981, 992], ["la vente en ligne peut cr\u00e9er des", "TREATMENT", 1063, 1095], ["la vente en ligne des m\u00e9dicaments", "TREATMENT", 1304, 1337]]], ["Une pratique a en effet pu \u00eatre observ\u00e9e : elle consiste \u00e0 dispenser le patient des frais de port lorsque sa commande d\u00e9passe un certain montant de commande.", [["patient", "ORGANISM", 72, 79], ["patient", "SPECIES", 72, 79]]], ["Au vu de ces enjeux, il est regrettable de constater qu\u2019une part importante permettait par le pass\u00e9 cette dispense (37,62 % des sites visit\u00e9s), le montant de la commande la d\u00e9clenchant allant de 35 \u00e0 100 euros, le plus fr\u00e9quemment 50 euros.Le d\u00e9veloppement probl\u00e9matique de comportements inadapt\u00e9s ::: Les risques importants de la vente en ligne des m\u00e9dicamentsLe second type de comportement qui pose probl\u00e8me porte sur les limites de commande, \u00e9l\u00e9ment important pour \u00e9viter la surconsommation de m\u00e9dicaments.", [["Au", "CHEMICAL", 0, 2], ["la vente en ligne des m\u00e9dicaments", "TREATMENT", 328, 361], ["le", "ANATOMY", 144, 146]]], ["Au-del\u00e0, aucune quantit\u00e9 minimale d\u2019achat ne peut \u00eatre exig\u00e9e ou sugg\u00e9r\u00e9e et le patient doit avoir la possibilit\u00e9 de ne commander qu\u2019une seule bo\u00eete d\u2019un m\u00e9dicament.", [["Au-del\u00e0", "CHEMICAL", 0, 7], ["Au", "CHEMICAL", 0, 2], ["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87]]], ["Le plus souvent, la limite est \u00e0 5 boites (53,4 % des sites pratiquant cette restriction) ou \u00e0 3 (14,77 % des sites pratiquant cette restriction).", [["la", "TEST", 17, 19], ["% des sites pratiquant cette restriction", "TREATMENT", 48, 88]]], ["La limitation est aussi faite dans d\u2019autres cas mais sur la base de motifs inadapt\u00e9s.", [["La limitation", "PROBLEM", 0, 13]]], ["Au final, les sites ne pratiquant aucune limitation repr\u00e9sentent tout de m\u00eame 15,74 % du total.", [["Au", "CHEMICAL", 0, 2], ["Au", "CHEMICAL", 0, 2]]], ["Au vu de tout cela, l\u2019int\u00e9r\u00eat du patient (la diminution du risque iatrog\u00e9nique) comme celui du pharmacien (une gestion optimum de son officine) impliquent la mise en place d\u2019une restriction automatique, ind\u00e9pendamment du simple respect des bonnes pratiques pr\u00e9vues par l\u2019arr\u00eat\u00e9.D\u00e9claration de liens d\u2019int\u00e9r\u00eatsLes auteurs d\u00e9clarent ne pas avoir de liens d\u2019int\u00e9r\u00eats.", [["Au", "CHEMICAL", 0, 2], ["patient", "ORGANISM", 33, 40], ["patient", "SPECIES", 33, 40]]]], "3c4eba7fc5ef54aefffff3808827f42c862cf20c": [["INTRODUCTIONSince 2012, the epidemiology of cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection reported to the World Health Organization (WHO) has been characterized largely by recurrent zoonotic spillover from the known animal reservoir-dromedary camels-and human-to-human transmission in health-care settings (1) .", [["Middle East respiratory syndrome coronavirus", "DISEASE", 53, 97], ["MERS-CoV) infection", "DISEASE", 99, 118], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 53, 97], ["MERS-CoV", "ORGANISM", 99, 107], ["human", "ORGANISM", 283, 288], ["human", "ORGANISM", 292, 297], ["human", "SPECIES", 283, 288], ["human", "SPECIES", 292, 297], ["Middle East respiratory syndrome coronavirus", "SPECIES", 53, 97], ["MERS-CoV", "SPECIES", 99, 107], ["human", "SPECIES", 283, 288], ["human", "SPECIES", 292, 297], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 53, 97], ["infection", "PROBLEM", 109, 118], ["recurrent zoonotic spillover", "PROBLEM", 201, 229], ["Middle", "ANATOMY_MODIFIER", 53, 59], ["respiratory syndrome", "OBSERVATION", 65, 85], ["recurrent", "OBSERVATION_MODIFIER", 201, 210], ["zoonotic spillover", "OBSERVATION", 211, 229]]], ["Outbreaks in health-care settings on occasion have resulted in large outbreaks (2) (3) (4) (5) (6) (7) (8) (9) .", [["large outbreaks (2) (3) (4) (5) (6) (7", "PROBLEM", 63, 101], ["large", "OBSERVATION_MODIFIER", 63, 68], ["outbreaks", "OBSERVATION", 69, 78]]], ["Of the 2,260 cases (including 803 deaths) reported to WHO, 83% of cases have been reported in the Kingdom of Saudi Arabia (10) .INTRODUCTIONThe clinical presentation of MERS-CoV infection ranges from asymptomatic to severe respiratory illness, with approximately 35.5% of cases resulting in death (1) .", [["respiratory", "ANATOMY", 223, 234], ["deaths", "DISEASE", 34, 40], ["MERS-CoV infection", "DISEASE", 169, 187], ["respiratory illness", "DISEASE", 223, 242], ["death", "DISEASE", 291, 296], ["MERS-CoV", "ORGANISM", 169, 177], ["MERS-CoV", "SPECIES", 169, 177], ["MERS", "PROBLEM", 169, 173], ["CoV infection", "PROBLEM", 174, 187], ["severe respiratory illness", "PROBLEM", 216, 242], ["death", "PROBLEM", 291, 296], ["severe", "OBSERVATION_MODIFIER", 216, 222], ["respiratory illness", "OBSERVATION", 223, 242]]], ["The role of asymptomatic or subclinical infections in human-tohuman transmission of MERS-CoV is not well understood, but there is evidence that laboratory-confirmed MERS-CoV infection in patients who are reported as asymptomatic may be transmitted to other individuals (11) .INTRODUCTIONFor many novel infectious pathogens, surveillance initially focuses on individuals with disease who seek care at health-care facilities, which undoubtedly underestimates the true prevalence of infection, because it will not account 70 Grant et al. for mild or asymptomatic infections not requiring medical care.", [["infections", "DISEASE", 40, 50], ["MERS-CoV infection", "DISEASE", 165, 183], ["infection", "DISEASE", 480, 489], ["infections", "DISEASE", 560, 570], ["human", "ORGANISM", 54, 59], ["MERS-CoV", "ORGANISM", 84, 92], ["MERS-CoV", "ORGANISM", 165, 173], ["patients", "ORGANISM", 187, 195], ["human", "SPECIES", 54, 59], ["patients", "SPECIES", 187, 195], ["human", "SPECIES", 54, 59], ["MERS-CoV", "SPECIES", 84, 92], ["MERS-CoV", "SPECIES", 165, 173], ["asymptomatic or subclinical infections in human", "PROBLEM", 12, 59], ["MERS", "PROBLEM", 165, 169], ["CoV infection", "PROBLEM", 170, 183], ["many novel infectious pathogens", "PROBLEM", 291, 322], ["disease", "PROBLEM", 375, 382], ["infection", "PROBLEM", 480, 489], ["mild or asymptomatic infections", "PROBLEM", 539, 570], ["medical care", "TREATMENT", 585, 597], ["asymptomatic", "OBSERVATION_MODIFIER", 12, 24], ["subclinical", "OBSERVATION_MODIFIER", 28, 39], ["infections", "OBSERVATION", 40, 50], ["infection", "OBSERVATION", 174, 183], ["infectious", "OBSERVATION_MODIFIER", 302, 312], ["infection", "OBSERVATION", 480, 489], ["mild", "OBSERVATION_MODIFIER", 539, 543], ["asymptomatic", "OBSERVATION_MODIFIER", 547, 559], ["infections", "OBSERVATION", 560, 570]]], ["Detailed outbreak investigations often include laboratory testing of close contacts and of health-care workers (HCWs), regardless of symptoms, and specialized serological investigations will include individuals thought to be at higher risk of infection, such as HCWs or those with occupational exposure to animal reservoirs.", [["infection", "DISEASE", 243, 252], ["Detailed outbreak investigations", "TEST", 0, 32], ["laboratory testing", "TEST", 47, 65], ["symptoms", "PROBLEM", 133, 141], ["specialized serological investigations", "TEST", 147, 185], ["infection", "PROBLEM", 243, 252], ["infection", "OBSERVATION", 243, 252]]], ["Estimates of the true prevalence of infection of high-risk pathogens are important to understand the populations required for vaccine candidates or specific therapeutic treatments as and when they become available.", [["infection", "DISEASE", 36, 45], ["infection of high-risk pathogens", "PROBLEM", 36, 68], ["vaccine candidates", "TREATMENT", 126, 144], ["specific therapeutic treatments", "TREATMENT", 148, 179], ["infection", "OBSERVATION", 36, 45]]], ["In addition, the role of subclinical or asymptomatic infection is critical in understanding chains of transmission missed by surveillance systems.", [["infection", "DISEASE", 53, 62], ["subclinical or asymptomatic infection", "PROBLEM", 25, 62], ["subclinical", "OBSERVATION_MODIFIER", 25, 36], ["asymptomatic", "OBSERVATION_MODIFIER", 40, 52], ["infection", "OBSERVATION", 53, 62]]], ["For MERS-CoV, asymptomatic infection has been reported to WHO, but the possibility of transmission prior to symptom onset is critical for recommending effective infection prevention and control measures and for reducing secondary MERS-CoV transmission.INTRODUCTIONThe role of asymptomatic infections in transmission of other respiratory viruses has been investigated previously.", [["infection", "DISEASE", 27, 36], ["infection", "DISEASE", 161, 170], ["infections", "DISEASE", 289, 299], ["respiratory viruses", "DISEASE", 325, 344], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 230, 238], ["MERS-CoV", "SPECIES", 4, 12], ["MERS-CoV", "SPECIES", 230, 238], ["MERS", "PROBLEM", 4, 8], ["asymptomatic infection", "PROBLEM", 14, 36], ["effective infection prevention", "TREATMENT", 151, 181], ["control measures", "TREATMENT", 186, 202], ["asymptomatic infections", "PROBLEM", 276, 299], ["other respiratory viruses", "PROBLEM", 319, 344], ["asymptomatic", "OBSERVATION_MODIFIER", 14, 26], ["infection", "OBSERVATION", 27, 36], ["infection", "OBSERVATION", 161, 170], ["asymptomatic", "OBSERVATION_MODIFIER", 276, 288], ["infections", "OBSERVATION", 289, 299], ["respiratory viruses", "OBSERVATION", 325, 344]]], ["Highly pathogenic avian influenza H5N1 RNA, for example, has been detected by polymerase chain reaction (PCR) from asymptomatic family contacts of ill patients, suggesting the possibility for onward transmission, even in the absence of symptoms (12) (13) (14) (15) .", [["ill", "DISEASE", 147, 150], ["avian influenza H5N1", "ORGANISM", 18, 38], ["patients", "ORGANISM", 151, 159], ["avian influenza H5N1 RNA", "RNA", 18, 42], ["avian influenza H5N1", "SPECIES", 18, 38], ["patients", "SPECIES", 151, 159], ["Highly pathogenic avian influenza H5N1 RNA", "PROBLEM", 0, 42], ["polymerase chain reaction", "PROBLEM", 78, 103], ["PCR", "TEST", 105, 108], ["symptoms", "PROBLEM", 236, 244], ["influenza H5N1", "OBSERVATION", 24, 38]]], ["For severe acute respiratory syndrome CoV, limited transmission to close contacts before symptom onset or hospitalization has been found in transmissionrisk studies outside health-care settings, whereas human-tohuman transmission within health-care settings was higher, likely due to higher viral load in hospitalized patients and more frequent exposure to the virus among HCWs (16) (17) (18) .INTRODUCTIONHere, we have reviewed available evidence of the extent of subclinical and asymptomatic infection of MERS-CoV stratified by evaluating studies in which infection within and outside of health-care settings has been measured, and the potential role of onward human-to-human transmission from asymptomatic cases.METHODSWe conducted a literature search in PubMed and EMBASE databases for observational epidemiologic studies of laboratory-confirmed MERS-CoV infection using the following search terms: \"MERS-CoV\" or \"MERS\" AND \"seroprevalence\" or \"prevalence\" or \"serological\" or \"infection\" or \"asymptomatic.\"", [["acute respiratory syndrome CoV", "DISEASE", 11, 41], ["infection", "DISEASE", 494, 503], ["infection", "DISEASE", 558, 567], ["MERS-CoV infection", "DISEASE", 850, 868], ["infection", "DISEASE", 982, 991], ["human", "ORGANISM", 203, 208], ["patients", "ORGANISM", 318, 326], ["MERS-CoV", "ORGANISM", 507, 515], ["human", "ORGANISM", 663, 668], ["human", "ORGANISM", 672, 677], ["MERS-CoV", "ORGANISM", 850, 858], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 904, 912], ["human", "SPECIES", 203, 208], ["patients", "SPECIES", 318, 326], ["human", "SPECIES", 663, 668], ["human", "SPECIES", 672, 677], ["severe acute respiratory syndrome CoV", "SPECIES", 4, 41], ["human", "SPECIES", 203, 208], ["MERS-CoV", "SPECIES", 507, 515], ["human", "SPECIES", 663, 668], ["human", "SPECIES", 672, 677], ["MERS-CoV", "SPECIES", 850, 858], ["severe acute respiratory syndrome CoV", "PROBLEM", 4, 41], ["higher viral load", "PROBLEM", 284, 301], ["subclinical and asymptomatic infection of MERS", "PROBLEM", 465, 511], ["evaluating studies", "TEST", 530, 548], ["infection", "PROBLEM", 558, 567], ["observational epidemiologic studies", "TEST", 790, 825], ["MERS", "PROBLEM", 850, 854], ["CoV infection", "PROBLEM", 855, 868], ["severe", "OBSERVATION_MODIFIER", 4, 10], ["acute", "OBSERVATION_MODIFIER", 11, 16], ["respiratory syndrome", "OBSERVATION", 17, 37], ["subclinical", "OBSERVATION_MODIFIER", 465, 476], ["asymptomatic", "OBSERVATION_MODIFIER", 481, 493], ["infection", "OBSERVATION", 494, 503], ["infection", "OBSERVATION", 558, 567], ["infection", "OBSERVATION", 859, 868]]], ["Additional studies were identified through consultation with the WHO MERS technical network and in the bibliography of a related recently published review (19) .", [["Additional studies", "TEST", 0, 18]]], ["We assessed the titles and abstracts of identified studies to determine their eligibility for inclusion in the study.", [["identified studies", "TEST", 40, 58], ["the study", "TEST", 107, 116]]], ["We stratified our analyses to evaluate subclinical and/or asymptomatic infection identified inside and outside health-care facilities.", [["infection", "DISEASE", 71, 80], ["our analyses", "TEST", 14, 26], ["asymptomatic infection", "PROBLEM", 58, 80], ["asymptomatic", "OBSERVATION_MODIFIER", 58, 70], ["infection", "OBSERVATION", 71, 80]]], ["For descriptive analysis of WHO case-based data, we used the ggplot2 in R, version 3.4.2.0 (R Foundation for Statistical Computing, Vienna, Austria.).METHODSFor MERS-CoV infections studied outside health-care settings, we included studies in which evidence of MERS-CoV infection was reported, using molecular and/or serolog-ical methods in either individuals with occupational exposure to dromedary camels; familial, occupational, or social contacts of patients with confirmed MERS outside of healthcare settings; the general population; or through national MERS surveillance records, when published.", [["MERS-CoV infections", "DISEASE", 161, 180], ["MERS-CoV infection", "DISEASE", 260, 278], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 161, 169], ["MERS-CoV", "ORGANISM", 260, 268], ["patients", "ORGANISM", 453, 461], ["ggplot2", "DNA", 61, 68], ["patients", "SPECIES", 453, 461], ["MERS-CoV", "SPECIES", 161, 169], ["MERS-CoV", "SPECIES", 260, 268], ["studies", "TEST", 231, 238], ["MERS", "PROBLEM", 260, 264], ["CoV infection", "PROBLEM", 265, 278], ["CoV", "OBSERVATION_MODIFIER", 265, 268], ["infection", "OBSERVATION", 269, 278]]], ["Eligible studies included reporting of the number of individuals tested and the number with molecular or serological evidence of MERS-CoV infection.METHODSTo evaluate MERS-CoV infections studied within healthcare settings, we included studies in which the authors reported evidence of MERS-CoV infection, using molecular and/or serological methods among HCW and among non-HCW contacts (e.g., family contacts) of confirmed MERS cases treated in health care settings.METHODSFor each eligible study, we extracted information on the year of publication, the year biological samples were collected, the country in which the study was conducted, the number of individuals tested, characteristics of the individuals tested, and the total number of confirmed MERS-CoV infections by molecular or serological assay.", [["MERS-CoV infection", "DISEASE", 129, 147], ["MERS-CoV infections", "DISEASE", 167, 186], ["MERS-CoV infection", "DISEASE", 285, 303], ["MERS", "DISEASE", 422, 426], ["MERS-CoV infections", "DISEASE", 751, 770], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 129, 137], ["MERS-CoV", "ORGANISM", 167, 175], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 285, 293], ["MERS-CoV", "ORGANISM", 751, 759], ["MERS-CoV", "SPECIES", 129, 137], ["MERS-CoV", "SPECIES", 167, 175], ["MERS-CoV", "SPECIES", 285, 293], ["MERS-CoV", "SPECIES", 751, 759], ["Eligible studies", "TEST", 0, 16], ["MERS", "PROBLEM", 129, 133], ["CoV infection", "PROBLEM", 134, 147], ["CoV infections", "PROBLEM", 172, 186], ["studies", "TEST", 235, 242], ["MERS", "PROBLEM", 285, 289], ["CoV infection", "PROBLEM", 290, 303], ["METHODSFor each eligible study", "TEST", 465, 495], ["the study", "TEST", 615, 624], ["CoV infections", "PROBLEM", 756, 770], ["serological assay", "TEST", 787, 804], ["CoV", "OBSERVATION_MODIFIER", 134, 137], ["infection", "OBSERVATION", 138, 147], ["CoV", "OBSERVATION_MODIFIER", 290, 293], ["infection", "OBSERVATION", 294, 303]]], ["Asymptomatic MERS-CoV infection was considered a laboratoryconfirmed infection with no reported symptoms at the time of sampling.METHODSIn addition, we evaluated the symptomatic profile and place of reporting among laboratory-confirmed MERS-CoV infections reported to WHO from September 2012 to November 27, 2018.", [["MERS-CoV infection", "DISEASE", 13, 31], ["infection", "DISEASE", 69, 78], ["MERS-CoV infections", "DISEASE", 236, 255], ["MERS-CoV", "ORGANISM", 13, 21], ["MERS-CoV", "ORGANISM", 236, 244], ["MERS-CoV", "SPECIES", 13, 21], ["MERS-CoV", "SPECIES", 236, 244], ["Asymptomatic MERS", "PROBLEM", 0, 17], ["CoV infection", "PROBLEM", 18, 31], ["a laboratoryconfirmed infection", "PROBLEM", 47, 78], ["reported symptoms", "PROBLEM", 87, 104], ["sampling", "TEST", 120, 128], ["CoV infections", "PROBLEM", 241, 255], ["CoV", "OBSERVATION_MODIFIER", 18, 21], ["infection", "OBSERVATION", 22, 31]]], ["Within WHO databases, cases are classified as primary cases if they were reported as such by the reporting Member State; if direct or indirect contact with dromedary camels or dromedary products was reported in the case; and/or the exposures were under investigation without known contact with a patient with probable or confirmed MERS.", [["MERS", "DISEASE", 331, 335], ["patient", "ORGANISM", 296, 303], ["patient", "SPECIES", 296, 303]]], ["Cases were classified as secondary cases due to human-to-human transmission if the patient reported recent direct contact with a patient known to have MERS-CoV infection and/or were identified as a household, occupational, or HCW contact of a patient known to have MERS-CoV infection.RESULTSIn total, we identified 43 studies in which MERS-CoV infections measured by serology and/or molecular testing were reported; 23 focused on individuals with exposures outside of health-care settings (4, 7, 11, (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) , and 20 focused on individuals with exposures inside health-care facilities (5, 7, 29, 32, (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) .", [["MERS-CoV infection", "DISEASE", 151, 169], ["MERS-CoV infection", "DISEASE", 265, 283], ["infections", "DISEASE", 344, 354], ["human", "ORGANISM", 48, 53], ["human", "ORGANISM", 57, 62], ["patient", "ORGANISM", 83, 90], ["patient", "ORGANISM", 129, 136], ["MERS-CoV", "ORGANISM", 151, 159], ["patient", "ORGANISM", 243, 250], ["MERS-CoV", "ORGANISM", 265, 273], ["MERS-CoV", "ORGANISM", 335, 343], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 57, 62], ["patient", "SPECIES", 83, 90], ["patient", "SPECIES", 129, 136], ["patient", "SPECIES", 243, 250], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 57, 62], ["MERS-CoV", "SPECIES", 151, 159], ["MERS-CoV", "SPECIES", 265, 273], ["MERS-CoV", "SPECIES", 335, 343], ["MERS", "PROBLEM", 151, 155], ["CoV infection", "PROBLEM", 156, 169], ["MERS", "PROBLEM", 265, 269], ["CoV infection", "PROBLEM", 270, 283], ["43 studies", "TEST", 315, 325], ["CoV infections", "PROBLEM", 340, 354], ["serology", "TEST", 367, 375], ["molecular testing", "TEST", 383, 400], ["infection", "OBSERVATION", 160, 169], ["CoV", "ANATOMY", 270, 273], ["infection", "OBSERVATION", 274, 283]]], ["The selection of identified and included studies is shown in Figure 1 .RESULTSThe 23 studies in which MERS-CoV infections were measured by serology and/or molecular testing outside of health-care settings are described in Table 1 .", [["infections", "DISEASE", 111, 121], ["MERS-CoV", "ORGANISM", 102, 110], ["MERS-CoV", "SPECIES", 102, 110], ["studies", "TEST", 41, 48], ["RESULTSThe 23 studies", "TEST", 71, 92], ["CoV infections", "PROBLEM", 107, 121], ["serology", "TEST", 139, 147], ["molecular testing", "TEST", 155, 172]]], ["The majority of studies focused on measuring seroprevalence of MERS-CoV in individuals with occupational exposure to dromedaries in the Middle East and Africa (20) (21) (22) (23) (24) (25) (26) (27) (28) .RESULTSIn the largest seroprevalence study conducted to date, 0.1% seroprevalence was calculated among general population samples collected in 2012-2013, 2% seroprevalence among shepherds of dromedaries, and 4% seroprevalence among slaughterhouse workers (37) .", [["samples", "ANATOMY", 327, 334], ["dromedaries", "CHEMICAL", 117, 128], ["dromedaries", "DISEASE", 396, 407], ["MERS-CoV", "ORGANISM", 63, 71], ["individuals", "ORGANISM", 75, 86], ["MERS-CoV", "SPECIES", 63, 71], ["studies", "TEST", 16, 23], ["the largest seroprevalence study", "TEST", 215, 247], ["dromedaries", "TREATMENT", 396, 407], ["Middle", "ANATOMY_MODIFIER", 136, 142]]], ["Additional estimates of seroprevalence among occupational high-risk populations ranged from 0% to 67%, with seropositivity being detected in Kingdom of Saudi Arabia, Qatar, and Kenya, and from 0% to 54% among contacts of patients with confirmed MERS in household settings largely in countries of the Middle East.", [["MERS", "DISEASE", 245, 249], ["patients", "ORGANISM", 221, 229], ["patients", "SPECIES", 221, 229], ["seropositivity", "PROBLEM", 108, 122], ["Middle", "ANATOMY_MODIFIER", 300, 306]]], ["Within these studies, the majority of infections detected by serology appeared to be asymptomatic.", [["infections", "DISEASE", 38, 48], ["these studies", "TEST", 7, 20], ["infections", "PROBLEM", 38, 48], ["serology", "TEST", 61, 69], ["asymptomatic", "PROBLEM", 85, 97], ["infections", "OBSERVATION", 38, 48]]], ["Within these studies, a high proportion of seropositive camel workers reported no symptoms (80%-100% among seropositive individuals).RESULTSThe 20 studies in which MERS-CoV infections were measured by serology and/or molecular testing within health-care settings are listed in Table 2 and include studies of HCWs and close contacts of patients with confirmed infection.", [["infections", "DISEASE", 173, 183], ["infection", "DISEASE", 359, 368], ["camel", "ORGANISM", 56, 61], ["MERS-CoV", "ORGANISM", 164, 172], ["patients", "ORGANISM", 335, 343], ["patients", "SPECIES", 335, 343], ["camel", "SPECIES", 56, 61], ["MERS-CoV", "SPECIES", 164, 172], ["these studies", "TEST", 7, 20], ["symptoms", "PROBLEM", 82, 90], ["RESULTSThe 20 studies", "TEST", 133, 154], ["CoV infections", "PROBLEM", 169, 183], ["serology", "TEST", 201, 209], ["molecular testing", "TEST", 217, 234], ["infection", "PROBLEM", 359, 368], ["no", "UNCERTAINTY", 79, 81], ["infection", "OBSERVATION", 359, 368]]], ["The largest molecular and serological studies among HCWs were conducted among 1,695 and 1,169 HCWs in Kingdom of Saudi Arabia (32) and the Republic of Korea (40), respectively; the authors reported evidence of infection of 1% and 1.5%, respectively.", [["infection", "DISEASE", 210, 219], ["HCWs", "ORGANISM", 52, 56], ["serological studies", "TEST", 26, 45], ["infection", "PROBLEM", 210, 219], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["evidence of", "UNCERTAINTY", 198, 209], ["infection", "OBSERVATION", 210, 219]]], ["Infection was more frequent among HCWs who did not use personal protective equipment when in contact with a patient with MERS (40) .RESULTSSince 2012, 298 of the 2,274 laboratory-confirmed cases (13.1%) reported to WHO have been reported as asymptomatic at the time of reporting, 164 of these patients were HCWs.", [["patient", "ORGANISM", 108, 115], ["patients", "ORGANISM", 293, 301], ["patient", "SPECIES", 108, 115], ["patients", "SPECIES", 293, 301], ["Infection", "PROBLEM", 0, 9], ["personal protective equipment", "TREATMENT", 55, 84], ["cases", "TEST", 189, 194]]], ["The demographic characteristics and clinical presentation of primary and secondary cases of MERS-CoV infection are listed in Table 3 .", [["MERS-CoV infection", "DISEASE", 92, 110], ["MERS-CoV", "ORGANISM", 92, 100], ["MERS-CoV", "SPECIES", 92, 100], ["MERS", "PROBLEM", 92, 96], ["CoV infection", "PROBLEM", 97, 110], ["CoV infection", "OBSERVATION", 97, 110]]], ["There were significantly more asymptomatic cases reported among secondary cases (n = 266 of 1,094; 24.3%) than among primary cases (n = 9 of 642 (1.4%); P < 0.001).", [["P", "TEST", 153, 154]]], ["Overall, no deaths were reported among patients with asymptomatic infections.", [["deaths", "DISEASE", 12, 18], ["infections", "DISEASE", 66, 76], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["deaths", "PROBLEM", 12, 18], ["asymptomatic infections", "PROBLEM", 53, 76], ["no", "UNCERTAINTY", 9, 11], ["infections", "OBSERVATION", 66, 76]]], ["Figure 2 shows the epidemic curve of MERS-CoV infections reported to WHO stratified by HCWs and non-HCWs.", [["MERS-CoV infections", "DISEASE", 37, 56], ["MERS-CoV", "ORGANISM", 37, 45], ["MERS-CoV", "SPECIES", 37, 45], ["CoV infections", "PROBLEM", 42, 56]]], ["Of the 414 MERS-CoV infections among HCWs that were reported to WHO, 164 (39.6%) were reported to be asymptomatic.Evidence of human-to-human transmission from an asymptomatic infectionWe found 4 studies that documented the duration of viral shedding from asymptomatic or mildly symptomatic individuals (55) (56) (57) (58) .", [["MERS-CoV infections", "DISEASE", 11, 30], ["MERS-CoV", "ORGANISM", 11, 19], ["human", "ORGANISM", 126, 131], ["human", "ORGANISM", 135, 140], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 135, 140], ["MERS-CoV", "SPECIES", 11, 19], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 135, 140], ["CoV infections", "PROBLEM", 16, 30], ["an asymptomatic infectionWe", "PROBLEM", 159, 186], ["viral shedding", "PROBLEM", 235, 249], ["mildly symptomatic individuals", "PROBLEM", 271, 301], ["mildly", "OBSERVATION_MODIFIER", 271, 277]]], ["Among asymptomatic, PCR-positive MERS-CoV infections, positive reverse transcriptase (RT)-PCR results were reported from the day of initial testing for as long as 28-42 days (55-58).Evidence of human-to-human transmission from an asymptomatic infectionWe found 1 study in which molecular and serological evidence of possible secondary transmission from asymptomatic individuals was reported (11) .", [["infections", "DISEASE", 42, 52], ["MERS-CoV", "ORGANISM", 33, 41], ["human", "ORGANISM", 194, 199], ["human", "ORGANISM", 203, 208], ["reverse transcriptase", "PROTEIN", 63, 84], ["human", "SPECIES", 194, 199], ["human", "SPECIES", 203, 208], ["MERS-CoV", "SPECIES", 33, 41], ["human", "SPECIES", 194, 199], ["human", "SPECIES", 203, 208], ["PCR", "TEST", 20, 23], ["CoV infections", "PROBLEM", 38, 52], ["PCR", "TEST", 90, 93], ["initial testing", "TEST", 132, 147], ["an asymptomatic infectionWe", "PROBLEM", 227, 254], ["1 study", "TEST", 261, 268], ["secondary transmission", "PROBLEM", 325, 347], ["asymptomatic individuals", "PROBLEM", 353, 377]]], ["The study was conducted as part of an investigation of 12 household contacts, in whom upper respiratory tract samples from 7 were PCR positive and an additional 5 samples were seropositive using recombinant immunofluorescence or plaque reduction neutralization test (11) .", [["upper respiratory tract samples", "ANATOMY", 86, 117], ["samples", "ANATOMY", 163, 170], ["plaque", "ANATOMY", 229, 235], ["upper respiratory tract samples", "CANCER", 86, 117], ["The study", "TEST", 0, 9], ["an investigation", "TEST", 35, 51], ["upper respiratory tract samples", "TEST", 86, 117], ["PCR", "TEST", 130, 133], ["an additional 5 samples", "TEST", 147, 170], ["recombinant immunofluorescence", "TEST", 195, 225], ["plaque reduction", "TREATMENT", 229, 245], ["neutralization test", "TEST", 246, 265], ["respiratory tract", "ANATOMY", 92, 109], ["plaque", "OBSERVATION", 229, 235]]], ["Eleven of these 12 individuals reported no symptoms at the time of sampling; this information, combined with epidemiologic data, indicated these people could have been involved in asymptomatic transmission within households.", [["individuals", "ORGANISM", 19, 30], ["people", "ORGANISM", 145, 151], ["people", "SPECIES", 145, 151], ["symptoms", "PROBLEM", 43, 51], ["epidemiologic data", "TEST", 109, 127]]], ["We found 9 studies that described molecular evidence of MERS-CoV infection among asymptomatic individuals in health-care settings (7, 32, 42, 43, 45, 46, 50, 51, 53) .", [["MERS-CoV infection", "DISEASE", 56, 74], ["MERS-CoV", "ORGANISM", 56, 64], ["MERS-CoV", "SPECIES", 56, 64], ["9 studies", "TEST", 9, 18], ["MERS", "PROBLEM", 56, 60], ["CoV infection", "PROBLEM", 61, 74], ["evidence of", "UNCERTAINTY", 44, 55], ["MERS", "OBSERVATION", 56, 60], ["CoV", "OBSERVATION_MODIFIER", 61, 64], ["infection", "OBSERVATION", 65, 74]]], ["Infectivity of an asymptomatic HCW infected with MERS-CoV was investigated in 1 study, but no evidence was found of secondary transmission to 82 HCWs with contact to the HCW with MERS-CoV infection (44) .DISCUSSIONIn this review, we found 43 studies in which molecular and/or serological evidence of MERS-CoV infection was reported.", [["MERS-CoV infection", "DISEASE", 179, 197], ["MERS-CoV infection", "DISEASE", 300, 318], ["MERS-CoV", "ORGANISM", 49, 57], ["MERS-CoV", "ORGANISM", 179, 187], ["MERS-CoV", "ORGANISM", 300, 308], ["MERS-CoV", "SPECIES", 49, 57], ["MERS-CoV", "SPECIES", 179, 187], ["MERS-CoV", "SPECIES", 300, 308], ["1 study", "TEST", 78, 85], ["CoV infection", "PROBLEM", 184, 197], ["43 studies", "TEST", 239, 249], ["MERS", "PROBLEM", 300, 304], ["CoV infection", "PROBLEM", 305, 318], ["asymptomatic", "OBSERVATION_MODIFIER", 18, 30], ["infected", "OBSERVATION", 35, 43], ["no evidence", "UNCERTAINTY", 91, 102], ["infection", "OBSERVATION", 188, 197], ["CoV", "OBSERVATION_MODIFIER", 305, 308], ["infection", "OBSERVATION", 309, 318]]], ["Outside of health-care settings, the evidence of MERS-CoV infection has largely been focused on individuals with occupational exposure to dromedaries.", [["infection", "DISEASE", 58, 67], ["dromedaries", "DISEASE", 138, 149], ["MERS-CoV", "ORGANISM", 49, 57], ["MERS-CoV", "SPECIES", 49, 57], ["MERS", "PROBLEM", 49, 53], ["CoV infection", "PROBLEM", 54, 67], ["MERS", "OBSERVATION", 49, 53], ["CoV", "OBSERVATION_MODIFIER", 54, 57], ["infection", "OBSERVATION", 58, 67]]], ["The results to date are heterogenous, and although attempts have been made to evaluate MERS-CoV genetic diversity (59, 60) , the differences in seroprevalence results to date likely reflect differences in the selection and characteristics of dromedary herds and humans tested.", [["humans", "ORGANISM", 262, 268], ["humans", "SPECIES", 262, 268], ["MERS-CoV", "SPECIES", 87, 95], ["humans", "SPECIES", 262, 268], ["dromedary herds", "TREATMENT", 242, 257], ["heterogenous", "OBSERVATION", 24, 36]]], ["The available evidence of the MERS-CoV epidemiologic and genetic characteristics does not suggest there are differences in the virus's ability to infect humans.", [["humans", "ORGANISM", 153, 159], ["humans", "SPECIES", 153, 159], ["humans", "SPECIES", 153, 159], ["the virus", "PROBLEM", 123, 132]]], ["Evidence supports that individuals with occupational exposure to dromedaries have higher rates of seroprevalence compared with household contacts of patients with confirmed MERS-CoV infection, likely reflecting more intense, unprotected exposures to MERS-CoV through dromedary secretions (61) .", [["MERS-CoV infection", "DISEASE", 173, 191], ["patients", "ORGANISM", 149, 157], ["MERS-CoV", "ORGANISM", 173, 181], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 250, 258], ["patients", "SPECIES", 149, 157], ["MERS-CoV", "SPECIES", 173, 181], ["MERS-CoV", "SPECIES", 250, 258], ["CoV infection", "PROBLEM", 178, 191], ["CoV through dromedary secretions", "PROBLEM", 255, 287], ["CoV", "ANATOMY", 178, 181], ["infection", "OBSERVATION", 182, 191], ["likely reflecting", "UNCERTAINTY", 193, 210], ["more intense", "OBSERVATION_MODIFIER", 211, 223]]], ["That these individuals have subclinical infection and do not develop disease is likely because those with occupational exposure tend to be younger and healthier, without underlying high-risk conditions such as hypertension, diabetes, and renal failure.", [["renal", "ANATOMY", 238, 243], ["infection", "DISEASE", 40, 49], ["hypertension", "DISEASE", 210, 222], ["diabetes", "DISEASE", 224, 232], ["renal failure", "DISEASE", 238, 251], ["individuals", "ORGANISM", 11, 22], ["renal", "ORGAN", 238, 243], ["subclinical infection", "PROBLEM", 28, 49], ["disease", "PROBLEM", 69, 76], ["underlying high-risk conditions", "PROBLEM", 170, 201], ["hypertension", "PROBLEM", 210, 222], ["diabetes", "PROBLEM", 224, 232], ["renal failure", "PROBLEM", 238, 251], ["subclinical", "OBSERVATION_MODIFIER", 28, 39], ["infection", "OBSERVATION", 40, 49], ["hypertension", "OBSERVATION", 210, 222], ["diabetes", "OBSERVATION", 224, 232], ["renal", "ANATOMY", 238, 243], ["failure", "OBSERVATION", 244, 251]]], ["Variations in the seroprevalence rates by study are also likely due to variations in methodologies, including the timing of sample collection, serologic assays used, and interpretation of assay results.DISCUSSIONAlthough the majority of human MERS-CoV infections have been reported to WHO from countries in the Arabian Peninsula, particularly Kingdom of Saudi Arabia, there is increasing evidence of infection in dromedary camels in herds throughout Africa and South Asia (62) .", [["sample", "ANATOMY", 124, 130], ["MERS-CoV infections", "DISEASE", 243, 262], ["infection", "DISEASE", 400, 409], ["human", "ORGANISM", 237, 242], ["MERS-CoV", "ORGANISM", 243, 251], ["human", "SPECIES", 237, 242], ["human MERS-CoV", "SPECIES", 237, 251], ["the seroprevalence rates", "TEST", 14, 38], ["variations in methodologies", "PROBLEM", 71, 98], ["sample collection", "TEST", 124, 141], ["serologic assays", "TEST", 143, 159], ["assay", "TEST", 188, 193], ["CoV infections", "PROBLEM", 248, 262], ["infection in dromedary camels", "PROBLEM", 400, 429], ["likely due to", "UNCERTAINTY", 57, 70], ["increasing", "OBSERVATION_MODIFIER", 377, 387], ["evidence of", "UNCERTAINTY", 388, 399], ["infection", "OBSERVATION", 400, 409]]], ["Additional serological and molecular epidemiology studies at the dromedary-human interface using a standardized approach and consistent methodology, in the Arabian Peninsula and in Africa and South Asia, are needed to further understand this observed heterogeneity-that is, whether the observed differences in evidence of infection outside health-care settings may be attributable to genetic variation of the virus across different geographic regions and/or to factors and behaviors in human populations in these regions, which may change the susceptibility to infection.", [["infection", "DISEASE", 322, 331], ["infection", "DISEASE", 561, 570], ["human", "ORGANISM", 75, 80], ["human", "ORGANISM", 486, 491], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 486, 491], ["human", "SPECIES", 486, 491], ["Additional serological", "TEST", 0, 22], ["molecular epidemiology studies", "TEST", 27, 57], ["a standardized approach", "TREATMENT", 97, 120], ["infection", "PROBLEM", 322, 331], ["genetic variation", "PROBLEM", 384, 401], ["the virus", "PROBLEM", 405, 414], ["the susceptibility to infection", "PROBLEM", 539, 570], ["Arabian Peninsula", "ANATOMY", 156, 173], ["infection", "OBSERVATION", 322, 331], ["infection", "OBSERVATION", 561, 570]]], ["WHO is currently supporting studies underway in several countries in the Middle East, Africa, and South Asia in which the extent of infection in occupationally exposed persons is being evaluated .", [["infection", "DISEASE", 132, 141], ["persons", "ORGANISM", 168, 175], ["persons", "SPECIES", 168, 175], ["infection", "PROBLEM", 132, 141], ["Middle", "ANATOMY_MODIFIER", 73, 79], ["infection", "OBSERVATION", 132, 141]]], ["The results of such studies can contribute to better understanding the geographic reach of MERS-CoV in dromedaries and humans.DISCUSSIONWithin health-care settings, the detection of asymptomatic, PCR-positive infection has been reported to WHO from affected member states and also documented in 10HCW Contacts of Patients With Confirmed MERS-CoVHealth published studies.", [["infection", "DISEASE", 209, 218], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 91, 99], ["humans", "ORGANISM", 119, 125], ["Patients", "ORGANISM", 313, 321], ["humans", "SPECIES", 119, 125], ["Patients", "SPECIES", 313, 321], ["MERS-CoV", "SPECIES", 91, 99], ["humans", "SPECIES", 119, 125], ["such studies", "TEST", 15, 27], ["the detection", "TEST", 165, 178], ["asymptomatic, PCR", "PROBLEM", 182, 199], ["positive infection", "PROBLEM", 200, 218], ["infection", "OBSERVATION", 209, 218]]], ["Although onward transmission was not investigated in those studies, the researchers did capture evidence of RNA shedding, which suggests human-tohuman transmission is possible from individuals with no signs or symptoms of infection.", [["infection", "DISEASE", 222, 231], ["human", "ORGANISM", 137, 142], ["tohuman", "GENE_OR_GENE_PRODUCT", 143, 150], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 137, 142], ["those studies", "TEST", 53, 66], ["RNA shedding", "PROBLEM", 108, 120], ["symptoms", "PROBLEM", 210, 218], ["infection", "PROBLEM", 222, 231], ["RNA shedding", "OBSERVATION", 108, 120], ["infection", "OBSERVATION", 222, 231]]], ["This is supported by evidence documenting duration of viral shedding beyond 3 weeks in patients with subclinical MERS-CoV infection (55) (56) (57) (58) .", [["MERS-CoV infection", "DISEASE", 113, 131], ["patients", "ORGANISM", 87, 95], ["MERS-CoV", "ORGANISM", 113, 121], ["patients", "SPECIES", 87, 95], ["MERS-CoV", "SPECIES", 113, 121], ["viral shedding", "PROBLEM", 54, 68], ["subclinical MERS", "PROBLEM", 101, 117], ["CoV infection", "PROBLEM", 118, 131], ["viral", "OBSERVATION_MODIFIER", 54, 59]]], ["At the same time, the evidence for acute, asymptomatic MERS-CoV infection described in this review does not represent the full extent of subclinical infection.", [["MERS-CoV infection", "DISEASE", 55, 73], ["infection", "DISEASE", 149, 158], ["MERS-CoV", "ORGANISM", 55, 63], ["MERS-CoV", "SPECIES", 55, 63], ["acute, asymptomatic MERS", "PROBLEM", 35, 59], ["CoV infection", "PROBLEM", 60, 73], ["subclinical infection", "PROBLEM", 137, 158], ["evidence for", "UNCERTAINTY", 22, 34], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["CoV", "OBSERVATION_MODIFIER", 60, 63], ["infection", "OBSERVATION", 64, 73], ["subclinical", "OBSERVATION_MODIFIER", 137, 148], ["infection", "OBSERVATION", 149, 158]]], ["Asymptomatic contacts clear the virus more quickly than do symptomatic patients (58) and antibody titers in the former are likely to be lower, if they seroconvert at all, than in infected patients exhibiting symptoms (63) .", [["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 188, 196], ["the virus", "PROBLEM", 28, 37], ["antibody titers", "TEST", 89, 104], ["symptoms", "PROBLEM", 208, 216], ["likely to be", "UNCERTAINTY", 123, 135], ["lower", "OBSERVATION", 136, 141]]], ["Timely and repeated biological specimen collection is needed to capture viral shedding and antibody kinetics of symptomatic and asymptomatic contacts (11) .", [["specimen", "ANATOMY", 31, 39], ["repeated biological specimen collection", "TEST", 11, 50], ["viral shedding", "PROBLEM", 72, 86], ["symptomatic and asymptomatic contacts", "PROBLEM", 112, 149]]], ["This can be achieved if all high-risk contacts of patients with confirmed MERS-CoV infection are identified during an outbreak and then tested using molecular and serologic laboratory assays, regardless of whether the individual exhibits symptoms.", [["MERS-CoV infection", "DISEASE", 74, 92], ["patients", "ORGANISM", 50, 58], ["MERS-CoV", "ORGANISM", 74, 82], ["patients", "SPECIES", 50, 58], ["MERS-CoV", "SPECIES", 74, 82], ["CoV infection", "PROBLEM", 79, 92], ["serologic laboratory assays", "TEST", 163, 190], ["the individual exhibits symptoms", "PROBLEM", 214, 246], ["infection", "OBSERVATION", 83, 92]]], ["In outbreak settings, without the inclusion of testing of all contacts, the identification of chains of transmission may be incomplete.HCW Contacts of Patients With Confirmed MERS-CoVIndeed, the latest WHO surveillance guidelines recommend that all contacts of patients with laboratoryconfirmed MERS outside of health care facilities should be placed under active surveillance for 14 days after the last exposure to the confirmed case and that any contacts with symptoms of respiratory illness should be tested for MERS-CoV infection (64) .", [["respiratory", "ANATOMY", 474, 485], ["respiratory illness", "DISEASE", 474, 493], ["MERS-CoV infection", "DISEASE", 515, 533], ["Patients", "ORGANISM", 151, 159], ["patients", "ORGANISM", 261, 269], ["MERS-CoV", "ORGANISM", 515, 523], ["Patients", "SPECIES", 151, 159], ["patients", "SPECIES", 261, 269], ["MERS-CoV", "SPECIES", 515, 523], ["testing", "TEST", 47, 54], ["symptoms", "PROBLEM", 462, 470], ["respiratory illness", "PROBLEM", 474, 493], ["MERS", "PROBLEM", 515, 519], ["CoV infection", "PROBLEM", 520, 533]]], ["If feasible, we recommend that follow-up should include molecular testing, regardless of the development of symptoms.", [["molecular testing", "TEST", 56, 73], ["symptoms", "PROBLEM", 108, 116]]], ["In addition, studies conducted of high-risk workers, which have typically only included serologic testing, should also include molecular testing of upper respiratory samples in an attempt to capture viral carriage.HCW Contacts of Patients With Confirmed MERS-CoVDespite these limitations in our current knowledge, the findings of our review reinforce the evidence that HCWs are more likely to be at risk of MERS-CoV infection due to close unprotected contact with patients with MERS patients prior to their diagnosis, particularly when aerosolizing procedures are performed.", [["upper respiratory samples", "ANATOMY", 148, 173], ["MERS-CoV infection", "DISEASE", 407, 425], ["Patients", "ORGANISM", 230, 238], ["HCWs", "ORGANISM", 369, 373], ["MERS-CoV", "ORGANISM", 407, 415], ["patients", "ORGANISM", 464, 472], ["patients", "ORGANISM", 483, 491], ["Patients", "SPECIES", 230, 238], ["patients", "SPECIES", 464, 472], ["patients", "SPECIES", 483, 491], ["MERS-CoV", "SPECIES", 407, 415], ["studies", "TEST", 13, 20], ["serologic testing", "TEST", 88, 105], ["molecular testing", "TEST", 127, 144], ["upper respiratory samples", "PROBLEM", 148, 173], ["viral carriage", "PROBLEM", 199, 213], ["MERS", "PROBLEM", 407, 411], ["CoV infection", "PROBLEM", 412, 425], ["aerosolizing procedures", "TREATMENT", 536, 559], ["upper", "ANATOMY_MODIFIER", 148, 153], ["respiratory", "ANATOMY", 154, 165]]], ["Because HCWs tend to be younger and healthier than patients in whom severe MERS develops, HCWs have fewer symptoms, if any, and present a silent risk of human-to-human transmission to others.", [["MERS", "DISEASE", 75, 79], ["HCWs", "ORGANISM", 8, 12], ["patients", "ORGANISM", 51, 59], ["human", "ORGANISM", 153, 158], ["human", "ORGANISM", 162, 167], ["patients", "SPECIES", 51, 59], ["human", "SPECIES", 153, 158], ["human", "SPECIES", 162, 167], ["human", "SPECIES", 153, 158], ["human", "SPECIES", 162, 167], ["fewer symptoms", "PROBLEM", 100, 114]]], ["Among HCW contacts, detailed studies of viral shedding and immune response of asymptomatic, PCR-positive MERS-CoV infections are urgently needed and should be conducted when outbreaks occur and enhanced surveillance is put in place by government and hospital officials.HCW Contacts of Patients With Confirmed MERS-CoVSurveillance and testing for MERS-CoV have improved substantially since the virus was first discovered in 2012.", [["infections", "DISEASE", 114, 124], ["MERS-CoV", "ORGANISM", 105, 113], ["Patients", "ORGANISM", 285, 293], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 346, 354], ["Patients", "SPECIES", 285, 293], ["MERS-CoV", "SPECIES", 105, 113], ["MERS-CoV", "SPECIES", 346, 354], ["viral shedding", "PROBLEM", 40, 54], ["asymptomatic", "PROBLEM", 78, 90], ["PCR", "TEST", 92, 95], ["positive MERS", "PROBLEM", 96, 109], ["CoV infections", "PROBLEM", 110, 124], ["enhanced surveillance", "TEST", 194, 215], ["testing", "TEST", 334, 341], ["MERS", "PROBLEM", 346, 350], ["CoV", "PROBLEM", 351, 354], ["the virus", "PROBLEM", 389, 398]]], ["In affected countries, visual respiratory triage systems before a patient enters the emergency department have been introduced; some emergency departments in affected countries have been restructured for enhanced triage of patients with respiratory symptoms; trainings specific to infection prevention and control of respiratory pathogens have been introduced and reintroduced in high-risk areas and hospitals with high turnover of HCWs; and audits of hospitals for compliance to specific infection prevention and control measures are regularly performed (6) .", [["respiratory", "ANATOMY", 237, 248], ["respiratory", "ANATOMY", 317, 328], ["respiratory symptoms", "DISEASE", 237, 257], ["infection", "DISEASE", 281, 290], ["respiratory pathogens", "DISEASE", 317, 338], ["infection", "DISEASE", 489, 498], ["patient", "ORGANISM", 66, 73], ["patients", "ORGANISM", 223, 231], ["patient", "SPECIES", 66, 73], ["patients", "SPECIES", 223, 231], ["respiratory symptoms", "PROBLEM", 237, 257], ["trainings", "TREATMENT", 259, 268], ["infection prevention", "TREATMENT", 281, 301], ["respiratory pathogens", "PROBLEM", 317, 338], ["specific infection prevention", "TREATMENT", 480, 509], ["infection", "OBSERVATION", 489, 498]]], ["In addition, the systematic testing of HCWs, extending beyond nurses and doctors to include reception staff, cleaners, technicians, and so forth, regardless of the development of symptoms, as required by the latest infection prevention and control guidelines for HCWs by WHO and Kingdom of Saudi Arabia, for example, has detected subclinical and asymptomatic infections that likely would have gone undetected in past outbreaks.", [["infection", "DISEASE", 215, 224], ["infections", "DISEASE", 359, 369], ["the systematic testing", "TEST", 13, 35], ["symptoms", "PROBLEM", 179, 187], ["the latest infection prevention", "TREATMENT", 204, 235], ["subclinical and asymptomatic infections", "PROBLEM", 330, 369], ["subclinical", "OBSERVATION_MODIFIER", 330, 341], ["asymptomatic", "OBSERVATION_MODIFIER", 346, 358], ["infections", "OBSERVATION", 359, 369]]], ["Asymptomatic infections may have played a role in extensive secondary transmission in health-care settings before the latest guidelines were introduced, and the impact of such policies may be reflected in the lower peaks on the global MERS-CoV epidemic curve since 2016.", [["infections", "DISEASE", 13, 23], ["Asymptomatic infections", "PROBLEM", 0, 23], ["infections", "OBSERVATION", 13, 23], ["lower peaks", "OBSERVATION_MODIFIER", 209, 220]]], ["Without this level of contact follow-up in community settings, the extent of asymptomatic infections in the community will remain unknown.HCW Contacts of Patients With Confirmed MERS-CoVScreening of HCWs with exposure to patients infected with MERS-CoV may be feasible for preventing human-tohuman transmission in health-care settings, and appears to be effective in Kingdom of Saudi Arabia and other affected countries in which this infection prevention and control measure has been introduced.", [["infections", "DISEASE", 90, 100], ["infection", "DISEASE", 434, 443], ["Patients", "ORGANISM", 154, 162], ["HCWs", "ORGANISM", 199, 203], ["patients", "ORGANISM", 221, 229], ["MERS-CoV", "ORGANISM", 244, 252], ["human", "ORGANISM", 284, 289], ["Patients", "SPECIES", 154, 162], ["patients", "SPECIES", 221, 229], ["human", "SPECIES", 284, 289], ["MERS-CoV", "SPECIES", 244, 252], ["human", "SPECIES", 284, 289], ["asymptomatic infections", "PROBLEM", 77, 100], ["this infection prevention", "TREATMENT", 429, 454], ["asymptomatic", "OBSERVATION_MODIFIER", 77, 89], ["infections", "OBSERVATION", 90, 100], ["infection", "OBSERVATION", 434, 443]]], ["Outside health-care settings, the feasibility of screening may be reduced, particularly given the difficulty in detecting asymptomatic infections.", [["infections", "DISEASE", 135, 145], ["screening", "TEST", 49, 58], ["asymptomatic infections", "PROBLEM", 122, 145], ["asymptomatic", "OBSERVATION_MODIFIER", 122, 134], ["infections", "OBSERVATION", 135, 145]]], ["Therefore, transmission of MERS-CoV outside health-care settings should be expected to continue until zoonotic spillover from dromedaries can be interrupted.", [["dromedaries", "DISEASE", 126, 137], ["MERS-CoV", "ORGANISM", 27, 35], ["MERS-CoV", "SPECIES", 27, 35]]]], "1e0f6c6844f4c0c4bce43b89c3642296545ba4ec": [["IntroductionSince many serotypes of viruses cause acute respiratory disease, vaccination against most of them is impracticable.", [["respiratory", "ANATOMY", 56, 67], ["acute respiratory disease", "DISEASE", 50, 75], ["viruses", "PROBLEM", 36, 43], ["acute respiratory disease", "PROBLEM", 50, 75], ["vaccination", "TREATMENT", 77, 88], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["respiratory disease", "OBSERVATION", 56, 75]]], ["The exploitation of viral interference for prophylaxis is especially attractive because of its wide application and the possibility of offering protection against agents for which no other means of prophylaxis is currently available.IntroductionIt appears that acute respiratory disease in man can be prevented by viral interference.", [["respiratory", "ANATOMY", 267, 278], ["acute respiratory disease", "DISEASE", 261, 286], ["man", "ORGANISM", 290, 293], ["man", "SPECIES", 290, 293], ["viral interference", "TREATMENT", 20, 38], ["prophylaxis", "TREATMENT", 43, 54], ["agents", "TREATMENT", 163, 169], ["prophylaxis", "TREATMENT", 198, 209], ["acute respiratory disease", "PROBLEM", 261, 286], ["viral interference", "OBSERVATION", 20, 38], ["acute", "OBSERVATION_MODIFIER", 261, 266], ["respiratory disease", "OBSERVATION", 267, 286]]], ["TYR~ELL and R~EO (1) showed that volunteers inoculated with influenza during the incubation period of a rhinovirus were protected against influenza infection, although this protection did not occur during the incubation period of a coronavirus.", [["influenza", "DISEASE", 60, 69], ["rhinovirus", "DISEASE", 104, 114], ["influenza infection", "DISEASE", 138, 157], ["coronavirus", "DISEASE", 232, 243], ["TYR", "GENE_OR_GENE_PRODUCT", 0, 3], ["volunteers", "ORGANISM", 33, 43], ["rhinovirus", "ORGANISM", 104, 114], ["coronavirus", "ORGANISM", 232, 243], ["TYR", "PROTEIN", 0, 3], ["TYR~ELL and R~EO", "TEST", 0, 16], ["influenza", "PROBLEM", 60, 69], ["a rhinovirus", "PROBLEM", 102, 114], ["influenza infection", "PROBLEM", 138, 157], ["a coronavirus", "PROBLEM", 230, 243], ["rhinovirus", "OBSERVATION", 104, 114]]], ["However, both viruses primarily affect the respiratory system, so that purely local factors may have operated.", [["respiratory system", "ANATOMY", 43, 61], ["viruses", "OBSERVATION", 14, 21], ["respiratory system", "ANATOMY", 43, 61]]], ["Interference by a heterologous virus was observed by VS~LLA et al. (2) when they showed that pre-school children vaccinated against rubella were protected against acute upper respiratory tract illness for at least 12 weeks after vaccination.", [["upper respiratory tract", "ANATOMY", 169, 192], ["rubella", "DISEASE", 132, 139], ["acute upper respiratory tract illness", "DISEASE", 163, 200], ["children", "ORGANISM", 104, 112], ["rubella", "ORGANISM", 132, 139], ["upper", "ORGANISM_SUBDIVISION", 169, 174], ["respiratory tract", "ORGANISM_SUBDIVISION", 175, 192], ["children", "SPECIES", 104, 112], ["rubella", "SPECIES", 132, 139], ["a heterologous virus", "PROBLEM", 16, 36], ["rubella", "PROBLEM", 132, 139], ["acute upper respiratory tract illness", "PROBLEM", 163, 200], ["vaccination", "TREATMENT", 229, 240], ["upper", "ANATOMY_MODIFIER", 169, 174], ["respiratory tract", "ANATOMY", 175, 192]]], ["This protection was greater than that afforded by a parainfluenza virus vaccine.IntroductionRecent epidemiological evidence from the U.S.S.R. has suggested that interference may be exploited by giving a live enterovirus as a vaccine to prevent viral respiratory disease, and that the protection induced is mediated by circulating interferon.", [["respiratory", "ANATOMY", 250, 261], ["parainfluenza", "DISEASE", 52, 65], ["enterovirus", "DISEASE", 208, 219], ["viral respiratory disease", "DISEASE", 244, 269], ["parainfluenza virus", "ORGANISM", 52, 71], ["enterovirus", "ORGANISM", 208, 219], ["interferon", "GENE_OR_GENE_PRODUCT", 330, 340], ["circulating interferon", "PROTEIN", 318, 340], ["parainfluenza", "SPECIES", 52, 65], ["parainfluenza virus", "SPECIES", 52, 71], ["This protection", "TREATMENT", 0, 15], ["a parainfluenza virus vaccine", "TREATMENT", 50, 79], ["a live enterovirus", "TREATMENT", 201, 219], ["a vaccine", "TREATMENT", 223, 232], ["viral respiratory disease", "PROBLEM", 244, 269], ["circulating interferon", "TREATMENT", 318, 340], ["respiratory disease", "OBSERVATION", 250, 269]]], ["VOROSRInOVA (3) reported that an enterovirns vaccine had been successfully used for the prophylaxis of influenza and other acute respiratory diseases.", [["respiratory", "ANATOMY", 129, 140], ["influenza", "DISEASE", 103, 112], ["acute respiratory diseases", "DISEASE", 123, 149], ["an enterovirns vaccine", "TREATMENT", 30, 52], ["influenza", "PROBLEM", 103, 112], ["other acute respiratory diseases", "PROBLEM", 117, 149], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["respiratory diseases", "OBSERVATION", 129, 149]]], ["In many trials, a 1.9 to 5.1-fold reduction in the incidence of these diseases was observed in vaccinees.", [["a 1.9 to 5.1-fold reduction", "TREATMENT", 16, 43], ["these diseases", "PROBLEM", 64, 78], ["reduction", "OBSERVATION_MODIFIER", 34, 43], ["diseases", "OBSERVATION", 70, 78]]], ["Furthermore, interferon was measurable in the blood, nasal washings and urine of vaccinees, the maximum titres being observed on the 5th to 8th days.", [["blood", "ANATOMY", 46, 51], ["nasal washings", "ANATOMY", 53, 67], ["urine", "ANATOMY", 72, 77], ["interferon", "GENE_OR_GENE_PRODUCT", 13, 23], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["nasal washings", "ORGANISM_SUBSTANCE", 53, 67], ["urine", "ORGANISM_SUBSTANCE", 72, 77], ["interferon", "PROTEIN", 13, 23], ["interferon", "TREATMENT", 13, 23], ["the blood", "TEST", 42, 51], ["nasal washings", "TEST", 53, 67], ["vaccinees", "TREATMENT", 81, 90], ["the maximum titres", "TEST", 92, 110], ["interferon", "OBSERVATION", 13, 23], ["nasal", "ANATOMY", 53, 58]]], ["However, no studies of the efficacy of the procedure in an isolation unit have been reported.", [["the procedure", "TREATMENT", 39, 52], ["an isolation unit", "TREATMENT", 56, 73]]], ["We thought it important to study the effect of a vaccine in isolated volunteers both by measuring interferon production and by the results of challenge with an interferon-sensitive virus.VaccineThe enterovirus, live epidemiological vaccine type 4 (LEV4), was kindly supplied by Professor M. X. Voroshilova.", [["enterovirus", "DISEASE", 198, 209], ["volunteers", "ORGANISM", 69, 79], ["interferon", "GENE_OR_GENE_PRODUCT", 98, 108], ["interferon", "GENE_OR_GENE_PRODUCT", 160, 170], ["enterovirus", "ORGANISM", 198, 209], ["LEV4", "ORGANISM", 248, 252], ["interferon", "PROTEIN", 98, 108], ["interferon", "PROTEIN", 160, 170], ["a vaccine", "TREATMENT", 47, 56], ["an interferon-sensitive virus", "PROBLEM", 157, 186], ["Vaccine", "TREATMENT", 187, 194], ["The enterovirus", "PROBLEM", 194, 209]]], ["The virus was completely neutralised by W.I-I.O. reference echo type 1 antiserum in monkey kidney tissue culture.", [["kidney tissue", "ANATOMY", 91, 104], ["monkey", "ORGANISM", 84, 90], ["kidney tissue", "TISSUE", 91, 104], ["monkey", "SPECIES", 84, 90], ["The virus", "PROBLEM", 0, 9], ["echo", "TEST", 59, 63], ["kidney tissue culture", "TEST", 91, 112], ["virus", "OBSERVATION", 4, 9], ["kidney", "ANATOMY", 91, 97]]], ["Other agents were excluded by cultivation in standard bacteriological media and tissue cultures.", [["tissue cultures", "ANATOMY", 80, 95], ["tissue cultures", "CELL", 80, 95], ["Other agents", "TREATMENT", 0, 12], ["tissue cultures", "TEST", 80, 95]]], ["The pathogenicity of LEVI for the central nervous system of cynomolgus monkeys (~FI. irus) was tested at the National Institute for Biological Standards and Control.", [["central nervous system", "ANATOMY", 34, 56], ["LEVI", "CHEMICAL", 21, 25], ["LEVI", "GENE_OR_GENE_PRODUCT", 21, 25], ["central nervous system", "ANATOMICAL_SYSTEM", 34, 56], ["cynomolgus monkeys", "ORGANISM", 60, 78], ["LEVI", "PROTEIN", 21, 25], ["cynomolgus monkeys", "SPECIES", 60, 78], ["cynomolgus monkeys", "SPECIES", 60, 78], ["LEVI", "TEST", 21, 25], ["Biological Standards and Control", "TREATMENT", 132, 164], ["central", "ANATOMY_MODIFIER", 34, 41], ["nervous system", "ANATOMY", 42, 56]]], ["The vaccine was injected directly into the thalamus and lumbo-saeral region of the spinal cord of 24 animals.", [["thalamus", "ANATOMY", 43, 51], ["lumbo-saeral region", "ANATOMY", 56, 75], ["spinal cord", "ANATOMY", 83, 94], ["thalamus", "CANCER", 43, 51], ["lumbo-saeral region", "TISSUE", 56, 75], ["spinal cord", "ORGAN", 83, 94], ["The vaccine", "TREATMENT", 0, 11], ["thalamus", "ANATOMY", 43, 51], ["lumbo", "ANATOMY_MODIFIER", 56, 61], ["-saeral", "ANATOMY_MODIFIER", 61, 68], ["region", "ANATOMY_MODIFIER", 69, 75], ["spinal cord", "ANATOMY", 83, 94]]], ["There were no clinical or histological responses attributable to viral activity.Challenge VirusThe challenge virus, rhinovirus type 4 (RV4) was prepared from nasal washings of infected volunteers and had not been passaged in tissue culture.Procedures in VolunteersThe subjects were healthy adults aged 18--50 who were housed in isolation at the Common Cold Unit, Salisbury, and observed by standardised methods described by Tu (4) .", [["nasal washings", "ANATOMY", 158, 172], ["tissue culture", "ANATOMY", 225, 239], ["Virus", "ORGANISM", 90, 95], ["rhinovirus type 4", "ORGANISM", 116, 133], ["RV4", "ORGANISM", 135, 138], ["volunteers", "ORGANISM", 185, 195], ["tissue", "TISSUE", 225, 231], ["RV4", "SPECIES", 135, 138], ["clinical or histological responses", "PROBLEM", 14, 48], ["viral activity", "PROBLEM", 65, 79], ["Challenge Virus", "TREATMENT", 80, 95], ["The challenge virus", "TREATMENT", 95, 114], ["rhinovirus type 4 (RV4)", "TREATMENT", 116, 139], ["nasal washings", "TREATMENT", 158, 172], ["infected volunteers", "PROBLEM", 176, 195], ["tissue culture", "TEST", 225, 239], ["no", "UNCERTAINTY", 11, 13], ["viral activity", "OBSERVATION", 65, 79], ["nasal", "ANATOMY", 158, 163], ["washings", "OBSERVATION", 164, 172], ["infected", "OBSERVATION", 176, 184]]], ["All clinical assessments were made under double blind conditions and at the end of the trial a clinical symptom score was calculated for each volunteer.", [["All clinical assessments", "TEST", 0, 24], ["a clinical symptom score", "TEST", 93, 117]]], ["We excluded volunteers with serum haemagglutination inhibition (HAI) titres of 1 in 4 or more against RV4 using the method of :REED and IIALL (5).2.g.", [["serum", "ANATOMY", 28, 33], ["volunteers", "ORGANISM", 12, 22], ["serum", "ORGANISM_SUBSTANCE", 28, 33], ["serum haemagglutination inhibition", "TEST", 28, 62]]], ["Specimens and Isolation o/LEVg, R V g and Inter/eronThroat swabs and faeces for enterovirus titration were collected before LEV4 inoculation and before and after RV 4 challenge.", [["Specimens", "ANATOMY", 0, 9], ["faeces", "ANATOMY", 69, 75], ["R V g", "GENE_OR_GENE_PRODUCT", 32, 37], ["faeces", "ORGANISM_SUBSTANCE", 69, 75], ["enterovirus", "ORGANISM", 80, 91], ["enterovirus", "SPECIES", 80, 91], ["LEV4", "SPECIES", 124, 128], ["Specimens", "TEST", 0, 9], ["LEVg", "TEST", 26, 30], ["R V g", "TREATMENT", 32, 37], ["Inter/eronThroat swabs", "TREATMENT", 42, 64], ["enterovirus titration", "TREATMENT", 80, 101], ["LEV4 inoculation", "TREATMENT", 124, 140], ["RV 4 challenge", "TREATMENT", 162, 176]]], ["Nasal washings for I~V 4 titration and interferon were ccllected before and on sever M oceassions after the :RV4 challenge.", [["Nasal", "ANATOMY", 0, 5], ["interferon", "GENE_OR_GENE_PRODUCT", 39, 49], ["interferon", "PROTEIN", 39, 49], ["Nasal washings", "TEST", 0, 14], ["I~V 4 titration", "TREATMENT", 19, 34], ["interferon", "TREATMENT", 39, 49], ["RV4 challenge", "TREATMENT", 109, 122]]], ["Blood was taken before the LEV 4 inoculation, on alternate days for 6 days afterwards, and about 17 days after rhinovirus challenge. ~ The first and last sera were used to measure tIAI and neutralising antibodies to RV4; interferon was measured in all specimens.", [["Blood", "ANATOMY", 0, 5], ["sera", "ANATOMY", 154, 158], ["specimens", "ANATOMY", 252, 261], ["LEV", "CHEMICAL", 27, 30], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["rhinovirus", "ORGANISM", 111, 121], ["sera", "ORGANISM_SUBSTANCE", 154, 158], ["tIAI", "GENE_OR_GENE_PRODUCT", 180, 184], ["interferon", "GENE_OR_GENE_PRODUCT", 221, 231], ["tIAI", "PROTEIN", 180, 184], ["neutralising antibodies", "PROTEIN", 189, 212], ["RV4", "PROTEIN", 216, 219], ["interferon", "PROTEIN", 221, 231], ["RV4", "SPECIES", 216, 219], ["Blood", "TEST", 0, 5], ["the LEV 4 inoculation", "TREATMENT", 23, 44], ["rhinovirus challenge", "TREATMENT", 111, 131], ["last sera", "TEST", 149, 158], ["tIAI", "TEST", 180, 184], ["neutralising antibodies", "TEST", 189, 212], ["interferon", "TREATMENT", 221, 231]]], ["All specimens were collected from both test and control groups.2.g.", [["specimens", "ANATOMY", 4, 13], ["All specimens", "TEST", 0, 13]]], ["Specimens and Isolation o/LEVg, R V g and Inter/eronFaeces were homogenised with sterile applicator sticks to make a 10 per cent suspension in nutrient broth with antibiotics.", [["Specimens", "ANATOMY", 0, 9], ["R V g", "GENE_OR_GENE_PRODUCT", 32, 37], ["Specimens", "TEST", 0, 9], ["LEVg", "TREATMENT", 26, 30], ["R V g", "TREATMENT", 32, 37], ["Inter/eronFaeces", "TREATMENT", 42, 58], ["sterile applicator sticks", "TREATMENT", 81, 106], ["antibiotics", "TREATMENT", 163, 174]]], ["Throat swabs were collected into a similar medium.", [["Throat swabs", "ANATOMY", 0, 12], ["Throat swabs", "ORGANISM_SUBSTANCE", 0, 12], ["Throat swabs", "TEST", 0, 12]]], ["Isolations and titrations were performed in continuous monkey kidney tissue culture, either VERO or V3, in which the enterovirus produced typical eytopathie effect.", [["kidney tissue", "ANATOMY", 62, 75], ["enterovirus", "DISEASE", 117, 128], ["monkey", "ORGANISM", 55, 61], ["kidney tissue", "TISSUE", 62, 75], ["enterovirus", "ORGANISM", 117, 128], ["eytopathie", "CANCER", 146, 156], ["titrations", "TREATMENT", 15, 25], ["continuous monkey kidney tissue culture", "TEST", 44, 83], ["the enterovirus", "PROBLEM", 113, 128], ["typical eytopathie effect", "PROBLEM", 138, 163], ["eytopathie effect", "OBSERVATION", 146, 163]]], ["Both these cell lines were insensitive to rhinovirus type 4.2.g.", [["cell lines", "ANATOMY", 11, 21], ["cell lines", "CELL", 11, 21], ["rhinovirus", "ORGANISM", 42, 52], ["cell lines", "CELL_LINE", 11, 21], ["rhinovirus type", "TEST", 42, 57], ["cell lines", "OBSERVATION", 11, 21]]], ["Specimens and Isolation o/LEVg, R V g and Inter/eronNasal washings were tested in parallel in rhinovirus-sensitive HeLa cells as described by S$OT~ and TYRRELL (6) , and in monkey kidney cells.", [["Specimens", "ANATOMY", 0, 9], ["HeLa cells", "ANATOMY", 115, 125], ["kidney cells", "ANATOMY", 180, 192], ["R V g", "GENE_OR_GENE_PRODUCT", 32, 37], ["rhinovirus", "ORGANISM", 94, 104], ["HeLa cells", "CELL", 115, 125], ["monkey", "ORGANISM", 173, 179], ["kidney cells", "CELL", 180, 192], ["HeLa cells", "CELL_LINE", 115, 125], ["monkey kidney cells", "CELL_TYPE", 173, 192], ["Specimens", "TEST", 0, 9], ["LEVg", "TEST", 26, 30], ["R V g", "TREATMENT", 32, 37], ["Inter/eronNasal washings", "TEST", 42, 66], ["rhinovirus", "PROBLEM", 94, 104], ["OT", "TEST", 144, 146], ["TYRRELL", "TEST", 152, 159], ["kidney", "ANATOMY", 180, 186]]], ["SpecimEns showing an enterovirus eytopathie effect in monkey kidney cells were re-tested in HeLa cells in the presence of antiserum to echovirus 1, used at 30 times its neutralising titre.", [["kidney cells", "ANATOMY", 61, 73], ["HeLa cells", "ANATOMY", 92, 102], ["SpecimEns", "GENE_OR_GENE_PRODUCT", 0, 9], ["enterovirus", "ORGANISM", 21, 32], ["monkey", "ORGANISM", 54, 60], ["kidney cells", "CELL", 61, 73], ["HeLa cells", "CELL", 92, 102], ["antiserum", "ORGANISM_SUBSTANCE", 122, 131], ["echovirus 1", "ORGANISM", 135, 146], ["monkey kidney cells", "CELL_TYPE", 54, 73], ["HeLa cells", "CELL_LINE", 92, 102], ["monkey", "SPECIES", 54, 60], ["echovirus 1", "SPECIES", 135, 146], ["SpecimEns", "TEST", 0, 9], ["an enterovirus eytopathie effect in monkey kidney cells", "PROBLEM", 18, 73], ["HeLa cells", "TEST", 92, 102], ["antiserum to echovirus", "PROBLEM", 122, 144], ["enterovirus eytopathie", "OBSERVATION", 21, 43], ["kidney", "ANATOMY", 61, 67], ["HeLa cells", "OBSERVATION", 92, 102]]], ["This procedure effectively suppressed growth of at least 1000 TCDs0 of LEV4 while leaving the growth of RV4 unaffected.2.g.", [["RV4", "CANCER", 104, 107], ["LEV4", "PROTEIN", 71, 75], ["RV4", "PROTEIN", 104, 107], ["This procedure", "TREATMENT", 0, 14]]], ["Specimens and Isolation o/LEVg, R V g and Inter/eronSera were screened for interferon by a plaque reduction method of MERmA~r (7) using bovine vesicular stomatitis virus in the semi-micro method of Zm~AX and MERt-GAN (8) .", [["Specimens", "ANATOMY", 0, 9], ["plaque", "ANATOMY", 91, 97], ["vesicular stomatitis", "DISEASE", 143, 163], ["Zm", "CHEMICAL", 198, 200], ["AX", "CHEMICAL", 201, 203], ["MERt-GAN", "CHEMICAL", 208, 216], ["MERt-GAN", "CHEMICAL", 208, 216], ["R V g", "GENE_OR_GENE_PRODUCT", 32, 37], ["eronSera", "GENE_OR_GENE_PRODUCT", 48, 56], ["interferon", "GENE_OR_GENE_PRODUCT", 75, 85], ["plaque", "PATHOLOGICAL_FORMATION", 91, 97], ["bovine", "ORGANISM", 136, 142], ["vesicular stomatitis virus", "ORGANISM", 143, 169], ["Zm~AX", "SIMPLE_CHEMICAL", 198, 203], ["MERt-GAN", "SIMPLE_CHEMICAL", 208, 216], ["Inter/eronSera", "DNA", 42, 56], ["interferon", "PROTEIN", 75, 85], ["bovine", "SPECIES", 136, 142], ["Specimens", "TEST", 0, 9], ["interferon", "TREATMENT", 75, 85], ["a plaque reduction method of MERmA~r", "TREATMENT", 89, 125], ["bovine vesicular stomatitis virus", "PROBLEM", 136, 169], ["vesicular stomatitis virus", "OBSERVATION", 143, 169]]], ["Titration of the referenee human interferon preparation B69/19 showed inhibition by 0.1 to 1 i.u. of human interferon per ml of sample tested.", [["sample", "ANATOMY", 128, 134], ["human", "ORGANISM", 27, 32], ["human", "ORGANISM", 101, 106], ["interferon", "GENE_OR_GENE_PRODUCT", 107, 117], ["B69/19", "CELL_LINE", 56, 62], ["human interferon", "PROTEIN", 101, 117], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 101, 106], ["the referenee human interferon preparation B69", "TREATMENT", 13, 59], ["human interferon", "TREATMENT", 101, 117]]], ["Samples were tested at a dilution of 1 : 10 to exclude non-specific interference.Pattern o/Enterovirus Excretion o/ VolunteersAll volunteers in the test group were successfully infected with LEV4 (Table 1) .", [["Samples", "ANATOMY", 0, 7], ["volunteers", "ORGANISM", 130, 140], ["Samples", "TEST", 0, 7], ["a dilution", "TEST", 23, 33], ["non-specific interference", "PROBLEM", 55, 80], ["Enterovirus Excretion", "PROBLEM", 91, 112], ["the test group", "TEST", 144, 158], ["Enterovirus", "OBSERVATION", 91, 102], ["infected", "OBSERVATION", 177, 185]]], ["Their pre-inoeulation specimens, and all the control group specimens, showed no enterovirus.", [["pre-inoeulation specimens", "ANATOMY", 6, 31], ["specimens", "ANATOMY", 59, 68], ["enterovirus", "DISEASE", 80, 91], ["enterovirus", "ORGANISM", 80, 91], ["Their pre-inoeulation specimens", "TEST", 0, 31], ["all the control group specimens", "TEST", 37, 68], ["enterovirus", "PROBLEM", 80, 91], ["no", "UNCERTAINTY", 77, 79], ["enterovirus", "OBSERVATION", 80, 91]]], ["Table 1 shows that the LEV4 was isolated from the nasopharynx of nearly half of those inoculated.", [["nasopharynx", "ANATOMY", 50, 61], ["LEV4", "GENE_OR_GENE_PRODUCT", 23, 27], ["nasopharynx", "ORGAN", 50, 61], ["LEV4", "DNA", 23, 27], ["nasopharynx", "ANATOMY", 50, 61]]], ["Daily titrations of faeces of 5 volunteers showed that excretion of LEV4 was maximal on days 4 or 5; overall, excretion of LEV4 was near maximum on days 1 or 2 so that infection was well established when the volunteers were challenged with rhinovirus.Overall E]/ects o] Rhinovirus 4 ChallengeEffects of challenge were monitored by both clinical response and virological evidence of infection, namely the isolation of RV4 from one or more nasal washings or a four-fold or greater rise in strum HAI or neutralising antibody titre to RV4.", [["nasal", "ANATOMY", 438, 443], ["strum", "ANATOMY", 487, 492], ["LEV4", "CHEMICAL", 68, 72], ["infection", "DISEASE", 168, 177], ["infection", "DISEASE", 382, 391], ["LEV4", "CHEMICAL", 68, 72], ["faeces", "ORGANISM_SUBSTANCE", 20, 26], ["volunteers", "ORGANISM", 32, 42], ["LEV4", "SIMPLE_CHEMICAL", 68, 72], ["LEV4", "SIMPLE_CHEMICAL", 123, 127], ["volunteers", "ORGANISM", 208, 218], ["rhinovirus", "ORGANISM", 240, 250], ["strum", "CANCER", 487, 492], ["RV4", "PROTEIN", 531, 534], ["RV4", "SPECIES", 417, 420], ["Daily titrations of faeces of 5 volunteers", "TEST", 0, 42], ["excretion of LEV4", "TEST", 55, 72], ["excretion of LEV4", "TEST", 110, 127], ["infection", "PROBLEM", 168, 177], ["rhinovirus", "PROBLEM", 240, 250], ["Rhinovirus", "PROBLEM", 270, 280], ["infection", "PROBLEM", 382, 391], ["the isolation of RV4", "PROBLEM", 400, 420], ["nasal washings", "TEST", 438, 452], ["a four-fold", "PROBLEM", 456, 467], ["greater rise in strum HAI", "PROBLEM", 471, 496], ["neutralising antibody titre", "TEST", 500, 527], ["infection", "OBSERVATION", 168, 177], ["rhinovirus", "OBSERVATION", 240, 250], ["infection", "OBSERVATION", 382, 391], ["washings", "OBSERVATION", 444, 452], ["greater", "OBSERVATION_MODIFIER", 471, 478], ["rise", "OBSERVATION_MODIFIER", 479, 483]]], ["Although only 25 per cent developed symptoms and 60 per cent were infected of the control group, no overall reduction in illness or infection was induced by prior LEV4 inoculation (Table 2 ).E//ect on Mean Daily R V 4 ExcretionThe mean titres of RV4 in nasal washings were calculated for each day (Fig. 1) .", [["nasal", "ANATOMY", 253, 258], ["illness", "DISEASE", 121, 128], ["infection", "DISEASE", 132, 141], ["LEV4", "CHEMICAL", 163, 167], ["RV4", "SIMPLE_CHEMICAL", 246, 249], ["nasal washings", "MULTI-TISSUE_STRUCTURE", 253, 267], ["symptoms", "PROBLEM", 36, 44], ["illness", "PROBLEM", 121, 128], ["infection", "PROBLEM", 132, 141], ["prior LEV4 inoculation", "TREATMENT", 157, 179], ["E", "TEST", 191, 192], ["ect", "TEST", 194, 197], ["Mean", "TEST", 201, 205], ["The mean titres", "TEST", 227, 242], ["RV4 in nasal washings", "TREATMENT", 246, 267], ["no", "UNCERTAINTY", 97, 99], ["overall", "OBSERVATION_MODIFIER", 100, 107], ["reduction", "OBSERVATION_MODIFIER", 108, 117], ["illness", "OBSERVATION", 121, 128], ["infection", "OBSERVATION", 132, 141], ["nasal", "ANATOMY", 253, 258]]], ["Although the mean in the control group was slightly higher than in the test group on the 3rd day after rhinovirus challenge, this difference was not significant.", [["rhinovirus", "ORGANISM", 103, 113], ["rhinovirus challenge", "TREATMENT", 103, 123], ["mean", "OBSERVATION_MODIFIER", 13, 17], ["slightly", "OBSERVATION_MODIFIER", 43, 51], ["higher", "OBSERVATION_MODIFIER", 52, 58], ["not", "UNCERTAINTY", 145, 148], ["significant", "OBSERVATION_MODIFIER", 149, 160]]], ["Rhinovirus excretion was not delayed in the vaccinated group.E//ect o] Presence o/ LEV 4 in NasopharynxThe five volunteers from whom LEV4 was isolated in the nasopharynx were considered separately to see if local interference occurred.", [["nasopharynx", "ANATOMY", 158, 169], ["Rhinovirus", "CHEMICAL", 0, 10], ["LEV", "CHEMICAL", 83, 86], ["Rhinovirus", "CHEMICAL", 0, 10], ["Rhinovirus", "SIMPLE_CHEMICAL", 0, 10], ["volunteers", "ORGANISM", 112, 122], ["LEV4", "GENE_OR_GENE_PRODUCT", 133, 137], ["nasopharynx", "ORGAN", 158, 169], ["LEV4", "DNA", 133, 137], ["Rhinovirus excretion", "PROBLEM", 0, 20], ["LEV 4 in Nasopharynx", "PROBLEM", 83, 103], ["local interference", "PROBLEM", 207, 225], ["Nasopharynx", "ANATOMY", 92, 103], ["nasopharynx", "ANATOMY", 158, 169]]], ["However, none of the indices of RV4 infection was significantly' lower in this group (Table 2) , and calculation of the daily mean titl'eS of RV4 in nasal washings (Fig. 1) confirmed that no interference occurred locally on any specific day.Presence o/Inter/eron in Serum and Nasal WashingsInterferon was found in the serum on the 5th day only (5 days after LEV4 or control inoculation and 3 days after RV4 challenge) in three volunteers, two of whom had not received LEV4.", [["nasal", "ANATOMY", 149, 154], ["Serum", "ANATOMY", 266, 271], ["serum", "ANATOMY", 318, 323], ["infection", "DISEASE", 36, 45], ["RV4", "CHEMICAL", 142, 145], ["LEV4", "CHEMICAL", 358, 362], ["LEV4", "CHEMICAL", 468, 472], ["LEV4", "CHEMICAL", 468, 472], ["RV4", "GENE_OR_GENE_PRODUCT", 32, 35], ["Serum", "ORGANISM_SUBSTANCE", 266, 271], ["Interferon", "GENE_OR_GENE_PRODUCT", 290, 300], ["serum", "ORGANISM_SUBSTANCE", 318, 323], ["volunteers", "ORGANISM", 427, 437], ["RV4 infection", "PROBLEM", 32, 45], ["nasal washings", "TREATMENT", 149, 163], ["Inter/eron", "TREATMENT", 252, 262], ["Serum", "TEST", 266, 271], ["Nasal WashingsInterferon", "TREATMENT", 276, 300], ["LEV4", "TREATMENT", 358, 362], ["control inoculation", "TREATMENT", 366, 385], ["RV4 challenge", "TREATMENT", 403, 416], ["LEV4", "TREATMENT", 468, 472], ["infection", "OBSERVATION", 36, 45], ["nasal", "ANATOMY", 149, 154], ["washings", "OBSERVATION", 155, 163], ["no", "UNCERTAINTY", 188, 190], ["interference", "OBSERVATION", 191, 203], ["Nasal", "ANATOMY", 276, 281]]], ["Presence of interferon in serum therefore seemed to be related to rhinovirus challenge (Table 3) .", [["serum", "ANATOMY", 26, 31], ["interferon", "GENE_OR_GENE_PRODUCT", 12, 22], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["rhinovirus", "ORGANISM", 66, 76], ["interferon", "PROTEIN", 12, 22], ["interferon in serum", "PROBLEM", 12, 31], ["rhinovirus challenge", "PROBLEM", 66, 86], ["interferon", "OBSERVATION", 12, 22], ["seemed to be related to", "UNCERTAINTY", 42, 65], ["rhinovirus", "OBSERVATION", 66, 76]]], ["Interferon in nasal washings (Table 3 ) also showed no relationship to LEV4 vaccination.", [["nasal", "ANATOMY", 14, 19], ["LEV4", "CHEMICAL", 71, 75], ["Interferon", "GENE_OR_GENE_PRODUCT", 0, 10], ["LEV4", "SIMPLE_CHEMICAL", 71, 75], ["Interferon", "PROTEIN", 0, 10], ["Interferon in nasal washings", "TREATMENT", 0, 28], ["LEV4 vaccination", "TREATMENT", 71, 87], ["nasal", "ANATOMY", 14, 19]]], ["Four of the seventeen volunteers who were symptom-free throughout the trial showed interferon in nasal washings compared with three of 7 who were symptomatic.", [["nasal", "ANATOMY", 97, 102], ["volunteers", "ORGANISM", 22, 32], ["interferon", "GENE_OR_GENE_PRODUCT", 83, 93], ["interferon", "PROTEIN", 83, 93], ["symptom", "PROBLEM", 42, 49], ["interferon in nasal washings", "TREATMENT", 83, 111], ["symptomatic", "PROBLEM", 146, 157], ["nasal", "ANATOMY", 97, 102], ["washings", "OBSERVATION", 103, 111]]], ["Thus interferon in nasal washings was associated with symptoms of rhinovirus infection but the difference did not ~ehieve statistical significance at the 0.05 level (%2 = 3.744, p <0.1).E//ect o/ Revaccination with LEV 4Two additional volunteers who were not studied in isolation were successfully infected with LEV4, but they were not challenged with RV4 and are therefore not included in the previous results.", [["nasal", "ANATOMY", 19, 24], ["rhinovirus infection", "DISEASE", 66, 86], ["LEV", "CHEMICAL", 215, 218], ["interferon", "GENE_OR_GENE_PRODUCT", 5, 15], ["nasal", "ORGAN", 19, 24], ["rhinovirus", "ORGANISM", 66, 76], ["volunteers", "ORGANISM", 235, 245], ["interferon", "PROTEIN", 5, 15], ["RV4", "SPECIES", 352, 355], ["interferon in nasal washings", "TREATMENT", 5, 33], ["symptoms", "PROBLEM", 54, 62], ["rhinovirus infection", "PROBLEM", 66, 86], ["Revaccination", "TREATMENT", 196, 209], ["LEV", "TREATMENT", 215, 218], ["LEV4", "TREATMENT", 312, 316], ["interferon", "OBSERVATION", 5, 15], ["nasal", "ANATOMY", 19, 24], ["washings", "OBSERVATION", 25, 33], ["rhinovirus", "OBSERVATION", 66, 76]]], ["LEV4 was obtained from throat swabs and faeces of both volunteers.", [["throat swabs", "ANATOMY", 23, 35], ["faeces", "ANATOMY", 40, 46], ["LEV4", "GENE_OR_GENE_PRODUCT", 0, 4], ["throat swabs", "ORGANISM_SUBSTANCE", 23, 35], ["faeces", "ORGANISM_SUBSTANCE", 40, 46], ["volunteers", "ORGANISM", 55, 65], ["LEV4", "DNA", 0, 4], ["LEV4", "SPECIES", 0, 4], ["throat swabs", "TEST", 23, 35]]], ["The course of enterovirus excretion was followed at first daily, then weekly; excretion definitely ceased after 12 weeks.", [["enterovirus", "ORGANISM", 14, 25], ["enterovirus excretion", "TREATMENT", 14, 35]]], ["NeutrMising antibodies to echo 1 virus in the serum rose after three weeks from titres of < 1/5 to titres of 1/7 and 1/14.", [["serum", "ANATOMY", 46, 51], ["echo 1 virus", "ORGANISM", 26, 38], ["serum", "ORGANISM_SUBSTANCE", 46, 51], ["NeutrMising antibodies", "PROTEIN", 0, 22], ["NeutrMising antibodies", "TEST", 0, 22], ["echo", "TEST", 26, 30], ["the serum", "TEST", 42, 51], ["titres", "TEST", 80, 86]]], ["No interferon was demonstrated in the serum at any stage of the enterovirus infection.E//ect o/ Revaccination with LEV 4These two volunteers were given 106 TCDs0 LEV4 three months after the first infection.", [["serum", "ANATOMY", 38, 43], ["enterovirus infection", "DISEASE", 64, 85], ["LEV", "CHEMICAL", 115, 118], ["infection", "DISEASE", 196, 205], ["interferon", "GENE_OR_GENE_PRODUCT", 3, 13], ["serum", "ORGANISM_SUBSTANCE", 38, 43], ["enterovirus", "ORGANISM", 64, 75], ["volunteers", "ORGANISM", 130, 140], ["interferon", "PROTEIN", 3, 13], ["interferon", "PROBLEM", 3, 13], ["the serum", "TEST", 34, 43], ["the enterovirus infection", "PROBLEM", 60, 85], ["Revaccination", "TREATMENT", 96, 109], ["LEV", "TREATMENT", 115, 118], ["the first infection", "PROBLEM", 186, 205], ["interferon", "OBSERVATION", 3, 13], ["enterovirus infection", "OBSERVATION", 64, 85], ["infection", "OBSERVATION", 196, 205]]], ["Virus could not be grown from any specimens of tht swabs or faeces, and it was concluded that the second close had failed to infect.DiscussionOur results do not agree with the epidemiological and laboratory data previously reported for LEV4 by VoaosltmOVA (3).", [["specimens", "ANATOMY", 34, 43], ["swabs", "ANATOMY", 51, 56], ["faeces", "ANATOMY", 60, 66], ["Virus", "ORGANISM", 0, 5], ["faeces", "ORGANISM_SUBSTANCE", 60, 66], ["Virus", "PROBLEM", 0, 5], ["tht swabs", "TEST", 47, 56], ["faeces", "PROBLEM", 60, 66], ["laboratory data", "TEST", 196, 211]]], ["In another Russian study by OBR0SOvA-S~RoVA et al. (9) a single dose of LEV4 was noted to be ineffective in a controlled study of the prevention of an influenza epidemic.", [["LEV4", "CHEMICAL", 72, 76], ["influenza", "DISEASE", 151, 160], ["LEV4", "CHEMICAL", 72, 76], ["LEV4", "SIMPLE_CHEMICAL", 72, 76], ["a single dose of LEV4", "TREATMENT", 55, 76], ["a controlled study", "TEST", 108, 126], ["an influenza epidemic", "PROBLEM", 148, 169], ["influenza", "OBSERVATION", 151, 160]]], ["SEIBtL et al. (10) , in an epidemiological study involving many thousands of subjects, claimed that multiple doses of vaccine, especially live poliovirus vaccine, were mote effective than a single dose in reducing respiratory illness.", [["respiratory", "ANATOMY", 214, 225], ["respiratory illness", "DISEASE", 214, 233], ["live poliovirus", "ORGANISM", 138, 153], ["an epidemiological study", "TEST", 24, 48], ["vaccine", "TREATMENT", 118, 125], ["live poliovirus vaccine", "TREATMENT", 138, 161], ["reducing respiratory illness", "PROBLEM", 205, 233], ["respiratory illness", "OBSERVATION", 214, 233]]], ["However, sinee ~e c6uld not achieve reinfection with LEVr it is difficult to see how multiple i'dose; could be more effective.DiscussionIf viral interference is to be a useful method of prophylaxis, our study should have shown some effect, however small, on the results of rhinovirus challenge in the test group.", [["i'dose", "SIMPLE_CHEMICAL", 94, 100], ["rhinovirus", "ORGANISM", 273, 283], ["viral interference", "PROBLEM", 139, 157], ["prophylaxis", "TREATMENT", 186, 197], ["our study", "TEST", 199, 208], ["rhinovirus challenge", "TREATMENT", 273, 293], ["small", "OBSERVATION_MODIFIER", 248, 253]]], ["All of the test group were infected and high titres of LEV4 were being excreted at the time of rhinovirus challenge.", [["LEV4", "CHEMICAL", 55, 59], ["LEV4", "GENE_OR_GENE_PRODUCT", 55, 59], ["rhinovirus", "ORGANISM", 95, 105], ["LEV4", "PROTEIN", 55, 59], ["LEV4", "SPECIES", 55, 59], ["the test group", "TEST", 7, 21], ["high titres of LEV4", "PROBLEM", 40, 59], ["rhinovirus challenge", "TREATMENT", 95, 115]]], ["Nevertheless no effect could be demonstrated on the symptoms produced, the mean total rhinovirus excretion, the mean daily rhinovirus excretion, or the number of four-fold or greater rises in l~V4 antibody titre.", [["rhinovirus", "ORGANISM", 86, 96], ["rhinovirus", "ORGANISM", 123, 133], ["the symptoms", "PROBLEM", 48, 60], ["the mean total rhinovirus excretion", "TEST", 71, 106], ["the mean daily rhinovirus excretion", "TEST", 108, 143], ["greater", "OBSERVATION_MODIFIER", 175, 182], ["rises", "OBSERVATION_MODIFIER", 183, 188]]], ["Furthermore the presence of the interfering virus locally in the nasopharynx conferred no apparent advantage in protection.DiscussionInterferon was present in nasal washings and serum, but its presence was not related to LEV4 vaccination; it was probably a result of rhinovirus challenge.", [["nasopharynx", "ANATOMY", 65, 76], ["nasal washings", "ANATOMY", 159, 173], ["serum", "ANATOMY", 178, 183], ["LEV4", "CHEMICAL", 221, 225], ["nasopharynx", "ORGAN", 65, 76], ["Interferon", "GENE_OR_GENE_PRODUCT", 133, 143], ["nasal washings", "ORGANISM_SUBSTANCE", 159, 173], ["serum", "ORGANISM_SUBSTANCE", 178, 183], ["rhinovirus", "ORGANISM", 267, 277], ["Interferon", "PROTEIN", 133, 143], ["the interfering virus", "PROBLEM", 28, 49], ["Interferon", "TREATMENT", 133, 143], ["nasal washings and serum", "TEST", 159, 183], ["LEV4 vaccination", "TREATMENT", 221, 237], ["rhinovirus challenge", "PROBLEM", 267, 287], ["interfering", "OBSERVATION_MODIFIER", 32, 43], ["virus", "OBSERVATION", 44, 49], ["nasopharynx", "ANATOMY", 65, 76], ["no apparent", "UNCERTAINTY", 87, 98], ["advantage", "OBSERVATION_MODIFIER", 99, 108], ["rhinovirus", "OBSERVATION", 267, 277]]], ["Interferon in the nasal washings was to some degree related to the expression of symptoms.", [["nasal washings", "ANATOMY", 18, 32], ["Interferon", "GENE_OR_GENE_PRODUCT", 0, 10], ["nasal washings", "MULTI-TISSUE_STRUCTURE", 18, 32], ["Interferon", "PROTEIN", 0, 10], ["Interferon", "TREATMENT", 0, 10], ["the nasal washings", "TREATMENT", 14, 32], ["symptoms", "PROBLEM", 81, 89], ["nasal", "ANATOMY", 18, 23], ["washings", "OBSERVATION", 24, 32]]], ["It does not appear that vaccination with live enteroviruses will provide a satisfactory method for the prevention of acute respiratory disease due to viruses.", [["respiratory", "ANATOMY", 123, 134], ["acute respiratory disease", "DISEASE", 117, 142], ["vaccination", "TREATMENT", 24, 35], ["live enteroviruses", "PROBLEM", 41, 59], ["a satisfactory method", "TREATMENT", 73, 94], ["acute respiratory disease", "PROBLEM", 117, 142], ["viruses", "PROBLEM", 150, 157], ["acute", "OBSERVATION_MODIFIER", 117, 122], ["respiratory disease", "OBSERVATION", 123, 142], ["viruses", "OBSERVATION", 150, 157]]]], "PMC7305515": [["Early assessment of the potential for global spread ::: IntroductionOutside the initial Wuhan epicentre, air travel passenger volumes were a key metric used to evaluate the risk of exportation of COVID-19 to other regions.", [["COVID-19", "CHEMICAL", 196, 204], ["COVID-19", "CHEMICAL", 196, 204], ["COVID-19", "DNA", 196, 204], ["Early assessment", "TEST", 0, 16], ["COVID", "TEST", 196, 201]]], ["Using the significant positive correlation between reported case counts outside of mainland China and daily air travel volume from Wuhan, models identified outlier countries with low case numbers compared with travel-related expected counts, suggesting several regions had low detection rates [8].Early assessment of the potential for global spread ::: IntroductionOther groups used more complex fully integrated air-travel models to predict changes in the COVID-19 epicentre and assess averted cases due to travel restrictions.", [["low detection rates", "PROBLEM", 273, 292], ["Early assessment", "TEST", 297, 313], ["IntroductionOther groups", "TREATMENT", 353, 377], ["the COVID-19 epicentre", "TREATMENT", 453, 475]]], ["For instance, a meta-population disease transmission model indicated that Australia reduced imported cases by 79% as a result of the government-imposed travel ban, potentially preventing Australia from becoming the Asia-Pacific epicentre [9].", [["a meta-population disease transmission model", "PROBLEM", 14, 58]]], ["Similar assessments were performed for African and South American countries, which were initially found to be at much lower risk relative to Asian (e.g., Thailand, Cambodia, Malaysia), North American and European countries, due to their lower connectivity with China [10].", [["Similar assessments", "TEST", 0, 19]]], ["However, the risk to South America and Africa was predicted to increase considerably once a second epicentre was established in Italy [11].Estimates of COVID-19 transmissibility ::: IntroductionAn important first step in characterising the transmission potential of any novel infectious pathogen is to estimate the basic reproduction number (R0), which quantifies the average number of secondary cases per infected individual in an infection-na\u00efve population.", [["infection", "DISEASE", 432, 441], ["a second epicentre", "TREATMENT", 90, 108], ["COVID", "TEST", 152, 157], ["any novel infectious pathogen", "PROBLEM", 266, 295], ["secondary cases", "PROBLEM", 386, 401], ["an infection", "PROBLEM", 429, 441], ["infectious", "OBSERVATION", 276, 286], ["infected", "OBSERVATION_MODIFIER", 406, 414], ["infection", "OBSERVATION", 432, 441]]], ["This parameter provides an important threshold for infection control: when R0 > 1 transmission is expected to be self-sustaining, whilst when R0 < 1 transmission inevitably dies out [12].Estimates of COVID-19 transmissibility ::: Introduction", [["infection", "DISEASE", 51, 60], ["infection control", "TREATMENT", 51, 68], ["COVID", "TEST", 200, 205]]]], "c2aa0e81868d75006b62f30a0ae0e4bcfe722832": [["IntroductionCompared with conventional platinum-based chemotherapy, immune checkpoint inhibitor (ICI) therapy can significantly improve progression-free survival (PFS) and overall survival (OS) of patients with non-small cell lung cancer (NSCLC).", [["non-small cell lung cancer", "ANATOMY", 211, 237], ["NSCLC", "ANATOMY", 239, 244], ["platinum", "CHEMICAL", 39, 47], ["ICI", "CHEMICAL", 97, 100], ["non-small cell lung cancer", "DISEASE", 211, 237], ["NSCLC", "DISEASE", 239, 244], ["platinum", "CHEMICAL", 39, 47], ["platinum", "SIMPLE_CHEMICAL", 39, 47], ["ICI", "SIMPLE_CHEMICAL", 97, 100], ["patients", "ORGANISM", 197, 205], ["non-small cell lung cancer", "CANCER", 211, 237], ["NSCLC", "CANCER", 239, 244], ["patients", "SPECIES", 197, 205], ["conventional platinum-based chemotherapy", "TREATMENT", 26, 66], ["immune checkpoint inhibitor (ICI) therapy", "TREATMENT", 68, 109], ["non-small cell lung cancer", "PROBLEM", 211, 237], ["non-small cell", "OBSERVATION", 211, 225], ["lung", "ANATOMY", 226, 230], ["cancer", "OBSERVATION", 231, 237], ["NSCLC", "OBSERVATION", 239, 244]]], ["Pembrolinzumab is an ICI which is recommended as first-line treatment for advanced NSCLC showing \u226550% expression of programmed death-ligand 1 (PD-L1), or treatment of patients with NSCLC whose tumors express PD-L1 \u2265 1% .", [["NSCLC", "ANATOMY", 83, 88], ["NSCLC", "ANATOMY", 181, 186], ["tumors", "ANATOMY", 193, 199], ["Pembrolinzumab", "CHEMICAL", 0, 14], ["ICI", "CHEMICAL", 21, 24], ["NSCLC", "DISEASE", 83, 88], ["NSCLC", "DISEASE", 181, 186], ["tumors", "DISEASE", 193, 199], ["Pembrolinzumab", "CHEMICAL", 0, 14], ["ICI", "CHEMICAL", 21, 24], ["Pembrolinzumab", "SIMPLE_CHEMICAL", 0, 14], ["ICI", "SIMPLE_CHEMICAL", 21, 24], ["NSCLC", "CANCER", 83, 88], ["programmed death-ligand 1", "GENE_OR_GENE_PRODUCT", 116, 141], ["PD-L1", "GENE_OR_GENE_PRODUCT", 143, 148], ["patients", "ORGANISM", 167, 175], ["NSCLC", "CANCER", 181, 186], ["tumors", "CANCER", 193, 199], ["programmed death-ligand 1", "PROTEIN", 116, 141], ["patients", "SPECIES", 167, 175], ["first-line treatment", "TREATMENT", 49, 69], ["advanced NSCLC", "PROBLEM", 74, 88], ["programmed death", "PROBLEM", 116, 132], ["treatment", "TREATMENT", 154, 163], ["NSCLC whose tumors", "PROBLEM", 181, 199], ["PD", "TEST", 208, 210], ["NSCLC", "OBSERVATION", 181, 186], ["tumors", "OBSERVATION", 193, 199], ["L1", "ANATOMY", 211, 213]]], ["1 As ICIs have been increasingly applied in lung cancer, immune-related adverse events (irAEs) have aroused greater attention.", [["lung cancer", "ANATOMY", 44, 55], ["lung cancer", "DISEASE", 44, 55], ["lung cancer", "CANCER", 44, 55], ["lung cancer", "PROBLEM", 44, 55], ["adverse events", "PROBLEM", 72, 86], ["lung", "ANATOMY", 44, 48], ["cancer", "OBSERVATION", 49, 55]]], ["Checkpoint inhibitor associated pneumonitis (CIP) is the most common serious irAE, as well as the leading cause of ICIrelated death.", [["pneumonitis", "DISEASE", 32, 43], ["CIP", "DISEASE", 45, 48], ["irAE", "DISEASE", 77, 81], ["death", "DISEASE", 126, 131], ["irAE", "CANCER", 77, 81], ["Checkpoint inhibitor associated pneumonitis", "PROBLEM", 0, 43], ["ICIrelated death", "PROBLEM", 115, 131], ["pneumonitis", "OBSERVATION", 32, 43], ["ICIrelated death", "OBSERVATION", 115, 131]]], ["Here, we report a significantly rare case of massive hemoptysis with pulmonary cavitation after eight cycles of pembrolinzumab monotherapy.Case reportA 55-year-old male with a 20 pack-year smoking status was admitted to our hospital with symptoms of dyspnea and bloody sputum in July 2019.", [["pulmonary", "ANATOMY", 69, 78], ["hemoptysis", "DISEASE", 53, 63], ["pulmonary cavitation", "DISEASE", 69, 89], ["pembrolinzumab", "CHEMICAL", 112, 126], ["dyspnea", "DISEASE", 250, 257], ["pembrolinzumab", "CHEMICAL", 112, 126], ["pulmonary", "ORGAN", 69, 78], ["pembrolinzumab", "SIMPLE_CHEMICAL", 112, 126], ["male", "ORGANISM", 164, 168], ["massive hemoptysis", "PROBLEM", 45, 63], ["pulmonary cavitation", "PROBLEM", 69, 89], ["pembrolinzumab monotherapy", "TREATMENT", 112, 138], ["symptoms", "PROBLEM", 238, 246], ["dyspnea", "PROBLEM", 250, 257], ["bloody sputum", "PROBLEM", 262, 275], ["massive", "OBSERVATION_MODIFIER", 45, 52], ["hemoptysis", "OBSERVATION", 53, 63], ["pulmonary", "ANATOMY", 69, 78], ["cavitation", "OBSERVATION", 79, 89], ["dyspnea", "OBSERVATION", 250, 257]]], ["He also complained of dysphagia and was unable to lie flat.", [["dysphagia", "DISEASE", 22, 31], ["He", "ORGANISM", 0, 2], ["dysphagia", "PROBLEM", 22, 31], ["dysphagia", "OBSERVATION", 22, 31]]], ["He was diagnosed with stage IV lung adenocarcinoma (Fig 1a) in April 2019 when epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) genomic aberrations were determined not to be present, but he was found to have a high PD-L1 expression of 60% (Fig 1b) .", [["lung adenocarcinoma", "ANATOMY", 31, 50], ["lung adenocarcinoma", "DISEASE", 31, 50], ["anaplastic lymphoma", "DISEASE", 123, 142], ["stage IV lung adenocarcinoma", "CANCER", 22, 50], ["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 79, 111], ["EGFR", "GENE_OR_GENE_PRODUCT", 113, 117], ["anaplastic lymphoma kinase", "GENE_OR_GENE_PRODUCT", 123, 149], ["ALK", "GENE_OR_GENE_PRODUCT", 151, 154], ["PD-L1", "GENE_OR_GENE_PRODUCT", 243, 248], ["epidermal growth factor receptor", "PROTEIN", 79, 111], ["EGFR", "PROTEIN", 113, 117], ["ALK", "PROTEIN", 151, 154], ["stage IV lung adenocarcinoma", "PROBLEM", 22, 50], ["epidermal growth factor receptor", "TEST", 79, 111], ["EGFR", "TEST", 113, 117], ["anaplastic lymphoma kinase (ALK) genomic aberrations", "PROBLEM", 123, 175], ["a high PD-L1 expression", "PROBLEM", 236, 259], ["Fig", "TEST", 268, 271], ["stage IV", "OBSERVATION_MODIFIER", 22, 30], ["lung", "ANATOMY", 31, 35], ["adenocarcinoma", "OBSERVATION", 36, 50], ["anaplastic lymphoma", "OBSERVATION", 123, 142]]], ["The patient had anaphylactic shock following brain enhanced magnetic resonance imaging (MRI) at the beginning of his illness and his previous medical history included short-term chemotherapy without any benefit before he presented at our clinic.", [["brain", "ANATOMY", 45, 50], ["anaphylactic shock", "DISEASE", 16, 34], ["patient", "ORGANISM", 4, 11], ["brain", "ORGAN", 45, 50], ["patient", "SPECIES", 4, 11], ["anaphylactic shock", "PROBLEM", 16, 34], ["brain enhanced magnetic resonance imaging", "TEST", 45, 86], ["MRI", "TEST", 88, 91], ["short-term chemotherapy", "TREATMENT", 167, 190]]], ["On admission, a significant physical examination revealed decreased breath sounds on the right side of the chest.", [["chest", "ANATOMY", 107, 112], ["chest", "ORGAN", 107, 112], ["a significant physical examination", "TEST", 14, 48], ["decreased breath sounds on the right side", "PROBLEM", 58, 99], ["decreased", "OBSERVATION_MODIFIER", 58, 67], ["breath sounds", "OBSERVATION", 68, 81], ["right", "ANATOMY_MODIFIER", 89, 94], ["chest", "ANATOMY", 107, 112]]], ["Thoracic computed tomography (CT) scan showed a giant mass lesion in the right lung with obvious compression of trachea, right brain bronchus and part of the esophagus (Fig 2a) .", [["giant mass lesion", "ANATOMY", 48, 65], ["right lung", "ANATOMY", 73, 83], ["trachea", "ANATOMY", 112, 119], ["right brain bronchus", "ANATOMY", 121, 141], ["esophagus", "ANATOMY", 158, 167], ["lung", "ORGAN", 79, 83], ["trachea", "ORGAN", 112, 119], ["brain bronchus", "MULTI-TISSUE_STRUCTURE", 127, 141], ["esophagus", "ORGAN", 158, 167], ["Thoracic computed tomography (CT) scan", "TEST", 0, 38], ["a giant mass lesion in the right lung", "PROBLEM", 46, 83], ["obvious compression of trachea", "PROBLEM", 89, 119], ["giant", "OBSERVATION_MODIFIER", 48, 53], ["mass", "OBSERVATION", 54, 58], ["lesion", "OBSERVATION", 59, 65], ["right", "ANATOMY_MODIFIER", 73, 78], ["lung", "ANATOMY", 79, 83], ["obvious", "OBSERVATION_MODIFIER", 89, 96], ["compression", "OBSERVATION", 97, 108], ["trachea", "ANATOMY", 112, 119], ["right", "ANATOMY_MODIFIER", 121, 126], ["brain bronchus", "ANATOMY", 127, 141], ["esophagus", "ANATOMY", 158, 167]]], ["Given the high PD-L1 expression of tumor cells, the patient received pembrolizumab monotherapy (100 mg/bodyweight) once every three weeks from 31 July.", [["tumor cells", "ANATOMY", 35, 46], ["tumor", "DISEASE", 35, 40], ["pembrolizumab", "CHEMICAL", 69, 82], ["pembrolizumab", "CHEMICAL", 69, 82], ["PD-L1", "GENE_OR_GENE_PRODUCT", 15, 20], ["tumor cells", "CELL", 35, 46], ["patient", "ORGANISM", 52, 59], ["pembrolizumab", "SIMPLE_CHEMICAL", 69, 82], ["L1", "DNA", 18, 20], ["tumor cells", "CELL_TYPE", 35, 46], ["patient", "SPECIES", 52, 59], ["tumor cells", "PROBLEM", 35, 46], ["pembrolizumab monotherapy", "TREATMENT", 69, 94], ["L1", "ANATOMY", 18, 20], ["tumor cells", "OBSERVATION", 35, 46]]], ["Subsequent surveillance with CT scan revealed shrinkage in the size of the mass but there was a large low density necrotic area in the center and significant compression release of the trachea and esophagus after four cycles (week 12) of ICI therapy (Fig 2b) .", [["mass", "ANATOMY", 75, 79], ["necrotic area", "ANATOMY", 114, 127], ["trachea", "ANATOMY", 185, 192], ["esophagus", "ANATOMY", 197, 206], ["necrotic", "DISEASE", 114, 122], ["ICI", "CHEMICAL", 238, 241], ["ICI", "CHEMICAL", 238, 241], ["trachea", "ORGAN", 185, 192], ["esophagus", "ORGAN", 197, 206], ["ICI", "SIMPLE_CHEMICAL", 238, 241], ["Subsequent surveillance", "TEST", 0, 23], ["CT scan", "TEST", 29, 36], ["shrinkage", "PROBLEM", 46, 55], ["the mass", "PROBLEM", 71, 79], ["a large low density necrotic area", "PROBLEM", 94, 127], ["significant compression release of the trachea and esophagus", "PROBLEM", 146, 206], ["ICI therapy", "TREATMENT", 238, 249], ["shrinkage", "OBSERVATION_MODIFIER", 46, 55], ["size", "OBSERVATION_MODIFIER", 63, 67], ["mass", "OBSERVATION", 75, 79], ["large", "OBSERVATION_MODIFIER", 96, 101], ["low density", "OBSERVATION_MODIFIER", 102, 113], ["necrotic", "OBSERVATION_MODIFIER", 114, 122], ["area", "OBSERVATION", 123, 127], ["significant", "OBSERVATION_MODIFIER", 146, 157], ["compression release", "OBSERVATION", 158, 177], ["trachea", "ANATOMY", 185, 192], ["esophagus", "ANATOMY", 197, 206]]], ["All the symptoms present on admission were relieved.", [["All the symptoms", "PROBLEM", 0, 16]]], ["His efficacy was considered as a partial response (PR) which complied with the Response Evaluation Criteria in Solid Tumors (REC-IST).", [["Solid Tumors", "CANCER", 111, 123], ["a partial response (PR)", "PROBLEM", 31, 54], ["the Response Evaluation", "TEST", 75, 98], ["Solid Tumors", "PROBLEM", 111, 123], ["Solid Tumors", "OBSERVATION", 111, 123]]], ["Moreover, his performance status, abiding by the Eastern Cooperative Oncology Group (ECOG), was elevated from four prior to therapy to one.", [["therapy", "TREATMENT", 124, 131]]], ["After 24 weeks of treatment with pembrolizumab, he returned to the clinic with recurrence of hemoptysis and shortness of breath, which coincided with the most serious period of the 2019 coronavirus disease (COVID-19) in China.", [["pembrolizumab", "CHEMICAL", 33, 46], ["hemoptysis", "DISEASE", 93, 103], ["shortness of breath", "DISEASE", 108, 127], ["coronavirus disease", "DISEASE", 186, 205], ["pembrolizumab", "CHEMICAL", 33, 46], ["pembrolizumab", "SIMPLE_CHEMICAL", 33, 46], ["treatment", "TREATMENT", 18, 27], ["pembrolizumab", "TREATMENT", 33, 46], ["hemoptysis", "PROBLEM", 93, 103], ["shortness of breath", "PROBLEM", 108, 127], ["the 2019 coronavirus disease", "PROBLEM", 177, 205], ["COVID", "TEST", 207, 212], ["hemoptysis", "OBSERVATION", 93, 103], ["coronavirus disease", "OBSERVATION", 186, 205]]], ["He had never been to Wuhan, nor had he had any contact with COVID- 19 patients.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78]]], ["His temperature had been normal since the onset of disease, and breath sounds on the right side of his chest were significantly stronger than previously.", [["chest", "ANATOMY", 103, 108], ["chest", "ORGAN", 103, 108], ["His temperature", "TEST", 0, 15], ["disease", "PROBLEM", 51, 58], ["breath sounds", "TEST", 64, 77], ["normal", "OBSERVATION", 25, 31], ["disease", "OBSERVATION", 51, 58], ["right", "ANATOMY_MODIFIER", 85, 90], ["chest", "ANATOMY", 103, 108], ["significantly", "OBSERVATION_MODIFIER", 114, 127], ["stronger", "OBSERVATION", 128, 136]]], ["There had been no administration of any anticoagulants or antiplatelet agent.", [["any anticoagulants", "TREATMENT", 36, 54], ["antiplatelet agent", "TREATMENT", 58, 76]]], ["Moreover, the results of his blood count, chemistry and coagulation tests were normal.", [["blood", "ANATOMY", 29, 34], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["his blood count", "TEST", 25, 40], ["chemistry", "TEST", 42, 51], ["coagulation tests", "TEST", 56, 73], ["normal", "OBSERVATION", 79, 85]]], ["CT scan showed progressive subpleural consolidation in the left lung after anti-infection treatment and a small transparent area was visible within the mass lesion in the right lung (Fig 2c) .", [["subpleural", "ANATOMY", 27, 37], ["left lung", "ANATOMY", 59, 68], ["area", "ANATOMY", 124, 128], ["mass lesion", "ANATOMY", 152, 163], ["right lung", "ANATOMY", 171, 181], ["lung", "ORGAN", 64, 68], ["lung", "ORGAN", 177, 181], ["CT scan", "TEST", 0, 7], ["progressive subpleural consolidation in the left lung", "PROBLEM", 15, 68], ["anti-infection treatment", "TREATMENT", 75, 99], ["a small transparent area", "PROBLEM", 104, 128], ["the mass lesion", "PROBLEM", 148, 163], ["progressive", "OBSERVATION_MODIFIER", 15, 26], ["subpleural", "ANATOMY_MODIFIER", 27, 37], ["consolidation", "OBSERVATION", 38, 51], ["left", "ANATOMY_MODIFIER", 59, 63], ["lung", "ANATOMY", 64, 68], ["anti-infection treatment", "OBSERVATION", 75, 99], ["small", "OBSERVATION_MODIFIER", 106, 111], ["transparent", "OBSERVATION_MODIFIER", 112, 123], ["area", "OBSERVATION_MODIFIER", 124, 128], ["visible", "OBSERVATION_MODIFIER", 133, 140], ["mass", "OBSERVATION_MODIFIER", 152, 156], ["lesion", "OBSERVATION", 157, 163], ["right", "ANATOMY_MODIFIER", 171, 176], ["lung", "ANATOMY", 177, 181]]], ["Pembrolizumab was stopped later (week 25) after a diagnosis of CIP (grade 3).", [["Pembrolizumab", "CHEMICAL", 0, 13], ["CIP", "DISEASE", 63, 66], ["Pembrolizumab", "CHEMICAL", 0, 13], ["Pembrolizumab", "SIMPLE_CHEMICAL", 0, 13], ["Pembrolizumab", "TREATMENT", 0, 13], ["CIP", "PROBLEM", 63, 66]]], ["Methylprednisolone treatment (40 mg b.i.d.) was initiated, which was decreased with subsequent regression of the left pulmonary lesions (Fig 2d) .", [["left pulmonary lesions", "ANATOMY", 113, 135], ["Methylprednisolone", "CHEMICAL", 0, 18], ["Methylprednisolone", "CHEMICAL", 0, 18], ["Methylprednisolone", "SIMPLE_CHEMICAL", 0, 18], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 118, 135], ["Methylprednisolone treatment", "TREATMENT", 0, 28], ["the left pulmonary lesions", "PROBLEM", 109, 135], ["left", "ANATOMY_MODIFIER", 113, 117], ["pulmonary", "ANATOMY", 118, 127], ["lesions", "OBSERVATION", 128, 135]]], ["However, the patient's symptoms were not completely relieved.", [["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20], ["the patient's symptoms", "PROBLEM", 9, 31]]], ["Furthermore, he still presented with hemoptysis, along with cavitation in the lesion in the right lung.", [["lesion", "ANATOMY", 78, 84], ["right lung", "ANATOMY", 92, 102], ["hemoptysis", "DISEASE", 37, 47], ["lesion", "CANCER", 78, 84], ["lung", "ORGAN", 98, 102], ["hemoptysis", "PROBLEM", 37, 47], ["cavitation in the lesion in the right lung", "PROBLEM", 60, 102], ["hemoptysis", "OBSERVATION", 37, 47], ["cavitation", "OBSERVATION_MODIFIER", 60, 70], ["lesion", "OBSERVATION", 78, 84], ["right", "ANATOMY_MODIFIER", 92, 97], ["lung", "ANATOMY", 98, 102]]], ["On week 28, the patient died of sudden massive hemoptysis.DiscussionHemoptysis is one of the most frequent symptoms of lung cancer and its pathophysiology remains unclear.", [["lung cancer", "ANATOMY", 119, 130], ["hemoptysis", "DISEASE", 47, 57], ["Hemoptysis", "DISEASE", 68, 78], ["lung cancer", "DISEASE", 119, 130], ["patient", "ORGANISM", 16, 23], ["lung cancer", "CANCER", 119, 130], ["patient", "SPECIES", 16, 23], ["sudden massive hemoptysis", "PROBLEM", 32, 57], ["Hemoptysis", "PROBLEM", 68, 78], ["lung cancer", "PROBLEM", 119, 130], ["sudden", "OBSERVATION_MODIFIER", 32, 38], ["massive", "OBSERVATION_MODIFIER", 39, 46], ["hemoptysis", "OBSERVATION", 47, 57], ["lung", "ANATOMY", 119, 123], ["cancer", "OBSERVATION", 124, 130]]], ["Pulmonary hemorrhage or hemoptysis events related to tumor treatment are often reported in clinical trials of NSCLC as the most common adverse events of antiangiogenic drugs, such as bevacizumab.", [["Pulmonary", "ANATOMY", 0, 9], ["tumor", "ANATOMY", 53, 58], ["NSCLC", "ANATOMY", 110, 115], ["Pulmonary hemorrhage", "DISEASE", 0, 20], ["hemoptysis", "DISEASE", 24, 34], ["tumor", "DISEASE", 53, 58], ["NSCLC", "DISEASE", 110, 115], ["bevacizumab", "CHEMICAL", 183, 194], ["bevacizumab", "CHEMICAL", 183, 194], ["Pulmonary", "ORGAN", 0, 9], ["tumor", "CANCER", 53, 58], ["NSCLC", "CANCER", 110, 115], ["bevacizumab", "SIMPLE_CHEMICAL", 183, 194], ["Pulmonary hemorrhage", "PROBLEM", 0, 20], ["hemoptysis events", "PROBLEM", 24, 41], ["tumor treatment", "TREATMENT", 53, 68], ["NSCLC", "PROBLEM", 110, 115], ["antiangiogenic drugs", "TREATMENT", 153, 173], ["bevacizumab", "TREATMENT", 183, 194], ["hemorrhage", "OBSERVATION", 10, 20], ["hemoptysis", "OBSERVATION", 24, 34], ["tumor", "OBSERVATION", 53, 58], ["NSCLC", "OBSERVATION", 110, 115]]], ["[1] [2] [3] [4] Some of these events are severe and even lead to fatal outcomes.", [["[1] [2] [3] [4", "SIMPLE_CHEMICAL", 0, 14], ["severe", "PROBLEM", 41, 47], ["severe", "OBSERVATION", 41, 47]]], ["However, different studies have achieved inconsistent risk factors of bleeding.", [["bleeding", "DISEASE", 70, 78], ["different studies", "TEST", 9, 26], ["bleeding", "PROBLEM", 70, 78], ["bleeding", "OBSERVATION", 70, 78]]], ["In a randomized phase II study, 9% of bevacizumab-treated patients experienced a life-threatening bleeding event and major hemoptysis was found to be related to squamous cell histology, tumor necrosis and cavitation, and disease location close to major blood vessels.", [["squamous cell", "ANATOMY", 161, 174], ["tumor", "ANATOMY", 186, 191], ["blood vessels", "ANATOMY", 253, 266], ["bevacizumab", "CHEMICAL", 38, 49], ["bleeding", "DISEASE", 98, 106], ["hemoptysis", "DISEASE", 123, 133], ["tumor", "DISEASE", 186, 191], ["necrosis", "DISEASE", 192, 200], ["bevacizumab", "CHEMICAL", 38, 49], ["bevacizumab", "SIMPLE_CHEMICAL", 38, 49], ["patients", "ORGANISM", 58, 66], ["squamous cell", "CELL", 161, 174], ["tumor", "CANCER", 186, 191], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 253, 266], ["patients", "SPECIES", 58, 66], ["a randomized phase II study", "TEST", 3, 30], ["bevacizumab", "TREATMENT", 38, 49], ["a life-threatening bleeding event", "PROBLEM", 79, 112], ["major hemoptysis", "PROBLEM", 117, 133], ["squamous cell histology", "PROBLEM", 161, 184], ["tumor necrosis", "PROBLEM", 186, 200], ["cavitation", "PROBLEM", 205, 215], ["disease location", "PROBLEM", 221, 237], ["hemoptysis", "OBSERVATION", 123, 133], ["squamous cell histology", "OBSERVATION", 161, 184], ["tumor", "OBSERVATION_MODIFIER", 186, 191], ["necrosis", "OBSERVATION", 192, 200], ["cavitation", "OBSERVATION_MODIFIER", 205, 215], ["blood vessels", "ANATOMY", 253, 266]]], ["5 As revealed in another retrospective case control analysis suggested that tumor cavitation at baseline could be a potential risk factor in bevacizumab-treated patients developing hemoptysis, while lesion location, size or vascular involvement appeared to be slightly related to severe hemoptysis.", [["tumor", "ANATOMY", 76, 81], ["lesion", "ANATOMY", 199, 205], ["vascular", "ANATOMY", 224, 232], ["tumor", "DISEASE", 76, 81], ["bevacizumab", "CHEMICAL", 141, 152], ["hemoptysis", "DISEASE", 181, 191], ["hemoptysis", "DISEASE", 287, 297], ["bevacizumab", "CHEMICAL", 141, 152], ["tumor", "CANCER", 76, 81], ["bevacizumab", "SIMPLE_CHEMICAL", 141, 152], ["patients", "ORGANISM", 161, 169], ["vascular", "MULTI-TISSUE_STRUCTURE", 224, 232], ["patients", "SPECIES", 161, 169], ["tumor cavitation", "PROBLEM", 76, 92], ["bevacizumab", "TREATMENT", 141, 152], ["hemoptysis", "PROBLEM", 181, 191], ["lesion location", "PROBLEM", 199, 214], ["vascular involvement", "PROBLEM", 224, 244], ["severe hemoptysis", "PROBLEM", 280, 297], ["tumor", "OBSERVATION", 76, 81], ["hemoptysis", "OBSERVATION", 181, 191], ["size", "OBSERVATION_MODIFIER", 216, 220], ["vascular", "ANATOMY", 224, 232], ["severe", "OBSERVATION_MODIFIER", 280, 286], ["hemoptysis", "OBSERVATION", 287, 297]]], ["6 As revealed by a consensus from a panel of experts, 7 patients with those risk factors of squamous cell carcinoma and a history of hemoptysis were restricted in bevacizumab use.", [["squamous cell carcinoma", "ANATOMY", 92, 115], ["squamous cell carcinoma", "DISEASE", 92, 115], ["hemoptysis", "DISEASE", 133, 143], ["bevacizumab", "CHEMICAL", 163, 174], ["bevacizumab", "CHEMICAL", 163, 174], ["patients", "ORGANISM", 56, 64], ["squamous cell carcinoma", "CANCER", 92, 115], ["bevacizumab", "SIMPLE_CHEMICAL", 163, 174], ["patients", "SPECIES", 56, 64], ["squamous cell carcinoma", "PROBLEM", 92, 115], ["hemoptysis", "PROBLEM", 133, 143], ["bevacizumab use", "TREATMENT", 163, 178], ["squamous cell carcinoma", "OBSERVATION", 92, 115], ["hemoptysis", "OBSERVATION", 133, 143]]], ["No other clinical radiological features (including cavitation and central tumor location) could reliable predict severe pulmonary hemorrhage in bevacizumab-treated patients, whereas major blood vessel infiltration and bronchial vessel infiltration, encasement and abutting may predict pulmonary hemorrhage.DiscussionPneumonitis is the most common serious AE associated with pembrolizumab in lung cancer trials and the leading AE that causes pembrolizumab discontinuation.", [["tumor", "ANATOMY", 74, 79], ["pulmonary", "ANATOMY", 120, 129], ["blood vessel", "ANATOMY", 188, 200], ["bronchial vessel", "ANATOMY", 218, 234], ["pulmonary", "ANATOMY", 285, 294], ["lung cancer", "ANATOMY", 391, 402], ["tumor", "DISEASE", 74, 79], ["pulmonary hemorrhage", "DISEASE", 120, 140], ["bevacizumab", "CHEMICAL", 144, 155], ["pulmonary hemorrhage", "DISEASE", 285, 305], ["Pneumonitis", "DISEASE", 316, 327], ["pembrolizumab", "CHEMICAL", 374, 387], ["lung cancer", "DISEASE", 391, 402], ["pembrolizumab", "CHEMICAL", 441, 454], ["bevacizumab", "CHEMICAL", 144, 155], ["pembrolizumab", "CHEMICAL", 374, 387], ["pembrolizumab", "CHEMICAL", 441, 454], ["tumor", "CANCER", 74, 79], ["pulmonary", "ORGAN", 120, 129], ["bevacizumab", "SIMPLE_CHEMICAL", 144, 155], ["patients", "ORGANISM", 164, 172], ["blood vessel", "MULTI-TISSUE_STRUCTURE", 188, 200], ["bronchial vessel", "MULTI-TISSUE_STRUCTURE", 218, 234], ["pulmonary", "ORGAN", 285, 294], ["pembrolizumab", "SIMPLE_CHEMICAL", 374, 387], ["lung cancer", "CANCER", 391, 402], ["pembrolizumab", "SIMPLE_CHEMICAL", 441, 454], ["patients", "SPECIES", 164, 172], ["other clinical radiological features", "PROBLEM", 3, 39], ["cavitation", "PROBLEM", 51, 61], ["central tumor location", "PROBLEM", 66, 88], ["severe pulmonary hemorrhage", "PROBLEM", 113, 140], ["bevacizumab", "TREATMENT", 144, 155], ["major blood vessel infiltration", "PROBLEM", 182, 213], ["bronchial vessel infiltration", "PROBLEM", 218, 247], ["encasement", "PROBLEM", 249, 259], ["pulmonary hemorrhage", "PROBLEM", 285, 305], ["Pneumonitis", "PROBLEM", 316, 327], ["pembrolizumab in lung cancer trials", "TREATMENT", 374, 409], ["the leading AE", "PROBLEM", 414, 428], ["pembrolizumab discontinuation", "TREATMENT", 441, 470], ["cavitation", "OBSERVATION_MODIFIER", 51, 61], ["central", "OBSERVATION_MODIFIER", 66, 73], ["tumor", "OBSERVATION", 74, 79], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["pulmonary", "ANATOMY", 120, 129], ["hemorrhage", "OBSERVATION", 130, 140], ["bevacizumab", "OBSERVATION", 144, 155], ["blood vessel", "ANATOMY", 188, 200], ["infiltration", "OBSERVATION", 201, 213], ["bronchial vessel", "ANATOMY", 218, 234], ["infiltration", "OBSERVATION", 235, 247], ["pulmonary", "ANATOMY", 285, 294], ["hemorrhage", "OBSERVATION", 295, 305], ["Pneumonitis", "OBSERVATION", 316, 327], ["most common", "OBSERVATION_MODIFIER", 335, 346], ["pembrolizumab", "OBSERVATION", 374, 387], ["lung", "ANATOMY", 391, 395], ["cancer", "OBSERVATION", 396, 402], ["pembrolizumab discontinuation", "OBSERVATION", 441, 470]]], ["8 CIP is also the leading cause of ICI-related death.", [["ICI", "CHEMICAL", 35, 38], ["death", "DISEASE", 47, 52], ["ICI", "CHEMICAL", 35, 38], ["ICI", "SIMPLE_CHEMICAL", 35, 38], ["ICI-related death", "PROBLEM", 35, 52]]], ["9 Bleeding events have been rarely reported with ICIs in clinical trials and the relevant risk factors are poorly understood.", [["Bleeding events", "PROBLEM", 2, 17], ["Bleeding", "OBSERVATION", 2, 10]]], ["Five lethal bleeding cases have been previously reported when atezolizumab was combined with chemotherapy and bevacizumab in nonsquamous NSCLC, four of which occurred in patients with potential high-risk features, such as tumor infiltration of great vessels or cavitation.", [["nonsquamous NSCLC", "ANATOMY", 125, 142], ["tumor", "ANATOMY", 222, 227], ["vessels", "ANATOMY", 250, 257], ["bleeding", "DISEASE", 12, 20], ["atezolizumab", "CHEMICAL", 62, 74], ["bevacizumab", "CHEMICAL", 110, 121], ["NSCLC", "DISEASE", 137, 142], ["tumor", "DISEASE", 222, 227], ["atezolizumab", "CHEMICAL", 62, 74], ["bevacizumab", "CHEMICAL", 110, 121], ["atezolizumab", "SIMPLE_CHEMICAL", 62, 74], ["bevacizumab", "SIMPLE_CHEMICAL", 110, 121], ["nonsquamous NSCLC", "CANCER", 125, 142], ["patients", "ORGANISM", 170, 178], ["tumor", "CANCER", 222, 227], ["vessels", "MULTI-TISSUE_STRUCTURE", 250, 257], ["patients", "SPECIES", 170, 178], ["Five lethal bleeding cases", "PROBLEM", 0, 26], ["atezolizumab", "TREATMENT", 62, 74], ["chemotherapy", "TREATMENT", 93, 105], ["bevacizumab", "TREATMENT", 110, 121], ["nonsquamous NSCLC", "PROBLEM", 125, 142], ["potential high-risk features", "PROBLEM", 184, 212], ["tumor infiltration", "PROBLEM", 222, 240], ["cavitation", "PROBLEM", 261, 271], ["lethal", "OBSERVATION_MODIFIER", 5, 11], ["bleeding", "OBSERVATION", 12, 20], ["nonsquamous NSCLC", "OBSERVATION", 125, 142], ["tumor", "OBSERVATION", 222, 227], ["great vessels", "ANATOMY", 244, 257], ["cavitation", "OBSERVATION", 261, 271]]], ["10 Another two fatal cases of hemoptysis have been previously reported after the first dose of pembrolizumab in patients with lung adenocarcinoma.", [["lung adenocarcinoma", "ANATOMY", 126, 145], ["hemoptysis", "DISEASE", 30, 40], ["pembrolizumab", "CHEMICAL", 95, 108], ["lung adenocarcinoma", "DISEASE", 126, 145], ["pembrolizumab", "CHEMICAL", 95, 108], ["pembrolizumab", "SIMPLE_CHEMICAL", 95, 108], ["patients", "ORGANISM", 112, 120], ["lung adenocarcinoma", "CANCER", 126, 145], ["patients", "SPECIES", 112, 120], ["hemoptysis", "PROBLEM", 30, 40], ["pembrolizumab", "TREATMENT", 95, 108], ["lung adenocarcinoma", "PROBLEM", 126, 145], ["hemoptysis", "OBSERVATION", 30, 40], ["lung", "ANATOMY", 126, 130], ["adenocarcinoma", "OBSERVATION", 131, 145]]], ["11, 12 As suggested by the authors, the achievement of a great response and rapid tumor shrinkage after treatment with ICIs may lead to massive hemoptysis in NSCLC with central localization, vascular involvement, as well as high PD-L1 expression.DiscussionIn the present study, we report a case of lesion shrinkage after four cycles of pembrolizumab monotherapy and recurrent hemoptysis accompanied by CIP after eight cycles.", [["tumor", "ANATOMY", 82, 87], ["NSCLC", "ANATOMY", 158, 163], ["vascular", "ANATOMY", 191, 199], ["lesion", "ANATOMY", 298, 304], ["tumor", "DISEASE", 82, 87], ["ICIs", "DISEASE", 119, 123], ["hemoptysis", "DISEASE", 144, 154], ["NSCLC", "DISEASE", 158, 163], ["pembrolizumab", "CHEMICAL", 336, 349], ["hemoptysis", "DISEASE", 376, 386], ["CIP", "DISEASE", 402, 405], ["pembrolizumab", "CHEMICAL", 336, 349], ["tumor", "CANCER", 82, 87], ["NSCLC", "CANCER", 158, 163], ["vascular", "MULTI-TISSUE_STRUCTURE", 191, 199], ["PD-L1", "GENE_OR_GENE_PRODUCT", 229, 234], ["pembrolizumab", "SIMPLE_CHEMICAL", 336, 349], ["a great response", "PROBLEM", 55, 71], ["rapid tumor shrinkage", "PROBLEM", 76, 97], ["treatment", "TREATMENT", 104, 113], ["ICIs", "TREATMENT", 119, 123], ["massive hemoptysis", "PROBLEM", 136, 154], ["NSCLC", "PROBLEM", 158, 163], ["central localization", "TEST", 169, 189], ["vascular involvement", "PROBLEM", 191, 211], ["high PD-L1 expression", "PROBLEM", 224, 245], ["the present study", "TEST", 259, 276], ["lesion shrinkage", "PROBLEM", 298, 314], ["pembrolizumab monotherapy", "TREATMENT", 336, 361], ["recurrent hemoptysis", "PROBLEM", 366, 386], ["CIP", "PROBLEM", 402, 405], ["rapid", "OBSERVATION_MODIFIER", 76, 81], ["tumor", "OBSERVATION", 82, 87], ["massive", "OBSERVATION_MODIFIER", 136, 143], ["hemoptysis", "OBSERVATION", 144, 154], ["NSCLC", "OBSERVATION", 158, 163], ["central", "ANATOMY_MODIFIER", 169, 176], ["vascular", "ANATOMY", 191, 199], ["involvement", "OBSERVATION", 200, 211], ["L1", "ANATOMY", 232, 234], ["lesion", "OBSERVATION", 298, 304], ["recurrent", "OBSERVATION_MODIFIER", 366, 375], ["hemoptysis", "OBSERVATION", 376, 386]]], ["The body temperature of the patient in our study was consistently normal, laboratory findings were not indicative of bacteria or fungal infection, and corticosteroids were not used before the appearance of the low density shadow and subsequent transparent area following ICI therapy.", [["body", "ANATOMY", 4, 8], ["fungal infection", "DISEASE", 129, 145], ["ICI", "CHEMICAL", 271, 274], ["corticosteroids", "CHEMICAL", 151, 166], ["ICI", "CHEMICAL", 271, 274], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["patient", "ORGANISM", 28, 35], ["corticosteroids", "SIMPLE_CHEMICAL", 151, 166], ["ICI", "SIMPLE_CHEMICAL", 271, 274], ["patient", "SPECIES", 28, 35], ["The body temperature", "TEST", 0, 20], ["our study", "TEST", 39, 48], ["laboratory findings", "TEST", 74, 93], ["bacteria", "PROBLEM", 117, 125], ["fungal infection", "PROBLEM", 129, 145], ["corticosteroids", "TREATMENT", 151, 166], ["the low density shadow", "PROBLEM", 206, 228], ["ICI therapy", "TREATMENT", 271, 282], ["body", "OBSERVATION_MODIFIER", 4, 8], ["not indicative of", "UNCERTAINTY", 99, 116], ["bacteria", "OBSERVATION", 117, 125], ["fungal", "OBSERVATION_MODIFIER", 129, 135], ["infection", "OBSERVATION", 136, 145], ["low density", "OBSERVATION_MODIFIER", 210, 221], ["shadow", "OBSERVATION_MODIFIER", 222, 228], ["transparent", "OBSERVATION_MODIFIER", 244, 255], ["area", "OBSERVATION_MODIFIER", 256, 260], ["ICI therapy", "OBSERVATION", 271, 282]]], ["Accordingly, the cavity formation and hemoptysis could not have been associated with corticosteroid therapy, nor were they consistent with aspergillus infection.", [["cavity", "ANATOMY", 17, 23], ["hemoptysis", "DISEASE", 38, 48], ["aspergillus infection", "DISEASE", 139, 160], ["cavity", "PATHOLOGICAL_FORMATION", 17, 23], ["corticosteroid", "SIMPLE_CHEMICAL", 85, 99], ["the cavity formation", "PROBLEM", 13, 33], ["hemoptysis", "PROBLEM", 38, 48], ["corticosteroid therapy", "TREATMENT", 85, 107], ["aspergillus infection", "PROBLEM", 139, 160], ["cavity", "OBSERVATION_MODIFIER", 17, 23], ["hemoptysis", "OBSERVATION", 38, 48], ["consistent with", "UNCERTAINTY", 123, 138], ["aspergillus", "OBSERVATION_MODIFIER", 139, 150], ["infection", "OBSERVATION", 151, 160]]], ["The case in our study is inconsistent with that reported by Zarogoulidis 13 et al. in which a lung mass turned into an abscess together with the patient suffering from fever, infection indicated by laboratory findings and effective antibiotic treatment.", [["lung mass", "ANATOMY", 94, 103], ["abscess", "ANATOMY", 119, 126], ["lung mass", "DISEASE", 94, 103], ["abscess", "DISEASE", 119, 126], ["fever", "DISEASE", 168, 173], ["infection", "DISEASE", 175, 184], ["lung", "ORGAN", 94, 98], ["abscess", "PATHOLOGICAL_FORMATION", 119, 126], ["patient", "ORGANISM", 145, 152], ["patient", "SPECIES", 145, 152], ["our study", "TEST", 12, 21], ["a lung mass", "PROBLEM", 92, 103], ["an abscess", "PROBLEM", 116, 126], ["fever", "PROBLEM", 168, 173], ["infection", "PROBLEM", 175, 184], ["laboratory findings", "TEST", 198, 217], ["effective antibiotic treatment", "TREATMENT", 222, 252], ["lung", "ANATOMY", 94, 98], ["mass", "OBSERVATION", 99, 103], ["abscess", "OBSERVATION", 119, 126], ["fever", "OBSERVATION", 168, 173]]], ["Reviewing the studies of hemoptysis related to tumor treatment together with the findings in our case, we believe that the severe bleeding event was caused by the giant central location of the tumor that was significantly PD-L1 positive, shrinkage of the mass and large area necrosis with cavity formation after immunotherapy, as well as possible vascular involvement.", [["tumor", "ANATOMY", 47, 52], ["tumor", "ANATOMY", 193, 198], ["mass", "ANATOMY", 255, 259], ["area", "ANATOMY", 270, 274], ["cavity", "ANATOMY", 289, 295], ["vascular", "ANATOMY", 347, 355], ["hemoptysis", "DISEASE", 25, 35], ["tumor", "DISEASE", 47, 52], ["bleeding", "DISEASE", 130, 138], ["tumor", "DISEASE", 193, 198], ["necrosis", "DISEASE", 275, 283], ["tumor", "CANCER", 47, 52], ["tumor", "CANCER", 193, 198], ["PD-L1", "GENE_OR_GENE_PRODUCT", 222, 227], ["cavity", "PATHOLOGICAL_FORMATION", 289, 295], ["vascular", "MULTI-TISSUE_STRUCTURE", 347, 355], ["the studies", "TEST", 10, 21], ["hemoptysis", "PROBLEM", 25, 35], ["tumor treatment", "TREATMENT", 47, 62], ["the severe bleeding event", "PROBLEM", 119, 144], ["the tumor", "PROBLEM", 189, 198], ["significantly PD-L1 positive", "PROBLEM", 208, 236], ["the mass", "PROBLEM", 251, 259], ["large area necrosis", "PROBLEM", 264, 283], ["cavity formation", "PROBLEM", 289, 305], ["immunotherapy", "TREATMENT", 312, 325], ["vascular involvement", "PROBLEM", 347, 367], ["hemoptysis", "OBSERVATION", 25, 35], ["tumor", "OBSERVATION", 47, 52], ["severe", "OBSERVATION_MODIFIER", 123, 129], ["bleeding", "OBSERVATION", 130, 138], ["giant", "OBSERVATION_MODIFIER", 163, 168], ["central", "OBSERVATION_MODIFIER", 169, 176], ["tumor", "OBSERVATION", 193, 198], ["shrinkage", "OBSERVATION_MODIFIER", 238, 247], ["mass", "OBSERVATION", 255, 259], ["large", "OBSERVATION_MODIFIER", 264, 269], ["area", "OBSERVATION_MODIFIER", 270, 274], ["necrosis", "OBSERVATION", 275, 283], ["cavity formation", "OBSERVATION", 289, 305], ["possible", "UNCERTAINTY", 338, 346], ["vascular", "ANATOMY", 347, 355], ["involvement", "OBSERVATION", 356, 367]]], ["However, in our case, vascular involvement was unclear as it was impacted by the lack of enhanced CT as a result of MRI contrast medium allergy in the patient; in addition, patient autopsy was refused.", [["vascular", "ANATOMY", 22, 30], ["allergy", "DISEASE", 136, 143], ["vascular", "MULTI-TISSUE_STRUCTURE", 22, 30], ["patient", "ORGANISM", 151, 158], ["patient", "ORGANISM", 173, 180], ["patient", "SPECIES", 151, 158], ["patient", "SPECIES", 173, 180], ["enhanced CT", "TEST", 89, 100], ["MRI", "TEST", 116, 119], ["vascular", "ANATOMY", 22, 30], ["involvement", "OBSERVATION", 31, 42]]], ["In conclusion, this study alerts clinicians to place more emphasis on hemoptysis which could be associated with the use of ICIs in NSCLC.", [["NSCLC", "ANATOMY", 131, 136], ["hemoptysis", "DISEASE", 70, 80], ["NSCLC", "DISEASE", 131, 136], ["NSCLC", "CANCER", 131, 136], ["this study", "TEST", 15, 25], ["hemoptysis", "PROBLEM", 70, 80], ["ICIs in NSCLC", "PROBLEM", 123, 136], ["hemoptysis", "OBSERVATION", 70, 80], ["NSCLC", "OBSERVATION", 131, 136]]]], "3bc70642b00cb1e53c8a6c83a584e429d626d199": [["BackgroundTransmissible gastroenteritis (TGE) is an acute viral disease, which is caused by TGEV infection and characterized by vomiting, dehydration, and severe diarrhea in pigs of all ages, especially less than 2-week-old suckling piglets.", [["Transmissible gastroenteritis", "DISEASE", 10, 39], ["TGE", "DISEASE", 41, 44], ["acute viral disease", "DISEASE", 52, 71], ["TGEV infection", "DISEASE", 92, 106], ["vomiting", "DISEASE", 128, 136], ["dehydration", "DISEASE", 138, 149], ["diarrhea", "DISEASE", 162, 170], ["TGEV", "ORGANISM", 92, 96], ["pigs", "ORGANISM", 174, 178], ["piglets", "ORGANISM", 233, 240], ["pigs", "SPECIES", 174, 178], ["piglets", "SPECIES", 233, 240], ["TGEV", "SPECIES", 92, 96], ["pigs", "SPECIES", 174, 178], ["BackgroundTransmissible gastroenteritis", "PROBLEM", 0, 39], ["an acute viral disease", "PROBLEM", 49, 71], ["TGEV infection", "PROBLEM", 92, 106], ["vomiting", "PROBLEM", 128, 136], ["dehydration", "PROBLEM", 138, 149], ["severe diarrhea", "PROBLEM", 155, 170], ["Transmissible", "OBSERVATION_MODIFIER", 10, 23], ["gastroenteritis", "OBSERVATION", 24, 39], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["viral disease", "OBSERVATION", 58, 71], ["TGEV", "OBSERVATION_MODIFIER", 92, 96], ["infection", "OBSERVATION", 97, 106], ["dehydration", "OBSERVATION_MODIFIER", 138, 149], ["severe", "OBSERVATION_MODIFIER", 155, 161], ["diarrhea", "OBSERVATION", 162, 170]]], ["TGEV can impair porcine intestinal epithelial cells and trigger inflammatory response, mitochondrial injury, apoptosis, and complete mitophagy in IPEC-J2 [1] .", [["intestinal epithelial cells", "ANATOMY", 24, 51], ["mitochondrial", "ANATOMY", 87, 100], ["mitochondrial injury", "DISEASE", 87, 107], ["TGEV", "ORGANISM", 0, 4], ["porcine", "ORGANISM", 16, 23], ["intestinal epithelial cells", "CELL", 24, 51], ["mitochondrial", "CELLULAR_COMPONENT", 87, 100], ["porcine intestinal epithelial cells", "CELL_TYPE", 16, 51], ["TGEV", "SPECIES", 0, 4], ["porcine", "SPECIES", 16, 23], ["TGEV", "SPECIES", 0, 4], ["porcine", "SPECIES", 16, 23], ["TGEV", "PROBLEM", 0, 4], ["impair porcine intestinal epithelial cells", "PROBLEM", 9, 51], ["inflammatory response", "PROBLEM", 64, 85], ["mitochondrial injury", "PROBLEM", 87, 107], ["apoptosis", "PROBLEM", 109, 118], ["intestinal epithelial cells", "OBSERVATION", 24, 51], ["inflammatory", "OBSERVATION_MODIFIER", 64, 76]]], ["Not only TGEV, but also other coronavirus such as Severe acute respiratory syndrome (SARS), Middle east respiratory syndrome coronavirus (MERS), Porcine epidemic diarrhea virus (PEDV) can cause severe inflammation response [2] [3] [4] [5] , indicating that inflammation response is a common pathological process during coronaviruses infection.BackgroundBecause of not coding, ncRNAs were previously known as junk RNAs.", [["Severe acute respiratory syndrome", "DISEASE", 50, 83], ["SARS", "DISEASE", 85, 89], ["Middle east respiratory syndrome coronavirus", "DISEASE", 92, 136], ["Porcine epidemic diarrhea virus", "DISEASE", 145, 176], ["inflammation", "DISEASE", 201, 213], ["inflammation", "DISEASE", 257, 269], ["coronaviruses infection", "DISEASE", 319, 342], ["TGEV", "ORGANISM", 9, 13], ["Middle east respiratory syndrome coronavirus", "ORGANISM", 92, 136], ["Porcine epidemic diarrhea virus", "ORGANISM", 145, 176], ["[2] [3] [4] [5]", "SIMPLE_CHEMICAL", 223, 238], ["coronaviruses", "ORGANISM", 319, 332], ["ncRNAs", "DNA", 376, 382], ["junk RNAs", "RNA", 408, 417], ["Porcine epidemic diarrhea virus", "SPECIES", 145, 176], ["TGEV", "SPECIES", 9, 13], ["Middle east respiratory syndrome coronavirus", "SPECIES", 92, 136], ["Porcine epidemic diarrhea virus", "SPECIES", 145, 176], ["PEDV", "SPECIES", 178, 182], ["TGEV", "PROBLEM", 9, 13], ["other coronavirus", "PROBLEM", 24, 41], ["Severe acute respiratory syndrome (SARS)", "PROBLEM", 50, 90], ["Middle east respiratory syndrome coronavirus (MERS)", "PROBLEM", 92, 143], ["Porcine epidemic diarrhea virus (PEDV", "PROBLEM", 145, 182], ["severe inflammation response", "PROBLEM", 194, 222], ["inflammation response", "PROBLEM", 257, 278], ["a common pathological process", "PROBLEM", 282, 311], ["coronaviruses infection", "PROBLEM", 319, 342], ["TGEV", "OBSERVATION", 9, 13], ["coronavirus", "OBSERVATION", 30, 41], ["Severe", "OBSERVATION_MODIFIER", 50, 56], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["respiratory syndrome", "OBSERVATION", 63, 83], ["Middle", "ANATOMY_MODIFIER", 92, 98], ["respiratory syndrome", "OBSERVATION", 104, 124], ["inflammation", "OBSERVATION", 257, 269], ["coronaviruses", "OBSERVATION_MODIFIER", 319, 332], ["infection", "OBSERVATION", 333, 342]]], ["However, increasing evidence shows that ncRNAs play important regulatory roles in many biological and pathological processes, such as inflammation, viral infection, and apoptosis [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] .", [["inflammation", "DISEASE", 134, 146], ["viral infection", "DISEASE", 148, 163], ["[6] [7] [8] [9] [10] [11] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 179, 224], ["ncRNAs", "DNA", 40, 46], ["many biological and pathological processes", "PROBLEM", 82, 124], ["inflammation", "PROBLEM", 134, 146], ["viral infection", "PROBLEM", 148, 163], ["apoptosis", "TEST", 169, 178], ["viral", "OBSERVATION_MODIFIER", 148, 153], ["infection", "OBSERVATION", 154, 163]]], ["We previously reported that TGEV infection led to 21 differentially expressed miRNAs, among which miR-4331 inhibited transcription of TGEV gene7 via targeting CDCA7 [16] , and miR-27b functioned as a negative regulator during TGEV-induced apoptosis [17] .", [["TGEV infection", "DISEASE", 28, 42], ["miR-4331", "CHEMICAL", 98, 106], ["TGEV", "ORGANISM", 28, 32], ["miR-4331", "GENE_OR_GENE_PRODUCT", 98, 106], ["TGEV", "ORGANISM", 134, 138], ["gene7", "GENE_OR_GENE_PRODUCT", 139, 144], ["CDCA7 [16]", "GENE_OR_GENE_PRODUCT", 159, 169], ["miR-27b", "GENE_OR_GENE_PRODUCT", 176, 183], ["TGEV", "ORGANISM", 226, 230], ["TGEV gene7", "DNA", 134, 144], ["CDCA7 [16]", "DNA", 159, 169], ["miR-27b", "DNA", 176, 183], ["TGEV", "SPECIES", 28, 32], ["TGEV", "SPECIES", 134, 138], ["TGEV", "SPECIES", 226, 230], ["TGEV infection", "PROBLEM", 28, 42], ["CDCA7", "TEST", 159, 164], ["miR", "TEST", 176, 179], ["infection", "OBSERVATION", 33, 42]]], ["Nevertheless, little is known about whether circRNAs are involved in TGEV-induced inflammation in porcine intestinal epithelial cells.BackgroundExcept for directly regulating genes, circRNAs may act as regulators by competing together with miRNAs to affect the stability of target RNAs or their translation. circRNAs harboring miRNA response elements (MREs) can function as miRNAs sponge to regulate gene expression.", [["intestinal epithelial cells", "ANATOMY", 106, 133], ["inflammation", "DISEASE", 82, 94], ["circRNAs", "GENE_OR_GENE_PRODUCT", 44, 52], ["TGEV", "ORGANISM", 69, 73], ["porcine", "ORGANISM", 98, 105], ["intestinal epithelial cells", "CELL", 106, 133], ["circRNAs", "GENE_OR_GENE_PRODUCT", 182, 190], ["circRNAs", "GENE_OR_GENE_PRODUCT", 308, 316], ["miRNA response elements", "GENE_OR_GENE_PRODUCT", 327, 350], ["MREs", "GENE_OR_GENE_PRODUCT", 352, 356], ["circRNAs", "PROTEIN", 44, 52], ["porcine intestinal epithelial cells", "CELL_TYPE", 98, 133], ["circRNAs", "DNA", 182, 190], ["target RNAs", "RNA", 274, 285], ["circRNAs", "PROTEIN", 308, 316], ["miRNA response elements", "DNA", 327, 350], ["MREs", "DNA", 352, 356], ["miRNAs sponge", "DNA", 374, 387], ["porcine", "SPECIES", 98, 105], ["TGEV", "SPECIES", 69, 73], ["porcine", "SPECIES", 98, 105], ["TGEV", "PROBLEM", 69, 73], ["inflammation in porcine intestinal epithelial cells", "PROBLEM", 82, 133], ["BackgroundExcept", "TREATMENT", 134, 150], ["circRNAs harboring miRNA response elements", "PROBLEM", 308, 350], ["miRNAs sponge", "TREATMENT", 374, 387], ["inflammation", "OBSERVATION", 82, 94], ["porcine", "ANATOMY_MODIFIER", 98, 105], ["intestinal epithelial cells", "OBSERVATION", 106, 133], ["response elements", "OBSERVATION", 333, 350]]], ["To investigate the effects of circRNAs during TGEV-induced inflammation, we performed RNA sequencing using NGS technology to test the alteration of mRNA, miRNA, and circRNA profiles during TGEV-induced inflammation in IPEC-J2 and con ducted bioinformatics analysis of differentially expressed mRNAs, miRNAs, and circRNAs.", [["circRNAs", "CHEMICAL", 30, 38], ["inflammation", "DISEASE", 59, 71], ["inflammation", "DISEASE", 202, 214], ["circRNAs", "GENE_OR_GENE_PRODUCT", 30, 38], ["TGEV", "ORGANISM", 46, 50], ["circRNA", "GENE_OR_GENE_PRODUCT", 165, 172], ["TGEV", "ORGANISM", 189, 193], ["IPEC-J2", "CELL", 218, 225], ["circRNAs", "GENE_OR_GENE_PRODUCT", 312, 320], ["circRNAs", "PROTEIN", 30, 38], ["mRNA", "RNA", 148, 152], ["mRNAs", "RNA", 293, 298], ["miRNAs", "RNA", 300, 306], ["circRNAs", "DNA", 312, 320], ["TGEV", "SPECIES", 46, 50], ["TGEV", "SPECIES", 189, 193], ["circRNAs", "PROBLEM", 30, 38], ["TGEV", "PROBLEM", 46, 50], ["inflammation", "PROBLEM", 59, 71], ["RNA sequencing", "TEST", 86, 100], ["NGS technology", "TEST", 107, 121], ["mRNA, miRNA, and circRNA profiles", "PROBLEM", 148, 181], ["TGEV", "PROBLEM", 189, 193], ["inflammation", "PROBLEM", 202, 214], ["IPEC", "TEST", 218, 222], ["con ducted bioinformatics analysis", "TEST", 230, 264], ["J2", "ANATOMY", 223, 225]]], ["We demonstrated that differentially expressed mRNAs, miRNAs, and circRNAs were mainly enriched in inflammation and immune response. ssc_circ_009380 attenuated TGEV-induced activation of NF-\u03baB pathway via binding miR-22.TGEV infection induces inflammatory response in IPEC-J2IPEC-J2 cells were infected with TGEV at 1.0 MOI for 12 h, 24 h, and 36 h.", [["IPEC-J2IPEC-J2 cells", "ANATOMY", 267, 287], ["inflammation", "DISEASE", 98, 110], ["ssc_circ_009380", "CHEMICAL", 132, 147], ["infection", "DISEASE", 224, 233], ["ssc_circ_009380", "CHEMICAL", 132, 147], ["circRNAs", "GENE_OR_GENE_PRODUCT", 65, 73], ["ssc_circ_009380", "SIMPLE_CHEMICAL", 132, 147], ["TGEV", "ORGANISM", 159, 163], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 186, 191], ["miR-22", "GENE_OR_GENE_PRODUCT", 212, 218], ["TGEV", "ORGANISM", 219, 223], ["IPEC-J2IPEC-J2 cells", "CELL", 267, 287], ["TGEV", "ORGANISM", 307, 311], ["mRNAs", "RNA", 46, 51], ["miRNAs", "RNA", 53, 59], ["circRNAs", "PROTEIN", 65, 73], ["NF-\u03baB", "PROTEIN", 186, 191], ["miR-22", "DNA", 212, 218], ["IPEC-J2IPEC-J2 cells", "CELL_LINE", 267, 287], ["TGEV", "SPECIES", 159, 163], ["TGEV", "SPECIES", 219, 223], ["TGEV", "SPECIES", 307, 311], ["differentially expressed mRNAs, miRNAs, and circRNAs", "PROBLEM", 21, 73], ["inflammation", "PROBLEM", 98, 110], ["binding miR", "TEST", 204, 215], ["TGEV infection", "PROBLEM", 219, 233], ["inflammatory response", "PROBLEM", 242, 263], ["IPEC", "TEST", 267, 271], ["J2 cells", "PROBLEM", 279, 287], ["TGEV", "PROBLEM", 307, 311], ["inflammation", "OBSERVATION", 98, 110], ["immune response", "OBSERVATION", 115, 130], ["infection", "OBSERVATION", 224, 233], ["inflammatory", "OBSERVATION_MODIFIER", 242, 254], ["J2 cells", "OBSERVATION_MODIFIER", 279, 287]]], ["The mRNA levels of IL-8, IL-6, and TNF-\u03b1 were examined.", [["IL-8", "GENE_OR_GENE_PRODUCT", 19, 23], ["IL-6", "GENE_OR_GENE_PRODUCT", 25, 29], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 35, 40], ["IL-8", "PROTEIN", 19, 23], ["IL-6", "PROTEIN", 25, 29], ["TNF", "PROTEIN", 35, 38], ["The mRNA levels", "TEST", 0, 15], ["IL", "TEST", 19, 21], ["IL", "TEST", 25, 27], ["TNF", "TEST", 35, 38], ["TNF", "ANATOMY", 35, 38]]], ["The results displayed that mRNA levels of IL-8, IL-6, and TNF-\u03b1 increased and reached to the peak at 24 h post infection (hpi) (Fig. 1) .Sequencing and analysis of ncRNAs and mRNAs of TGEVinfected IPEC-J2The total RNA was extracted and sequenced using the NGS technology.", [["infection", "DISEASE", 111, 120], ["IL-8", "GENE_OR_GENE_PRODUCT", 42, 46], ["IL-6", "GENE_OR_GENE_PRODUCT", 48, 52], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 58, 63], ["IL-6", "PROTEIN", 48, 52], ["TNF", "PROTEIN", 58, 61], ["ncRNAs", "DNA", 164, 170], ["mRNAs", "RNA", 175, 180], ["TGEVinfected IPEC-J2The total RNA", "RNA", 184, 217], ["mRNA levels", "TEST", 27, 38], ["IL", "TEST", 42, 44], ["IL", "TEST", 48, 50], ["TNF", "TEST", 58, 61], ["infection", "PROBLEM", 111, 120], ["Sequencing", "TEST", 137, 147], ["analysis", "TEST", 152, 160], ["ncRNAs", "TEST", 164, 170], ["mRNAs", "TEST", 175, 180], ["TGEVinfected IPEC", "TEST", 184, 201], ["J2The total RNA", "TREATMENT", 202, 217], ["the NGS technology", "TEST", 252, 270], ["infection", "OBSERVATION", 111, 120]]], ["In total, 523 differentially expressed mRNAs (including 462 up-regulated mRNAs and 61 down-regulated mRNAs), 65 differentially expressed miRNAs (including 46 up-regulated miRNAs and 19 down-regulated miRNAs) and 123 differentially expressed circRNAs (including 69 upregulated circRNAs and 54 down-regulated circRNAs) were obtained (Fig. 2 ).", [["circRNAs", "GENE_OR_GENE_PRODUCT", 241, 249], ["circRNAs", "GENE_OR_GENE_PRODUCT", 276, 284], ["circRNAs", "GENE_OR_GENE_PRODUCT", 307, 315], ["mRNAs", "RNA", 39, 44], ["462 up-regulated mRNAs", "RNA", 56, 78], ["mRNAs", "RNA", 101, 106], ["miRNAs", "RNA", 137, 143], ["circRNAs", "PROTEIN", 241, 249], ["circRNAs", "PROTEIN", 276, 284], ["circRNAs", "PROTEIN", 307, 315], ["mRNAs", "TEST", 39, 44], ["mRNAs", "TEST", 73, 78], ["miRNAs", "TEST", 137, 143], ["miRNAs", "TEST", 171, 177], ["circRNAs", "TEST", 241, 249], ["circRNAs", "TEST", 276, 284], ["miRNAs", "ANATOMY", 137, 143]]], ["In addition, there were 45 novel miRNAs in the differentially expressed miRNAs.", [["45 novel miRNAs", "PROBLEM", 24, 39], ["miRNAs", "OBSERVATION", 33, 39], ["differentially", "OBSERVATION_MODIFIER", 47, 61], ["expressed miRNAs", "OBSERVATION", 62, 78]]], ["More detailed information is respectively presented in Additional file 1: Tables S1-S3.KEGG analysis of differentially expressed miRNAs, circRNAs, and mRNAsWe predicted the targets of differentially expressed miRNAs and source genes of differentially expressed circRNAs.", [["circRNAs", "GENE_OR_GENE_PRODUCT", 137, 145], ["mRNAsWe", "GENE_OR_GENE_PRODUCT", 151, 158], ["circRNAs", "GENE_OR_GENE_PRODUCT", 261, 269], ["miRNAs", "RNA", 129, 135], ["circRNAs", "DNA", 137, 145], ["mRNAsWe", "DNA", 151, 158], ["source genes", "DNA", 220, 232], ["circRNAs", "PROTEIN", 261, 269], ["KEGG analysis", "TEST", 87, 100], ["circRNAs", "TEST", 137, 145], ["circRNAs", "OBSERVATION", 261, 269]]], ["7571 target genes of miRNAs and 98 source genes of circRNAs were obtained (Additional file 1: Tables S4 and S5 ).", [["circRNAs", "GENE_OR_GENE_PRODUCT", 51, 59], ["7571 target genes", "DNA", 0, 17], ["miRNAs", "DNA", 21, 27], ["circRNAs", "DNA", 51, 59], ["miRNAs", "TEST", 21, 27]]], ["These Fig. 1 The effects of TGEV infection on IL-1\u03b2, IL-6, and TNF-\u03b1 at transcriptional level. a The relative mRNA level of IL-8 in IPEC-J2 infected with TGEV for 0 h, 12 h, 24 h, or 36 h. b The relative mRNA level of IL-6 in IPEC-J2 infected with TGEV for 0 h, 12 h, 24 h, or 36 h. c The relative mRNA level of TNF-\u03b1 in IPEC-J2 infected with TGEV for 0 h, 12 h, 24 h, or 36 h.", [["IPEC-J2", "ANATOMY", 132, 139], ["IPEC-J2", "ANATOMY", 226, 233], ["IPEC-J2", "ANATOMY", 321, 328], ["infection", "DISEASE", 33, 42], ["TGEV", "ORGANISM", 28, 32], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 46, 51], ["IL-6", "GENE_OR_GENE_PRODUCT", 53, 57], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 63, 68], ["IL-8", "GENE_OR_GENE_PRODUCT", 124, 128], ["IPEC-J2", "CELL", 132, 139], ["TGEV", "ORGANISM", 154, 158], ["IL-6", "GENE_OR_GENE_PRODUCT", 218, 222], ["IPEC-J2", "CELL", 226, 233], ["TGEV", "ORGANISM", 248, 252], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 312, 317], ["IPEC-J2", "CELL", 321, 328], ["TGEV", "ORGANISM", 343, 347], ["TNF", "PROTEIN", 63, 66], ["IL-8", "PROTEIN", 124, 128], ["IL-6", "PROTEIN", 218, 222], ["TNF-\u03b1", "PROTEIN", 312, 317], ["TGEV", "SPECIES", 28, 32], ["TGEV", "SPECIES", 154, 158], ["TGEV", "SPECIES", 248, 252], ["TGEV", "SPECIES", 343, 347], ["TGEV infection", "PROBLEM", 28, 42], ["IL", "TEST", 46, 48], ["IL", "TEST", 53, 55], ["TNF", "TEST", 63, 66], ["IL", "TEST", 124, 126], ["IL", "TEST", 218, 220], ["The relative mRNA level", "TEST", 285, 308], ["TNF", "TEST", 312, 315], ["\u03b1", "TEST", 316, 317], ["IPEC", "TEST", 321, 325], ["TGEV", "OBSERVATION_MODIFIER", 28, 32], ["infection", "OBSERVATION", 33, 42], ["J2", "ANATOMY", 137, 139], ["J2", "ANATOMY", 231, 233], ["J2", "ANATOMY", 326, 328]]], ["The relative mRNA level was normalized to GAPDH. * p < 0.05 in comparison with the Mock. ** p < 0.01 in comparison with the Mock genes and differentially expressed mRNAs were respectively searched for functional enrichments by a KEGG database search (http://www.genome.jp/kegg/).", [["GAPDH", "GENE_OR_GENE_PRODUCT", 42, 47], ["Mock", "GENE_OR_GENE_PRODUCT", 124, 128], ["GAPDH", "PROTEIN", 42, 47], ["Mock genes", "DNA", 124, 134], ["mRNAs", "RNA", 164, 169], ["The relative mRNA level", "TEST", 0, 23], ["GAPDH", "PROBLEM", 42, 47]]], ["KEGG analysis results indicated that differentially expressed mRNAs were mostly involved in Toll-like receptor, RIG-I-like receptor, TNF, NOD-like receptor, Jak-STAT, and NF-\u03baB pathways (Fig. 3a) .", [["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 92, 110], ["RIG-I-like receptor", "GENE_OR_GENE_PRODUCT", 112, 131], ["TNF", "GENE_OR_GENE_PRODUCT", 133, 136], ["NOD-like receptor", "GENE_OR_GENE_PRODUCT", 138, 155], ["Jak-STAT", "GENE_OR_GENE_PRODUCT", 157, 165], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 171, 176], ["mRNAs", "RNA", 62, 67], ["Toll-like receptor", "PROTEIN", 92, 110], ["RIG-I-like receptor", "PROTEIN", 112, 131], ["TNF", "PROTEIN", 133, 136], ["NOD-like receptor", "PROTEIN", 138, 155], ["Jak-STAT", "PROTEIN", 157, 165], ["NF-\u03baB", "PROTEIN", 171, 176], ["KEGG analysis", "TEST", 0, 13], ["TNF", "TEST", 133, 136], ["NOD", "TEST", 138, 141], ["NF", "TEST", 171, 173]]], ["Differentially expressed miRNAs were primarily enriched in B cell receptor and Toll-like receptor pathways (Fig. 3b) .", [["B cell", "ANATOMY", 59, 65], ["B cell receptor", "GENE_OR_GENE_PRODUCT", 59, 74], ["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 79, 97], ["B cell receptor", "PROTEIN", 59, 74], ["Toll-like receptor", "PROTEIN", 79, 97], ["Differentially expressed miRNAs", "PROBLEM", 0, 31], ["B cell receptor", "TREATMENT", 59, 74], ["Toll-like receptor pathways", "TREATMENT", 79, 106]]], ["The source genes of differentially expressed circRNAs were involved in RIG-I-like receptor, TNF, NOD-like receptor, and NF-\u03baB pathways (Fig. 3c) .Analysis of ncRNA-mRNA regulatory networkTo predict the interaction between ncRNAs and mRNAs during TGEV infection, the intersection of differentially expressed targets of miRNAs and mRNAs were collected.", [["TGEV infection", "DISEASE", 246, 260], ["circRNAs", "GENE_OR_GENE_PRODUCT", 45, 53], ["RIG-I-like receptor", "GENE_OR_GENE_PRODUCT", 71, 90], ["TNF", "GENE_OR_GENE_PRODUCT", 92, 95], ["NOD-like receptor", "GENE_OR_GENE_PRODUCT", 97, 114], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 120, 125], ["Fig. 3c", "GENE_OR_GENE_PRODUCT", 136, 143], ["TGEV", "ORGANISM", 246, 250], ["circRNAs", "PROTEIN", 45, 53], ["RIG-I-like receptor", "PROTEIN", 71, 90], ["TNF", "PROTEIN", 92, 95], ["NOD-like receptor", "PROTEIN", 97, 114], ["NF-\u03baB", "PROTEIN", 120, 125], ["ncRNA", "DNA", 158, 163], ["ncRNAs", "DNA", 222, 228], ["mRNAs", "RNA", 233, 238], ["miRNAs", "RNA", 318, 324], ["mRNAs", "RNA", 329, 334], ["TGEV", "SPECIES", 246, 250], ["TNF", "TEST", 92, 95], ["NOD", "TEST", 97, 100], ["NF", "TEST", 120, 122], ["the interaction between ncRNAs", "PROBLEM", 198, 228], ["TGEV infection", "PROBLEM", 246, 260], ["miRNAs and mRNAs", "PROBLEM", 318, 334]]], ["Then, 133 genes were obtained (Fig. 4a) .", [["133 genes", "DNA", 6, 15]]], ["The interaction network of the 133 genes was constructed (Fig. 4b) (More detailed information is shown in Additional file 1: Table S6 ). circRNA-miRNA-mRNA regulation network was generated ( Fig. 5a and Additional file 1: Table S7 ).", [["circRNA-miRNA", "GENE_OR_GENE_PRODUCT", 137, 150], ["133 genes", "DNA", 31, 40], ["circRNA-miRNA", "PROTEIN", 137, 150]]], ["The mRNAs in circRNA-miRNA-mRNA regulatory network were searched against KEGG database for pathway enrichment.", [["circRNA-miRNA", "GENE_OR_GENE_PRODUCT", 13, 26], ["mRNAs", "RNA", 4, 9], ["The mRNAs in circRNA-miRNA", "TEST", 0, 26], ["pathway enrichment", "PROBLEM", 91, 109]]], ["The results indicated that these mRNAs were most significantly involved in RIG-I-like receptor, TNF, NOD-like receptor, Toll-like receptor, and NF-\u03baB pathways (Fig. 5b) .Validation of ncRNAs and mRNAs by qRT-PCRBoth divergent primers and convergent primers were designed and synthesized for identification of circular form.", [["RIG-I-like receptor", "GENE_OR_GENE_PRODUCT", 75, 94], ["TNF", "GENE_OR_GENE_PRODUCT", 96, 99], ["NOD-like receptor", "GENE_OR_GENE_PRODUCT", 101, 118], ["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 120, 138], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 144, 149], ["mRNAs", "RNA", 33, 38], ["RIG-I-like receptor", "PROTEIN", 75, 94], ["TNF", "PROTEIN", 96, 99], ["NOD-like receptor", "PROTEIN", 101, 118], ["Toll-like receptor", "PROTEIN", 120, 138], ["NF-\u03baB", "PROTEIN", 144, 149], ["ncRNAs", "DNA", 184, 190], ["mRNAs", "RNA", 195, 200], ["qRT-PCRBoth divergent primers", "DNA", 204, 233], ["mRNAs", "TEST", 195, 200], ["qRT", "TEST", 204, 207], ["PCRBoth divergent primers", "TREATMENT", 208, 233], ["convergent primers", "TEST", 238, 256]]], ["Head-to-tail splicing was validated by PCR.", [["tail", "ANATOMY", 8, 12]]], ["The results showed that ssc_circ_001964, ssc_circ_000470, ssc_circ_005884, and ssc_circ_009380 are circular (Fig. 6a) .", [["ssc_circ_001964", "GENE_OR_GENE_PRODUCT", 24, 39], ["ssc_circ_000470", "GENE_OR_GENE_PRODUCT", 41, 56], ["ssc_circ_005884", "GENE_OR_GENE_PRODUCT", 58, 73], ["ssc_circ_009380", "GENE_OR_GENE_PRODUCT", 79, 94], ["ssc_circ_001964", "DNA", 24, 39], ["ssc_circ_000470", "DNA", 41, 56], ["ssc_circ_005884", "DNA", 58, 73], ["ssc_circ_009380", "PROTEIN", 79, 94], ["ssc_circ_001964", "TEST", 24, 39], ["ssc_circ_000470", "TEST", 41, 56], ["ssc_circ_005884", "TEST", 58, 73]]], ["To validate the reliability of RNA sequencing, the expression levels of differentially expressed miRNAs (miR-218, mir-2413, mir-492, mir-7550, mir-2510, and miR-22), mRNAs (DDX58, CCL5, and IL-6), and cir-cRNAs (ssc_circ_001964, ssc_circ_000470, ssc_circ_ 005884, and ssc_circ_009380) were measured by qRT-PCR.", [["miR-218", "GENE_OR_GENE_PRODUCT", 105, 112], ["mir-2413", "GENE_OR_GENE_PRODUCT", 114, 122], ["mir-492", "GENE_OR_GENE_PRODUCT", 124, 131], ["mir-7550", "GENE_OR_GENE_PRODUCT", 133, 141], ["mir-2510", "GENE_OR_GENE_PRODUCT", 143, 151], ["miR-22", "GENE_OR_GENE_PRODUCT", 157, 163], ["DDX58", "GENE_OR_GENE_PRODUCT", 173, 178], ["CCL5", "GENE_OR_GENE_PRODUCT", 180, 184], ["IL-6", "GENE_OR_GENE_PRODUCT", 190, 194], ["cir-cRNAs", "GENE_OR_GENE_PRODUCT", 201, 210], ["ssc_circ_001964", "GENE_OR_GENE_PRODUCT", 212, 227], ["ssc_circ_000470", "GENE_OR_GENE_PRODUCT", 229, 244], ["ssc_circ_ 005884", "GENE_OR_GENE_PRODUCT", 246, 262], ["ssc_circ_009380", "GENE_OR_GENE_PRODUCT", 268, 283], ["miR-218", "DNA", 105, 112], ["mir-2413", "DNA", 114, 122], ["mir-7550", "DNA", 133, 141], ["mir-2510", "DNA", 143, 151], ["miR-22", "DNA", 157, 163], ["mRNAs", "RNA", 166, 171], ["DDX58", "DNA", 173, 178], ["CCL5", "DNA", 180, 184], ["IL-6", "DNA", 190, 194], ["cir-cRNAs", "DNA", 201, 210], ["ssc_circ_001964", "DNA", 212, 227], ["ssc_circ_000470", "DNA", 229, 244], ["ssc_circ_ 005884", "DNA", 246, 262], ["ssc_circ_009380", "DNA", 268, 283], ["RNA sequencing", "TEST", 31, 45], ["miR", "TEST", 105, 108], ["mir-", "TEST", 114, 118], ["mir", "TEST", 124, 127], ["mir", "TEST", 133, 136], ["mir", "TEST", 143, 146], ["miR", "TEST", 157, 160], ["mRNAs", "TEST", 166, 171], ["DDX58", "TEST", 173, 178], ["CCL5", "TEST", 180, 184], ["IL", "TEST", 190, 192], ["cir-cRNAs", "TEST", 201, 210], ["ssc_circ_001964", "TEST", 212, 227], ["ssc_circ_000470", "TEST", 229, 244], ["ssc_circ_", "TEST", 246, 255], ["ssc_circ_", "TEST", 268, 277]]], ["The results were consistent with that of RNA sequencing (Fig. 6b) .miR-22 directly binds to ssc_circ_009380In the present study, we demonstrated that TGEV infection activated inflammation-related pathways and up-regulated miR-22.", [["TGEV infection", "DISEASE", 150, 164], ["inflammation", "DISEASE", 175, 187], [".miR-22", "GENE_OR_GENE_PRODUCT", 66, 73], ["ssc_circ_009380", "GENE_OR_GENE_PRODUCT", 92, 107], ["TGEV", "ORGANISM", 150, 154], ["miR-22", "GENE_OR_GENE_PRODUCT", 222, 228], [".miR-22", "DNA", 66, 73], ["ssc_circ_009380", "DNA", 92, 107], ["miR-22", "DNA", 222, 228], ["TGEV", "SPECIES", 150, 154], ["RNA sequencing", "TEST", 41, 55], ["Fig.", "TEST", 57, 61], ["the present study", "TEST", 110, 127], ["TGEV infection activated inflammation", "PROBLEM", 150, 187], ["consistent with", "UNCERTAINTY", 17, 32], ["TGEV", "OBSERVATION_MODIFIER", 150, 154], ["infection", "OBSERVATION", 155, 164]]], ["It was reported that miR-22 was involved in regulating inflammation and immune response [18, 19] .", [["inflammation", "DISEASE", 55, 67], ["miR-22", "GENE_OR_GENE_PRODUCT", 21, 27], ["miR-22", "DNA", 21, 27], ["regulating inflammation", "PROBLEM", 44, 67], ["inflammation", "OBSERVATION", 55, 67]]], ["Therefore, we speculated that miR-22 might play a role in TGEV-induced inflammation response.", [["inflammation", "DISEASE", 71, 83], ["miR-22", "GENE_OR_GENE_PRODUCT", 30, 36], ["TGEV", "ORGANISM", 58, 62], ["miR-22", "DNA", 30, 36], ["TGEV", "SPECIES", 58, 62], ["TGEV", "PROBLEM", 58, 62], ["inflammation response", "PROBLEM", 71, 92], ["inflammation", "OBSERVATION", 71, 83]]], ["Based on bioinformatics analysis, miR-22 might bind to ssc_circ_009380.", [["miR-22", "GENE_OR_GENE_PRODUCT", 34, 40], ["ssc_circ_009380", "GENE_OR_GENE_PRODUCT", 55, 70], ["miR-22", "DNA", 34, 40], ["ssc_circ_009380", "DNA", 55, 70], ["bioinformatics analysis", "TEST", 9, 32], ["miR", "TEST", 34, 37]]], ["To confirm that, the sequence of ssc_circ_009380 was amplified by PCR and cloned into 3 \u2032 UTR of Renilla luciferase in psiCHECK-2 to construct wild-type (WT) recombinant plasmid psi-ssc_circ_009380-WT.", [["ssc_circ_009380", "GENE_OR_GENE_PRODUCT", 33, 48], ["luciferase", "GENE_OR_GENE_PRODUCT", 105, 115], ["psiCHECK-2", "GENE_OR_GENE_PRODUCT", 119, 129], ["wild-type (WT", "ORGANISM", 143, 156], ["ssc_circ_009380", "DNA", 33, 48], ["3 \u2032 UTR", "DNA", 86, 93], ["Renilla luciferase", "DNA", 97, 115], ["psiCHECK-2", "DNA", 119, 129], ["wild-type (WT) recombinant plasmid", "DNA", 143, 177], ["ssc_circ_009380", "TEST", 33, 48], ["PCR", "TEST", 66, 69], ["Renilla luciferase", "TEST", 97, 115], ["psiCHECK", "TEST", 119, 127], ["Renilla luciferase", "ANATOMY", 97, 115]]], ["The binding sites of miR-22 in ssc_circ_009380 were mutated by point mutation to construct mutant recombinant plasmid psi-ssc_circ_ 009380-Mut ( Fig. 7a and b) .", [["miR-22", "GENE_OR_GENE_PRODUCT", 21, 27], ["ssc_circ_009380", "GENE_OR_GENE_PRODUCT", 31, 46], ["binding sites", "DNA", 4, 17], ["miR-22", "DNA", 21, 27], ["ssc_circ_009380", "DNA", 31, 46], ["mutant recombinant plasmid psi-ssc_circ_ 009380", "DNA", 91, 138], ["Mut", "DNA", 139, 142]]], ["The recombinant plasmids were respectively co-transfected into IPEC-J2 cells together with miR-22 mimics (or miRNA mimics control, miR-22 inhibitors, miRNA inhibitors control). miR-22 was overexpressed using miR-22 mimics and inhibited using miR-22 inhibitors ( Fig. 7c and d) .", [["plasmids", "ANATOMY", 16, 24], ["IPEC-J2 cells", "ANATOMY", 63, 76], ["IPEC-J2 cells", "CELL", 63, 76], ["miR-22", "GENE_OR_GENE_PRODUCT", 91, 97], ["miR-22", "GENE_OR_GENE_PRODUCT", 131, 137], ["miR-22", "GENE_OR_GENE_PRODUCT", 177, 183], ["miR-22", "GENE_OR_GENE_PRODUCT", 208, 214], ["miR-22", "GENE_OR_GENE_PRODUCT", 242, 248], ["recombinant plasmids", "DNA", 4, 24], ["IPEC-J2 cells", "CELL_LINE", 63, 76], ["miR-22 mimics", "DNA", 91, 104], ["miR-22", "DNA", 177, 183], ["The recombinant plasmids", "TREATMENT", 0, 24], ["miR", "TEST", 91, 94], ["miRNA mimics control", "TREATMENT", 109, 129], ["miR-22 inhibitors", "TREATMENT", 131, 148], ["miRNA inhibitors control", "TREATMENT", 150, 174], ["miR-22 mimics", "TREATMENT", 208, 221], ["miR-22 inhibitors", "TREATMENT", 242, 259]]], ["The luciferase activities of psi-ssc_circ_009380-WT was decreased at 62% by miR-22 mimics and not affected by miR-22 inhibitors ( Fig. 7e and f) .", [["luciferase", "GENE_OR_GENE_PRODUCT", 4, 14], ["psi-ssc_circ_009380", "GENE_OR_GENE_PRODUCT", 29, 48], ["miR-22", "GENE_OR_GENE_PRODUCT", 76, 82], ["miR-22", "GENE_OR_GENE_PRODUCT", 110, 116], ["luciferase", "PROTEIN", 4, 14], ["psi-ssc_circ_009380-WT", "PROTEIN", 29, 51], ["The luciferase activities", "TEST", 0, 25], ["psi-ssc_circ_009380-WT", "TEST", 29, 51]]], ["However, the luciferase activities of psi-ssc_ci rc_009380-Mut was not affected by miR-22 mimics and inhibitors ( Fig. 7e and f ) .The effects of miR-22 and ssc_circ_009380 on TGEV-induced activation of NF-\u03baB in IPEC-J2.miR-22 directly binds to ssc_circ_009380To evaluate the effect of miR-22 on TGEV-induced NF-\u03baB activation, IPEC-J2 cells were transfected with miR-22 mimics (or miRNA mimics control, miR-22 inhibitors, miRNA inhibitors control) and subsequently infected with TGEV at 1 MOI for 24 h.", [["IPEC-J2 cells", "ANATOMY", 327, 340], ["luciferase", "GENE_OR_GENE_PRODUCT", 13, 23], ["psi-ssc_ci rc_009380-Mut", "GENE_OR_GENE_PRODUCT", 38, 62], ["miR-22", "GENE_OR_GENE_PRODUCT", 83, 89], ["miR-22", "GENE_OR_GENE_PRODUCT", 146, 152], ["ssc_circ_009380", "GENE_OR_GENE_PRODUCT", 157, 172], ["TGEV", "ORGANISM", 176, 180], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 203, 208], ["IPEC-J2", "CELL", 212, 219], ["miR-22", "GENE_OR_GENE_PRODUCT", 220, 226], ["ssc_circ_009380To", "GENE_OR_GENE_PRODUCT", 245, 262], ["miR-22", "GENE_OR_GENE_PRODUCT", 286, 292], ["TGEV", "ORGANISM", 296, 300], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 309, 314], ["IPEC-J2 cells", "CELL", 327, 340], ["miR-22", "GENE_OR_GENE_PRODUCT", 363, 369], ["miR-22", "GENE_OR_GENE_PRODUCT", 403, 409], ["TGEV", "ORGANISM", 479, 483], ["luciferase", "PROTEIN", 13, 23], ["psi-ssc_ci rc_009380", "PROTEIN", 38, 58], ["Mut", "PROTEIN", 59, 62], ["miR-22", "DNA", 146, 152], ["NF-\u03baB", "PROTEIN", 203, 208], ["IPEC-J2", "CELL_LINE", 212, 219], ["miR-22", "DNA", 220, 226], ["ssc_circ_009380To", "DNA", 245, 262], ["miR-22", "DNA", 286, 292], ["NF-\u03baB", "PROTEIN", 309, 314], ["IPEC-J2 cells", "CELL_LINE", 327, 340], ["miR-22 mimics", "DNA", 363, 376], ["TGEV", "SPECIES", 176, 180], ["TGEV", "SPECIES", 296, 300], ["TGEV", "SPECIES", 479, 483], ["the luciferase activities", "TEST", 9, 34], ["psi-ssc_ci", "TEST", 38, 48], ["miR", "TEST", 146, 149], ["TGEV", "TEST", 176, 180], ["NF", "TEST", 203, 205], ["miR", "TEST", 286, 289], ["TGEV", "TREATMENT", 296, 300], ["NF", "PROBLEM", 309, 311], ["B activation", "PROBLEM", 313, 325], ["IPEC", "TEST", 327, 331], ["J2 cells", "PROBLEM", 332, 340], ["miR", "TEST", 363, 366], ["miRNA mimics control", "TREATMENT", 381, 401], ["miR-22 inhibitors", "TREATMENT", 403, 420], ["miRNA inhibitors control", "TREATMENT", 422, 446], ["J2", "ANATOMY", 217, 219]]], ["The miR-22 was overexpressed by miR-22 mimics and inhibited by miR-22 inhibitors ( Fig. 8a and b) . p-I\u03baB-\u03b1 and nucleic distribution of p65 were suppressed by miR-22 mimics and increased by miR-22 inhibitors, but not affected by miR-22 mimics and inhibitors in cytoplasm ( Fig. 8d and e) .miR-22 directly binds to ssc_circ_009380To evaluate the effect of ssc_circ_009380 on TGEVinduced activation of NF-\u03baB, IPEC-J2 cells were transfected with siRNA of ssc_circ_009380 (siCirc009380) (or negative control) and subsequently infected with TGEV at 1 MOI for 24 h.", [["cytoplasm", "ANATOMY", 261, 270], ["IPEC-J2 cells", "ANATOMY", 407, 420], ["ssc_circ_009380", "CHEMICAL", 355, 370], ["siCirc009380", "CHEMICAL", 469, 481], ["siCirc009380", "CHEMICAL", 469, 481], ["miR-22", "GENE_OR_GENE_PRODUCT", 4, 10], ["miR-22", "GENE_OR_GENE_PRODUCT", 32, 38], ["miR-22", "GENE_OR_GENE_PRODUCT", 63, 69], ["p-I\u03baB-\u03b1", "GENE_OR_GENE_PRODUCT", 100, 107], ["p65", "GENE_OR_GENE_PRODUCT", 136, 139], ["miR-22", "GENE_OR_GENE_PRODUCT", 159, 165], ["miR-22", "GENE_OR_GENE_PRODUCT", 190, 196], ["miR-22", "GENE_OR_GENE_PRODUCT", 229, 235], ["cytoplasm", "ORGANISM_SUBSTANCE", 261, 270], [".miR-22", "GENE_OR_GENE_PRODUCT", 288, 295], ["ssc_circ_009380To", "GENE_OR_GENE_PRODUCT", 314, 331], ["ssc_circ_009380", "SIMPLE_CHEMICAL", 355, 370], ["TGEVinduced", "SIMPLE_CHEMICAL", 374, 385], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 400, 405], ["IPEC-J2 cells", "CELL", 407, 420], ["ssc_circ_009380", "SIMPLE_CHEMICAL", 452, 467], ["siCirc009380", "SIMPLE_CHEMICAL", 469, 481], ["TGEV", "ORGANISM", 536, 540], ["miR-22", "DNA", 4, 10], ["I\u03baB", "PROTEIN", 102, 105], ["p65", "PROTEIN", 136, 139], ["ssc_circ_009380To", "DNA", 314, 331], ["NF-\u03baB", "PROTEIN", 400, 405], ["IPEC-J2 cells", "CELL_LINE", 407, 420], ["TGEV", "SPECIES", 536, 540], ["The miR", "TEST", 0, 7], ["p65", "PROBLEM", 136, 139], ["inhibitors in cytoplasm", "PROBLEM", 247, 270], ["NF", "TEST", 400, 402], ["IPEC", "TEST", 407, 411], ["J2 cells", "PROBLEM", 412, 420], ["siRNA", "TEST", 443, 448], ["J2", "ANATOMY", 412, 414]]], ["The ssc_circ_009380 level was down-regulated by siCirc009380 (Fig. 8c) . p-I\u03baB-\u03b1 and p65 in nucleus were decreased by siCirc009380 and not affected in cytoplasm (Fig. 8f ).DiscussionIn the present study, differentially expressed 523 mRNAs, 65 miRNAs, and 123 circRNAs were obtained.", [["nucleus", "ANATOMY", 92, 99], ["cytoplasm", "ANATOMY", 151, 160], ["siCirc009380", "CHEMICAL", 48, 60], ["siCirc009380", "CHEMICAL", 118, 130], ["ssc_circ_009380", "GENE_OR_GENE_PRODUCT", 4, 19], ["p-I\u03baB-\u03b1", "GENE_OR_GENE_PRODUCT", 73, 80], ["p65", "GENE_OR_GENE_PRODUCT", 85, 88], ["nucleus", "CELLULAR_COMPONENT", 92, 99], ["siCirc009380", "SIMPLE_CHEMICAL", 118, 130], ["cytoplasm", "ORGANISM_SUBSTANCE", 151, 160], ["circRNAs", "GENE_OR_GENE_PRODUCT", 259, 267], ["ssc_circ_009380", "DNA", 4, 19], ["siCirc009380", "PROTEIN", 48, 60], ["p-I\u03baB", "PROTEIN", 73, 78], ["\u03b1", "PROTEIN", 79, 80], ["p65", "PROTEIN", 85, 88], ["siCirc009380", "PROTEIN", 118, 130], ["523 mRNAs", "RNA", 229, 238], ["65 miRNAs", "RNA", 240, 249], ["The ssc_circ_009380 level", "TEST", 0, 25], ["I\u03baB-\u03b1 and p65 in nucleus", "TEST", 75, 99], ["the present study", "TEST", 185, 202], ["mRNAs", "TEST", 233, 238], ["miRNAs", "TEST", 243, 249], ["123 circRNAs", "TEST", 255, 267], ["nucleus", "ANATOMY", 92, 99], ["decreased", "OBSERVATION_MODIFIER", 105, 114]]], ["KEGG analysis showed that differentially expressed mRNAs and ncRNAs were primarily enriched in inflammation-related pathways. circRNA ssc_circ_009380 was identified as the sponge of miR-22 and enhanced activation of NF-\u03baB pathway through binding miR-22 during TGEV infection.DiscussionDuring viral infection, host pathogen recognition receptors (PRRs), including Toll-like receptor, RIG-I-like receptor, NOD-like receptor, are responsible for recognizing viruses.", [["inflammation", "DISEASE", 95, 107], ["TGEV infection", "DISEASE", 260, 274], ["viral infection", "DISEASE", 292, 307], ["circRNA", "GENE_OR_GENE_PRODUCT", 126, 133], ["miR-22", "GENE_OR_GENE_PRODUCT", 182, 188], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 216, 221], ["miR-22", "GENE_OR_GENE_PRODUCT", 246, 252], ["TGEV", "ORGANISM", 260, 264], ["host pathogen recognition receptors", "GENE_OR_GENE_PRODUCT", 309, 344], ["PRRs", "GENE_OR_GENE_PRODUCT", 346, 350], ["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 363, 381], ["RIG-I-like receptor", "GENE_OR_GENE_PRODUCT", 383, 402], ["NOD-like receptor", "GENE_OR_GENE_PRODUCT", 404, 421], ["mRNAs", "RNA", 51, 56], ["ssc_circ_009380", "DNA", 134, 149], ["miR-22", "DNA", 182, 188], ["NF-\u03baB", "PROTEIN", 216, 221], ["miR-22", "DNA", 246, 252], ["host pathogen recognition receptors", "PROTEIN", 309, 344], ["PRRs", "PROTEIN", 346, 350], ["Toll-like receptor", "PROTEIN", 363, 381], ["RIG-I-like receptor", "PROTEIN", 383, 402], ["NOD-like receptor", "PROTEIN", 404, 421], ["TGEV", "SPECIES", 260, 264], ["KEGG analysis", "TEST", 0, 13], ["differentially expressed mRNAs and ncRNAs", "PROBLEM", 26, 67], ["inflammation", "PROBLEM", 95, 107], ["the sponge of miR", "TEST", 168, 185], ["NF", "TEST", 216, 218], ["binding miR", "TEST", 238, 249], ["TGEV infection", "PROBLEM", 260, 274], ["viral infection", "PROBLEM", 292, 307], ["recognizing viruses", "PROBLEM", 443, 462], ["inflammation", "OBSERVATION", 95, 107], ["infection", "OBSERVATION", 265, 274], ["infection", "OBSERVATION", 298, 307], ["viruses", "OBSERVATION", 455, 462]]], ["Then, the recognition initiates a series of signaling cascades, including Jak-STAT, TNF, and NF-\u03baB pathways to induce antiviral response [20] .", [["Jak-STAT", "GENE_OR_GENE_PRODUCT", 74, 82], ["TNF", "GENE_OR_GENE_PRODUCT", 84, 87], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 93, 98], ["Jak", "PROTEIN", 74, 77], ["STAT", "PROTEIN", 78, 82], ["TNF", "PROTEIN", 84, 87], ["NF-\u03baB", "PROTEIN", 93, 98], ["signaling cascades", "PROBLEM", 44, 62], ["Jak", "TEST", 74, 77], ["TNF", "TREATMENT", 84, 87]]], ["In this study, the 523 differentially expressed mRNAs are enriched in Toll-like receptors, RIG-I-like receptors, TNF, NOD-like receptors, Jak-STAT, and NF-\u03baB signaling pathways.", [["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 70, 89], ["RIG-I-like receptors", "GENE_OR_GENE_PRODUCT", 91, 111], ["TNF", "GENE_OR_GENE_PRODUCT", 113, 116], ["NOD-like receptors", "GENE_OR_GENE_PRODUCT", 118, 136], ["Jak-STAT", "GENE_OR_GENE_PRODUCT", 138, 146], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 152, 157], ["523 differentially expressed mRNAs", "RNA", 19, 53], ["Toll-like receptors", "PROTEIN", 70, 89], ["RIG-I-like receptors", "PROTEIN", 91, 111], ["TNF", "PROTEIN", 113, 116], ["NOD-like receptors", "PROTEIN", 118, 136], ["Jak-STAT", "PROTEIN", 138, 146], ["NF-\u03baB", "PROTEIN", 152, 157], ["this study", "TEST", 3, 13], ["TNF", "TEST", 113, 116], ["NOD", "TEST", 118, 121], ["NF", "TEST", 152, 154]]], ["NF-\u03baB pathway is a crucial pathway in inflammatory process and can be activated by Jak-STAT, TNF, Toll-like receptor, and RIG-I-like receptor pathways, which can Target genes of differentially expressed miRNAs. c Source genes of differentially expressed circRNAs.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["Jak-", "GENE_OR_GENE_PRODUCT", 83, 87], ["STAT", "GENE_OR_GENE_PRODUCT", 87, 91], ["TNF", "GENE_OR_GENE_PRODUCT", 93, 96], ["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 98, 116], ["RIG-I-like receptor", "GENE_OR_GENE_PRODUCT", 122, 141], ["circRNAs", "GENE_OR_GENE_PRODUCT", 254, 262], ["NF-\u03baB", "PROTEIN", 0, 5], ["Jak-STAT", "PROTEIN", 83, 91], ["TNF", "PROTEIN", 93, 96], ["Toll-like receptor", "PROTEIN", 98, 116], ["RIG-I", "PROTEIN", 122, 127], ["Target genes", "DNA", 162, 174], ["circRNAs", "PROTEIN", 254, 262], ["inflammatory process", "PROBLEM", 38, 58], ["inflammatory", "OBSERVATION", 38, 50], ["differentially expressed circRNAs", "OBSERVATION", 229, 262]]], ["The degree of KEGG enrichment is assessed by the Rich Factor, P-value, and Gene Number.", [["KEGG enrichment", "PROBLEM", 14, 29], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["KEGG enrichment", "OBSERVATION", 14, 29]]], ["The closer the P-value is to zero, the greater the Rich factor is.", [["P", "DNA", 15, 16], ["Rich factor", "PROTEIN", 51, 62], ["The closer the P-value", "TEST", 0, 22]]], ["The greater the Gene Number is, the more the enrichment is significant be activated by TGEV infection [21] [22] [23] [24] [25] [26] [27] .", [["infection", "DISEASE", 92, 101], ["TGEV", "ORGANISM", 87, 91], ["[21] [22] [23] [24] [25] [26] [27]", "SIMPLE_CHEMICAL", 102, 136], ["TGEV", "SPECIES", 87, 91], ["TGEV infection", "PROBLEM", 87, 101], ["greater", "OBSERVATION_MODIFIER", 4, 11]]], ["RIG-I is a dsRNA helicase enzyme encoded by the DDX58 gene and recognizes viral double-stranded (ds) RNA to interfere with viral infection [28, 29] .", [["viral infection", "DISEASE", 123, 138], ["RIG-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["DDX58", "GENE_OR_GENE_PRODUCT", 48, 53], ["RIG-I", "PROTEIN", 0, 5], ["dsRNA helicase enzyme", "PROTEIN", 11, 32], ["DDX58 gene", "DNA", 48, 58], ["viral double-stranded (ds) RNA", "RNA", 74, 104], ["a dsRNA helicase enzyme", "TEST", 9, 32], ["viral double-stranded (ds) RNA", "TREATMENT", 74, 104], ["viral infection", "PROBLEM", 123, 138]]], ["Recently, it has been confirmed that TGEV infection significantly upregulates RIG-I and activates NF-\u03baB pathway [27] .", [["TGEV infection", "DISEASE", 37, 51], ["TGEV", "ORGANISM", 37, 41], ["RIG-I", "GENE_OR_GENE_PRODUCT", 78, 83], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 98, 103], ["RIG-I", "PROTEIN", 78, 83], ["NF-\u03baB", "PROTEIN", 98, 103], ["TGEV", "SPECIES", 37, 41], ["TGEV infection", "PROBLEM", 37, 51], ["TGEV", "OBSERVATION_MODIFIER", 37, 41], ["infection", "OBSERVATION", 42, 51]]], ["Toll-like receptors (TLRs) are a class of proteins and play a key role in innate immune response by recognizing viral component [30] .", [["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 0, 19], ["TLRs", "GENE_OR_GENE_PRODUCT", 21, 25], ["Toll-like receptors", "PROTEIN", 0, 19], ["TLRs", "PROTEIN", 21, 25]]], ["TLR3, a member of TLR family, has a fundamental role in recognizing dsRNA of viruses and activation of IRF3 and NF-\u03baB pathway [31] .", [["TLR3", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR", "GENE_OR_GENE_PRODUCT", 18, 21], ["IRF3", "GENE_OR_GENE_PRODUCT", 103, 107], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 112, 117], ["TLR3", "PROTEIN", 0, 4], ["TLR family", "PROTEIN", 18, 28], ["IRF3", "PROTEIN", 103, 107], ["NF-\u03baB", "PROTEIN", 112, 117]]], ["In addition, other viruses, such as PSV and Influenza A virus, also give rise to activation of NF-\u03baB pathway via recognition of viral RNA by TLR3 [32, 33] .", [["PSV", "GENE_OR_GENE_PRODUCT", 36, 39], ["Influenza A virus", "ORGANISM", 44, 61], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 95, 100], ["TLR3", "GENE_OR_GENE_PRODUCT", 141, 145], ["NF-\u03baB", "PROTEIN", 95, 100], ["viral RNA", "RNA", 128, 137], ["TLR3", "PROTEIN", 141, 145], ["Influenza A virus", "SPECIES", 44, 61], ["Influenza A virus", "SPECIES", 44, 61], ["other viruses", "PROBLEM", 13, 26], ["PSV", "TREATMENT", 36, 39], ["Influenza A virus", "PROBLEM", 44, 61], ["NF", "TEST", 95, 97], ["viral RNA", "PROBLEM", 128, 137], ["viruses", "OBSERVATION", 19, 26], ["viral RNA", "OBSERVATION", 128, 137]]], ["Consistently, we find TGEV infection upregulates RIG-I and TLR3 and induces the activation of NF-\u03baB pathway in IPEC-J2 cells, indicating TGEV may activate NF-\u03baB pathway via RIG-I and TLR3 signaling.", [["IPEC-J2 cells", "ANATOMY", 111, 124], ["infection", "DISEASE", 27, 36], ["TGEV", "ORGANISM", 22, 26], ["RIG-I", "GENE_OR_GENE_PRODUCT", 49, 54], ["TLR3", "GENE_OR_GENE_PRODUCT", 59, 63], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 94, 99], ["IPEC-J2 cells", "CELL", 111, 124], ["TGEV", "ORGANISM", 137, 141], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 155, 160], ["RIG-I", "GENE_OR_GENE_PRODUCT", 173, 178], ["TLR3", "GENE_OR_GENE_PRODUCT", 183, 187], ["RIG-I", "PROTEIN", 49, 54], ["TLR3", "PROTEIN", 59, 63], ["NF-\u03baB", "PROTEIN", 94, 99], ["IPEC-J2 cells", "CELL_LINE", 111, 124], ["NF-\u03baB", "PROTEIN", 155, 160], ["TLR3", "PROTEIN", 183, 187], ["TGEV", "SPECIES", 22, 26], ["TGEV", "SPECIES", 137, 141], ["TGEV infection", "PROBLEM", 22, 36], ["TLR3", "TREATMENT", 59, 63], ["NF", "TEST", 94, 96], ["J2 cells", "PROBLEM", 116, 124], ["TGEV", "PROBLEM", 137, 141], ["NF", "TEST", 155, 157], ["infection", "OBSERVATION", 27, 36], ["J2", "ANATOMY", 116, 118]]], ["Jak-STAT signaling modulates transmission of signal from cell-membrane receptors to the nucleus and is essential for cytokines and growth factors, which cause critical cellular events such as immune responses, cell death, antiviral response [34] .", [["cell", "ANATOMY", 57, 61], ["membrane", "ANATOMY", 62, 70], ["nucleus", "ANATOMY", 88, 95], ["cellular", "ANATOMY", 168, 176], ["cell", "ANATOMY", 210, 214], ["death", "DISEASE", 215, 220], ["Jak-", "GENE_OR_GENE_PRODUCT", 0, 4], ["STAT", "GENE_OR_GENE_PRODUCT", 4, 8], ["cell-membrane", "CELLULAR_COMPONENT", 57, 70], ["nucleus", "CELLULAR_COMPONENT", 88, 95], ["cellular", "CELL", 168, 176], ["cell", "CELL", 210, 214], ["STAT", "PROTEIN", 4, 8], ["cell-membrane receptors", "PROTEIN", 57, 80], ["cytokines", "PROTEIN", 117, 126], ["growth factors", "PROTEIN", 131, 145], ["cytokines", "PROBLEM", 117, 126], ["growth factors", "PROBLEM", 131, 145], ["critical cellular events", "PROBLEM", 159, 183], ["immune responses", "PROBLEM", 192, 208], ["cell death", "PROBLEM", 210, 220], ["antiviral response", "TEST", 222, 240], ["nucleus", "ANATOMY", 88, 95], ["essential for", "UNCERTAINTY", 103, 116]]], ["It is found that Jak-STAT pathway induced p65 phosphorylation and activation of NF-\u03baB signaling during TGEV infection [26, 35] .", [["TGEV infection", "DISEASE", 103, 117], ["Jak-", "GENE_OR_GENE_PRODUCT", 17, 21], ["STAT", "GENE_OR_GENE_PRODUCT", 21, 25], ["p65", "GENE_OR_GENE_PRODUCT", 42, 45], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 80, 85], ["TGEV", "ORGANISM", 103, 107], ["STAT", "PROTEIN", 21, 25], ["p65", "PROTEIN", 42, 45], ["NF-\u03baB", "PROTEIN", 80, 85], ["TGEV", "SPECIES", 103, 107], ["p65 phosphorylation", "TREATMENT", 42, 61], ["NF", "PROBLEM", 80, 82], ["B signaling", "PROBLEM", 84, 95], ["TGEV infection", "PROBLEM", 103, 117]]], ["In this Fig. 5 Regulatory network analysis of lncRNA-miRNA-mRNA and circRNA-miRNA-mRNA. a The interaction network of circRNA-miRNA-mRNA.", [["lncRNA", "GENE_OR_GENE_PRODUCT", 46, 52], ["-miRNA", "GENE_OR_GENE_PRODUCT", 52, 58], ["circRNA-miRNA", "GENE_OR_GENE_PRODUCT", 68, 81], ["circRNA", "GENE_OR_GENE_PRODUCT", 117, 124], ["-miRNA", "GENE_OR_GENE_PRODUCT", 124, 130], ["lncRNA-miRNA-mRNA and circRNA-miRNA-mRNA", "RNA", 46, 86], ["circRNA-miRNA-mRNA", "RNA", 117, 135], ["lncRNA-miRNA", "TEST", 46, 58], ["circRNA", "OBSERVATION", 68, 75], ["circRNA-miRNA", "OBSERVATION", 117, 130]]], ["Red and green respectively represent up-and down-regulated genes.", [["regulated genes", "DNA", 49, 64], ["green respectively", "OBSERVATION", 8, 26]]], ["Hexagon, triangle, and rhombus respectively indicate lncRNA circRNA, and mRNA. b circRNA-miRNA-mRNA regulatory network interaction.", [["Hexagon", "CHEMICAL", 0, 7], ["Hexagon", "SIMPLE_CHEMICAL", 0, 7], ["lncRNA circRNA", "GENE_OR_GENE_PRODUCT", 53, 67], ["b circRNA-miRNA", "GENE_OR_GENE_PRODUCT", 79, 94], ["Hexagon, triangle, and rhombus", "RNA", 0, 30], ["lncRNA circRNA", "RNA", 53, 67], ["mRNA", "RNA", 73, 77], ["circRNA-miRNA", "PROTEIN", 81, 94], ["Hexagon", "TEST", 0, 7], ["lncRNA circRNA", "PROBLEM", 53, 67], ["triangle", "OBSERVATION_MODIFIER", 9, 17], ["lncRNA circRNA", "OBSERVATION", 53, 67]]], ["In this graphic, the degree of KEGG enrichment is assessed by the Rich Factor, P-value, and Gene Number.", [["KEGG enrichment", "PROBLEM", 31, 46], ["KEGG enrichment", "OBSERVATION", 31, 46]]], ["The closer the P-value is to zero, the greater the Rich factor is.", [["P", "DNA", 15, 16], ["Rich factor", "PROTEIN", 51, 62], ["The closer the P-value", "TEST", 0, 22]]], ["The greater the Gene Number is, the more the enrichment is significant study, TGEV infection activates the Jak-STAT signaling pathway in IPEC-J2 cells, consistent with previous studies.", [["IPEC-J2 cells", "ANATOMY", 137, 150], ["infection", "DISEASE", 83, 92], ["TGEV", "ORGANISM", 78, 82], ["Jak-", "GENE_OR_GENE_PRODUCT", 107, 111], ["STAT", "GENE_OR_GENE_PRODUCT", 111, 115], ["IPEC-J2 cells", "CELL", 137, 150], ["STAT", "PROTEIN", 111, 115], ["IPEC-J2 cells", "CELL_LINE", 137, 150], ["TGEV", "SPECIES", 78, 82], ["significant study", "PROBLEM", 59, 76], ["TGEV infection", "PROBLEM", 78, 92], ["previous studies", "TEST", 168, 184], ["greater", "OBSERVATION_MODIFIER", 4, 11], ["significant", "OBSERVATION_MODIFIER", 59, 70], ["TGEV", "OBSERVATION_MODIFIER", 78, 82], ["infection", "OBSERVATION", 83, 92], ["J2 cells", "OBSERVATION", 142, 150], ["consistent with", "UNCERTAINTY", 152, 167]]], ["IL-6 is a key mediator in response to acute inflammation caused by viral infection, including TGEV, PEDV, Head strong violence (HSV), H1N1 influenza virus, and hepatitis B virus (HBV) [36] [37] [38] [39] .", [["inflammation", "DISEASE", 44, 56], ["viral infection", "DISEASE", 67, 82], ["Head strong violence (HSV)", "DISEASE", 106, 132], ["influenza virus", "DISEASE", 139, 154], ["hepatitis B", "DISEASE", 160, 171], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["TGEV", "ORGANISM", 94, 98], ["Head strong violence", "ORGANISM", 106, 126], ["HSV", "ORGANISM", 128, 131], ["H1N1 influenza virus", "ORGANISM", 134, 154], ["hepatitis B virus", "ORGANISM", 160, 177], ["HBV", "ORGANISM", 179, 182], ["IL-6", "PROTEIN", 0, 4], ["H1N1 influenza virus", "SPECIES", 134, 154], ["hepatitis B virus", "SPECIES", 160, 177], ["TGEV", "SPECIES", 94, 98], ["PEDV", "SPECIES", 100, 104], ["HSV", "SPECIES", 128, 131], ["H1N1 influenza virus", "SPECIES", 134, 154], ["hepatitis B virus", "SPECIES", 160, 177], ["HBV", "SPECIES", 179, 182], ["acute inflammation", "PROBLEM", 38, 56], ["viral infection", "PROBLEM", 67, 82], ["TGEV", "PROBLEM", 94, 98], ["PEDV", "PROBLEM", 100, 104], ["Head strong violence (HSV)", "PROBLEM", 106, 132], ["H1N1 influenza virus", "PROBLEM", 134, 154], ["hepatitis B virus", "PROBLEM", 160, 177], ["acute", "OBSERVATION_MODIFIER", 38, 43], ["inflammation", "OBSERVATION", 44, 56], ["viral", "OBSERVATION_MODIFIER", 67, 72], ["infection", "OBSERVATION", 73, 82]]], ["Here, we have observed that TGEV infection up-regulates cytokines IL-6, TNF-\u03b1, IL-8, and CCL5.", [["TGEV infection", "DISEASE", 28, 42], ["TGEV", "ORGANISM", 28, 32], ["IL-6", "GENE_OR_GENE_PRODUCT", 66, 70], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 72, 77], ["IL-8", "GENE_OR_GENE_PRODUCT", 79, 83], ["CCL5", "GENE_OR_GENE_PRODUCT", 89, 93], ["cytokines", "PROTEIN", 56, 65], ["IL-6", "PROTEIN", 66, 70], ["TNF", "PROTEIN", 72, 75], ["IL-8", "PROTEIN", 79, 83], ["CCL5", "PROTEIN", 89, 93], ["TGEV", "SPECIES", 28, 32], ["TGEV infection", "PROBLEM", 28, 42], ["cytokines IL", "TEST", 56, 68], ["TNF", "TEST", 72, 75], ["IL", "TEST", 79, 81], ["CCL5", "PROBLEM", 89, 93], ["infection", "OBSERVATION", 33, 42], ["CCL5", "ANATOMY", 89, 93]]], ["IL-6 is both a proinflammatory cytokine and an anti-inflammatory cytokine.", [["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-6", "PROTEIN", 0, 4], ["proinflammatory cytokine", "PROTEIN", 15, 39], ["anti-inflammatory cytokine", "PROTEIN", 47, 73], ["a proinflammatory cytokine", "TREATMENT", 13, 39], ["an anti-inflammatory cytokine", "TREATMENT", 44, 73], ["proinflammatory cytokine", "OBSERVATION", 15, 39], ["anti-inflammatory cytokine", "OBSERVATION", 47, 73]]], ["IL-6 induces Jak-STAT signaling pathway and subsequently activates NF-KB signaling by binding to IL6R.", [["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["Jak-", "GENE_OR_GENE_PRODUCT", 13, 17], ["STAT", "GENE_OR_GENE_PRODUCT", 17, 21], ["NF-KB", "GENE_OR_GENE_PRODUCT", 67, 72], ["IL6R", "GENE_OR_GENE_PRODUCT", 97, 101], ["IL-6", "PROTEIN", 0, 4], ["STAT", "PROTEIN", 17, 21], ["NF-KB", "PROTEIN", 67, 72], ["IL6R", "PROTEIN", 97, 101]]], ["Moreover, activation of NF-KB can promote transcription of IL-6 [41, 42] .DiscussionmiRNAs and circular RNAs are crucial non-coding RNAs and implicated in various biological and pathological processes such as viral infection, immune responses, and inflammation.", [["viral infection", "DISEASE", 209, 224], ["inflammation", "DISEASE", 248, 260], ["NF-KB", "GENE_OR_GENE_PRODUCT", 24, 29], ["IL-6", "GENE_OR_GENE_PRODUCT", 59, 63], ["NF-KB", "PROTEIN", 24, 29], ["IL", "PROTEIN", 59, 61], ["circular RNAs", "RNA", 95, 108], ["non-coding RNAs", "RNA", 121, 136], ["DiscussionmiRNAs", "TREATMENT", 74, 90], ["circular RNAs", "TREATMENT", 95, 108], ["crucial non-coding RNAs", "PROBLEM", 113, 136], ["various biological and pathological processes", "PROBLEM", 155, 200], ["viral infection", "PROBLEM", 209, 224], ["inflammation", "PROBLEM", 248, 260], ["circular RNAs", "OBSERVATION", 95, 108], ["non-coding RNAs", "OBSERVATION", 121, 136], ["viral", "OBSERVATION_MODIFIER", 209, 214], ["infection", "OBSERVATION", 215, 224], ["inflammation", "OBSERVATION", 248, 260]]], ["It was reported that cellular miRNA profiles were altered during TGEV infection in PK-15 cells and ST cells [16, 43] .", [["cellular", "ANATOMY", 21, 29], ["PK-15 cells", "ANATOMY", 83, 94], ["ST cells", "ANATOMY", 99, 107], ["infection", "DISEASE", 70, 79], ["cellular", "CELL", 21, 29], ["TGEV", "ORGANISM", 65, 69], ["PK-15 cells", "CELL", 83, 94], ["ST cells", "CELL", 99, 107], ["PK-15 cells", "CELL_LINE", 83, 94], ["ST cells", "CELL_LINE", 99, 107], ["TGEV", "SPECIES", 65, 69], ["cellular miRNA profiles", "PROBLEM", 21, 44], ["TGEV infection", "PROBLEM", 65, 79], ["PK", "TEST", 83, 85], ["ST cells", "TEST", 99, 107], ["cellular miRNA", "OBSERVATION", 21, 35]]], ["In this study, miRNAs profile and circRNAs profile were changed during TGEV infection in IPEC-J2 cell line.", [["IPEC-J2 cell line", "ANATOMY", 89, 106], ["infection", "DISEASE", 76, 85], ["circRNAs", "GENE_OR_GENE_PRODUCT", 34, 42], ["TGEV", "ORGANISM", 71, 75], ["IPEC-J2 cell line", "CELL", 89, 106], ["IPEC-J2 cell line", "CELL_LINE", 89, 106], ["TGEV", "SPECIES", 71, 75], ["this study", "TEST", 3, 13], ["miRNAs profile", "TEST", 15, 29], ["circRNAs profile", "TEST", 34, 50], ["TGEV infection", "PROBLEM", 71, 85], ["J2 cell line", "TREATMENT", 94, 106], ["infection", "OBSERVATION", 76, 85], ["J2 cell line", "OBSERVATION", 94, 106]]], ["In comparison with the miRNAs profile of ST cells and PK-15 cells infected with TGEV, we observed a distinct miRNAs profile, indicating miRNAs are tissue specific. miR-22 is involved in inhibition of myocardial ischemia-reperfusion injury by an anti-inflammation mechanism [26] .", [["ST cells", "ANATOMY", 41, 49], ["PK-15 cells", "ANATOMY", 54, 65], ["tissue", "ANATOMY", 147, 153], ["myocardial", "ANATOMY", 200, 210], ["myocardial ischemia-reperfusion injury", "DISEASE", 200, 238], ["ST cells", "CELL", 41, 49], ["PK-15 cells", "CELL", 54, 65], ["TGEV", "ORGANISM", 80, 84], ["tissue", "TISSUE", 147, 153], ["miR-22", "GENE_OR_GENE_PRODUCT", 164, 170], ["myocardial", "MULTI-TISSUE_STRUCTURE", 200, 210], ["ST cells", "CELL_TYPE", 41, 49], ["PK-15 cells", "CELL_LINE", 54, 65], ["miR-22", "DNA", 164, 170], ["TGEV", "SPECIES", 80, 84], ["ST cells", "TEST", 41, 49], ["PK", "TEST", 54, 56], ["TGEV", "PROBLEM", 80, 84], ["a distinct miRNAs profile", "PROBLEM", 98, 123], ["myocardial ischemia-reperfusion injury", "PROBLEM", 200, 238], ["an anti-inflammation mechanism", "TREATMENT", 242, 272], ["distinct", "OBSERVATION_MODIFIER", 100, 108], ["miRNAs profile", "OBSERVATION", 109, 123], ["miRNAs", "OBSERVATION", 136, 142], ["myocardial", "ANATOMY", 200, 210], ["ischemia-reperfusion injury", "OBSERVATION", 211, 238]]], ["We demonstrated that miR-22 was up-regulated by TGEV infection and had an anti-inflammation effect by targeting IL-6 and restraining DDX58, and CCL5, which is correlated with previous reports, but through different mechanisms. cir-cRNAs are an abundant class of endogenous ncRNAs and function as a regulator via various mechanisms such as miRNA sponge, binding to RNA-binding protein, and regulating transcription and translation of gene [44] [45] [46] .", [["infection", "DISEASE", 53, 62], ["miR-22", "GENE_OR_GENE_PRODUCT", 21, 27], ["TGEV", "ORGANISM", 48, 52], ["IL-6", "GENE_OR_GENE_PRODUCT", 112, 116], ["DDX58", "GENE_OR_GENE_PRODUCT", 133, 138], ["CCL5", "GENE_OR_GENE_PRODUCT", 144, 148], ["cir-cRNAs", "GENE_OR_GENE_PRODUCT", 227, 236], ["RNA-binding protein", "GENE_OR_GENE_PRODUCT", 364, 383], ["miR-22", "DNA", 21, 27], ["IL-6", "PROTEIN", 112, 116], ["DDX58", "PROTEIN", 133, 138], ["CCL5", "PROTEIN", 144, 148], ["cir-cRNAs", "PROTEIN", 227, 236], ["endogenous ncRNAs", "DNA", 262, 279], ["RNA-binding protein", "PROTEIN", 364, 383], ["TGEV", "SPECIES", 48, 52], ["miR", "TEST", 21, 24], ["TGEV infection", "PROBLEM", 48, 62], ["an anti-inflammation effect", "TREATMENT", 71, 98], ["targeting IL", "TREATMENT", 102, 114], ["miRNA sponge", "TREATMENT", 339, 351], ["binding protein", "TEST", 368, 383], ["TGEV", "OBSERVATION_MODIFIER", 48, 52], ["infection", "OBSERVATION", 53, 62], ["anti-inflammation effect", "OBSERVATION", 74, 98], ["endogenous ncRNAs", "OBSERVATION", 262, 279]]], ["We found that miR-22 could be directly attached to ssc_circ_9380 and mediate TGEV-induced inflammation response, suggesting ssc_circ_9380 acts as the sponge of miR-22.ConclusionsIn the present study, we performed the next generation sequencing to obtain the profiles of mRNAs, miRNAs, and circRNAs of IPEC-J2 cells during TGEV infection and investigated the effects of differentially expressed Fig. 6 qRT-PCR validation of ncRNAs and mRNAs. a Both divergent primers ( ) and convergent primers ( ) were designed to detect the circular and linear form.", [["IPEC-J2 cells", "ANATOMY", 301, 314], ["inflammation", "DISEASE", 90, 102], ["ssc_circ_9380", "CHEMICAL", 124, 137], ["TGEV infection", "DISEASE", 322, 336], ["miR-22", "GENE_OR_GENE_PRODUCT", 14, 20], ["ssc_circ_9380", "GENE_OR_GENE_PRODUCT", 51, 64], ["TGEV", "ORGANISM", 77, 81], ["ssc_circ_9380", "GENE_OR_GENE_PRODUCT", 124, 137], ["miR-22", "GENE_OR_GENE_PRODUCT", 160, 166], ["IPEC-J2 cells", "CELL", 301, 314], ["TGEV", "ORGANISM", 322, 326], ["miR-22", "DNA", 14, 20], ["ssc_circ_9380", "PROTEIN", 51, 64], ["miR-22", "DNA", 160, 166], ["mRNAs", "RNA", 270, 275], ["miRNAs", "RNA", 277, 283], ["IPEC-J2 cells", "CELL_LINE", 301, 314], ["ncRNAs", "RNA", 423, 429], ["mRNAs", "RNA", 434, 439], ["TGEV", "SPECIES", 322, 326], ["TGEV", "SPECIES", 77, 81], ["TGEV", "SPECIES", 322, 326], ["mediate TGEV", "PROBLEM", 69, 81], ["inflammation response", "PROBLEM", 90, 111], ["ssc_circ_", "TEST", 124, 133], ["the sponge of miR", "TEST", 146, 163], ["the present study", "TEST", 181, 198], ["miRNAs", "TEST", 277, 283], ["J2 cells", "PROBLEM", 306, 314], ["TGEV infection", "PROBLEM", 322, 336], ["qRT", "TEST", 401, 404], ["PCR validation", "TEST", 405, 419], ["ncRNAs and mRNAs", "PROBLEM", 423, 439], ["convergent primers", "TEST", 474, 492], ["inflammation", "OBSERVATION", 90, 102], ["infection", "OBSERVATION", 327, 336], ["ncRNAs", "OBSERVATION", 423, 429], ["linear", "OBSERVATION_MODIFIER", 538, 544]]], ["The divergent primers were used to amplify circRNAs using cDNA but not gDNA as template. b The relative levels of differentially expressed mRNAs, miRNAs, and circRNAs.", [["circRNAs", "GENE_OR_GENE_PRODUCT", 43, 51], ["gDNA", "CELLULAR_COMPONENT", 71, 75], ["circRNAs", "GENE_OR_GENE_PRODUCT", 158, 166], ["circRNAs", "DNA", 43, 51], ["cDNA but not gDNA as template", "DNA", 58, 87], ["mRNAs", "RNA", 139, 144], ["miRNAs", "RNA", 146, 152], ["circRNAs", "DNA", 158, 166], ["The divergent primers", "TREATMENT", 0, 21], ["circRNAs using cDNA", "TREATMENT", 43, 62]]], ["The fold change was determined normalized to U6 using the 2-\u0394\u0394Ct method.", [["U6", "DNA", 45, 47], ["The fold change", "PROBLEM", 0, 15], ["the 2-\u0394\u0394Ct method", "TREATMENT", 54, 71], ["fold", "OBSERVATION_MODIFIER", 4, 8], ["change", "OBSERVATION", 9, 15]]], ["The data from real-time PCR are shown as mean \u00b1 standard deviation (S.D.) ncRNAs on TGEV induced inflammatory response.", [["TGEV", "ORGANISM", 84, 88], ["TGEV", "SPECIES", 84, 88], ["The data", "TEST", 0, 8], ["real-time PCR", "TEST", 14, 27], ["mean \u00b1 standard deviation (S.D.) ncRNAs", "PROBLEM", 41, 80], ["TGEV induced inflammatory response", "PROBLEM", 84, 118], ["inflammatory response", "OBSERVATION", 97, 118]]], ["The data reveal that the differentially expressed mRNAs and ncRNAs are enriched in inflammation-related pathways and ssc_circ_009380 potentiate TGEV-induced activation of NF-\u03baB pathway through attaching to miR-22.Antibodies, cells, and virusHistone H3 monoclonal antibody, phospho-I-\u03baB monoclonal antibody, and NF-\u03baB p65 (L8F6) mouse monoclonal antibody were purchased from Cell Signaling Technology (US). \u03b2-actin monoclonal antibody was purchased from Santa Cruz (US).", [["cells", "ANATOMY", 225, 230], ["Cell", "ANATOMY", 374, 378], ["inflammation", "DISEASE", 83, 95], ["ssc_circ_009380", "GENE_OR_GENE_PRODUCT", 117, 132], ["TGEV", "ORGANISM", 144, 148], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 171, 176], ["miR-22", "GENE_OR_GENE_PRODUCT", 206, 212], ["cells", "CELL", 225, 230], ["Histone H3", "GENE_OR_GENE_PRODUCT", 241, 251], ["phospho-I-\u03baB", "GENE_OR_GENE_PRODUCT", 273, 285], ["NF-\u03baB p65", "GENE_OR_GENE_PRODUCT", 311, 320], ["L8F6", "GENE_OR_GENE_PRODUCT", 322, 326], ["mouse", "ORGANISM", 328, 333], ["Cell", "CELL", 374, 378], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 406, 413], ["mRNAs", "RNA", 50, 55], ["NF-\u03baB", "PROTEIN", 171, 176], ["miR-22", "DNA", 206, 212], ["virusHistone H3 monoclonal antibody", "PROTEIN", 236, 271], ["phospho-I-\u03baB monoclonal antibody", "PROTEIN", 273, 305], ["NF-\u03baB p65 (L8F6) mouse monoclonal antibody", "PROTEIN", 311, 353], ["\u03b2-actin monoclonal antibody", "PROTEIN", 406, 433], ["Santa Cruz", "PROTEIN", 453, 463], ["mouse", "SPECIES", 328, 333], ["TGEV", "SPECIES", 144, 148], ["mouse", "SPECIES", 328, 333], ["The data", "TEST", 0, 8], ["the differentially expressed mRNAs and ncRNAs", "PROBLEM", 21, 66], ["inflammation", "PROBLEM", 83, 95], ["TGEV", "PROBLEM", 144, 148], ["NF", "PROBLEM", 171, 173], ["Antibodies", "TEST", 213, 223], ["cells", "TEST", 225, 230], ["virusHistone", "TEST", 236, 248], ["monoclonal antibody", "TEST", 252, 271], ["phospho", "TEST", 273, 280], ["I", "TEST", 281, 282], ["B monoclonal antibody", "TEST", 284, 305], ["NF", "TEST", 311, 313], ["\u03baB", "TEST", 314, 316], ["L8F6", "TEST", 322, 326], ["mouse monoclonal antibody", "TEST", 328, 353], ["\u03b2-actin monoclonal antibody", "TEST", 406, 433]]], ["Horseradish peroxidase (HRP)-conjugated secondary antibody was purchased from Pierce (US).", [["Horseradish peroxidase", "SIMPLE_CHEMICAL", 0, 22], ["HRP", "SIMPLE_CHEMICAL", 24, 27], ["Horseradish peroxidase (HRP)-conjugated secondary antibody", "PROTEIN", 0, 58], ["Horseradish", "SPECIES", 0, 11], ["Horseradish peroxidase (HRP)", "PROBLEM", 0, 28], ["conjugated secondary antibody", "PROBLEM", 29, 58]]], ["Dylight594-conjugated secondary antibody was purchased from Genshare Biological (China).", [["Dylight594", "CHEMICAL", 0, 10], ["Dylight594", "CHEMICAL", 0, 10], ["Dylight594", "SIMPLE_CHEMICAL", 0, 10], ["Dylight594-conjugated secondary antibody", "PROTEIN", 0, 40]]], ["IPEC-J2 cell line was kindly gifted by Dr. Zhanyong Wei (Henan Agricultural University, China).", [["IPEC-J2 cell line", "ANATOMY", 0, 17], ["IPEC-J2 cell line", "CELL", 0, 17], ["IPEC-J2 cell line", "CELL_LINE", 0, 17], ["IPEC", "TEST", 0, 4], ["J2 cell line", "TREATMENT", 5, 17], ["J2 cell line", "OBSERVATION", 5, 17]]], ["Cells were cultured in Dulbecco's Modified Eagle Medium (DMEM)/F-12/HAM (Thermo Fisher Scientific, US) supplemented with 100 IU of penicillin and 100 mg of streptomycin per ml, at 37\u00b0C in an incubator with 5% CO 2 .", [["Cells", "ANATOMY", 0, 5], ["penicillin", "CHEMICAL", 131, 141], ["streptomycin", "CHEMICAL", 156, 168], ["penicillin", "CHEMICAL", 131, 141], ["streptomycin", "CHEMICAL", 156, 168], ["CO 2", "CHEMICAL", 209, 213], ["Cells", "CELL", 0, 5], ["penicillin", "SIMPLE_CHEMICAL", 131, 141], ["streptomycin", "SIMPLE_CHEMICAL", 156, 168], ["Cells", "TEST", 0, 5], ["Dulbecco", "TEST", 23, 31], ["penicillin", "TREATMENT", 131, 141], ["streptomycin", "TREATMENT", 156, 168]]], ["The TGEV Shaanxi strain was separated from TGEV-infected piglets [47] . miR-22 mimics, miRNA mimics control, miR-22 inhibitors, miRNA inhibitors control, siCirc009380, and negative control were synthesized by GenePharma (China) (The sequences were shown in Additional file 1: Table S8 ).Antibodies, cells, and virusStrand-specific library construction and sequencing of mRNA and circRNA IPEC-J2 cells were infected with TGEV at 1 MOI for 24 h (indicated by T1 and T2).", [["cells", "ANATOMY", 299, 304], ["IPEC-J2 cells", "ANATOMY", 387, 400], ["TGEV Shaanxi", "ORGANISM", 4, 16], ["TGEV", "ORGANISM", 43, 47], ["piglets", "ORGANISM", 57, 64], ["miR-22", "GENE_OR_GENE_PRODUCT", 72, 78], ["miR-22", "GENE_OR_GENE_PRODUCT", 109, 115], ["siCirc009380", "SIMPLE_CHEMICAL", 154, 166], ["cells", "CELL", 299, 304], ["circRNA IPEC-J2 cells", "CELL", 379, 400], ["TGEV", "ORGANISM", 420, 424], ["miR-22", "DNA", 72, 78], ["virusStrand", "PROTEIN", 310, 321], ["mRNA", "RNA", 370, 374], ["circRNA IPEC-J2 cells", "CELL_LINE", 379, 400], ["piglets", "SPECIES", 57, 64], ["TGEV", "SPECIES", 4, 8], ["TGEV", "SPECIES", 43, 47], ["TGEV", "SPECIES", 420, 424], ["The TGEV Shaanxi strain", "PROBLEM", 0, 23], ["TGEV", "PROBLEM", 43, 47], ["miR", "TEST", 72, 75], ["miRNA mimics control", "TREATMENT", 87, 107], ["miR-22 inhibitors", "TREATMENT", 109, 126], ["miRNA inhibitors control", "TREATMENT", 128, 152], ["Antibodies", "TEST", 287, 297], ["cells", "TEST", 299, 304], ["virusStrand", "TEST", 310, 321], ["specific library construction", "TREATMENT", 322, 351], ["mRNA", "TEST", 370, 374], ["circRNA IPEC", "TEST", 379, 391], ["J2 cells", "PROBLEM", 392, 400], ["TGEV", "PROBLEM", 420, 424], ["J2 cells", "OBSERVATION_MODIFIER", 392, 400]]], ["Meanwhile, the mock infection (indicated by M1 and M2) was carried out.", [["infection", "DISEASE", 20, 29], ["the mock infection", "PROBLEM", 11, 29], ["infection", "OBSERVATION", 20, 29]]], ["Total RNA was extracted with Trizol reagent (Invitrogen, Carlsbad, CA, US).", [["Total RNA", "TREATMENT", 0, 9], ["Trizol reagent", "TREATMENT", 29, 43], ["Invitrogen", "TEST", 45, 55]]], ["Then rRNAs were removed to retain mRNAs and ncRNAs.", [["rRNAs", "RNA", 5, 10], ["mRNAs", "RNA", 34, 39], ["ncRNAs", "DNA", 44, 50]]], ["The mRNAs and ncRNAs were fragmented into short fragments using fragmentation buffer and reversely transcribed into cDNA using M-MLV kit (Invitrogen, US).", [["fragments", "ANATOMY", 48, 57], ["mRNAs", "RNA", 4, 9], ["ncRNAs", "DNA", 14, 20], ["cDNA", "DNA", 116, 120], ["The mRNAs and ncRNAs", "PROBLEM", 0, 20], ["short fragments", "PROBLEM", 42, 57], ["fragmentation buffer", "TREATMENT", 64, 84], ["fragmented", "OBSERVATION_MODIFIER", 26, 36], ["short fragments", "OBSERVATION_MODIFIER", 42, 57]]], ["Second-strand cDNA were synthesized by DNA polymerase I, RNase H, dNTP (dUTP instead of dTTP) and buffer.", [["dNTP", "CHEMICAL", 66, 70], ["dUTP", "CHEMICAL", 72, 76], ["dTTP", "CHEMICAL", 88, 92], ["dNTP", "CHEMICAL", 66, 70], ["dUTP", "CHEMICAL", 72, 76], ["dTTP", "CHEMICAL", 88, 92], ["DNA polymerase I", "GENE_OR_GENE_PRODUCT", 39, 55], ["RNase H", "GENE_OR_GENE_PRODUCT", 57, 64], ["dNTP", "SIMPLE_CHEMICAL", 66, 70], ["dUTP", "SIMPLE_CHEMICAL", 72, 76], ["dTTP", "SIMPLE_CHEMICAL", 88, 92], ["Second-strand cDNA", "DNA", 0, 18], ["DNA polymerase I", "PROTEIN", 39, 55], ["RNase H", "PROTEIN", 57, 64], ["Second-strand cDNA", "TREATMENT", 0, 18], ["dNTP (dUTP", "TREATMENT", 66, 76], ["dTTP)", "TREATMENT", 88, 93], ["buffer", "TREATMENT", 98, 104]]], ["Next, the cDNA fragments were purified with QiaQuick PCR extraction kit, end repaired, poly(A) added, and ligated to Illumina sequencing adapters.", [["poly(A", "CHEMICAL", 87, 93], ["poly(A", "SIMPLE_CHEMICAL", 87, 93], ["cDNA fragments", "DNA", 10, 24], ["Illumina sequencing adapters", "DNA", 117, 145], ["the cDNA fragments", "TREATMENT", 6, 24], ["QiaQuick PCR extraction kit", "TREATMENT", 44, 71], ["end repaired, poly(A)", "TREATMENT", 73, 94], ["Illumina sequencing adapters", "TREATMENT", 117, 145]]], ["Then UNG (Uracil-N-Glycosylase) was used to digest the second-strand cDNA.", [["UNG", "CHEMICAL", 5, 8], ["Uracil-N-Glycosylase", "CHEMICAL", 10, 30], ["Uracil", "CHEMICAL", 10, 16], ["UNG", "GENE_OR_GENE_PRODUCT", 5, 8], ["Uracil-N-Glycosylase", "GENE_OR_GENE_PRODUCT", 10, 30], ["UNG", "PROTEIN", 5, 8], ["Uracil-N-Glycosylase", "PROTEIN", 10, 30], ["second-strand cDNA", "DNA", 55, 73], ["UNG", "TEST", 5, 8], ["Uracil-N-Glycosylase)", "TREATMENT", 10, 31]]], ["The digested products were separated using agarose gel electrophoresis, amplified through PCR, and sequenced using Illumina HiSeqTM 2500 by Gene Denovo Biotechnology Co. (Guangzhou, China).Alignment with reference genomeTo get high quality clean reads, reads containing adapters, low quality reads, and rRNA reads were removed and then mapped to Sus scrofa reference genome (Sus scrofa 10.2) by TopHat2 (version 2.0.3.12) with default options.Transcripts reconstructionThe reconstruction of transcripts was carried out using Cufflinks (V2.2.1).", [["agarose", "SIMPLE_CHEMICAL", 43, 50], ["rRNA", "CELLULAR_COMPONENT", 303, 307], ["Sus scrofa", "ORGANISM", 346, 356], ["Sus scrofa", "ORGANISM", 375, 385], ["Illumina HiSeqTM 2500", "DNA", 115, 136], ["reference genome", "DNA", 204, 220], ["rRNA reads", "DNA", 303, 313], ["Sus scrofa reference genome", "DNA", 346, 373], ["Sus scrofa", "SPECIES", 346, 356], ["Sus scrofa", "SPECIES", 375, 385], ["Sus scrofa", "SPECIES", 346, 356], ["Sus scrofa", "SPECIES", 375, 385], ["The digested products", "TREATMENT", 0, 21], ["agarose gel electrophoresis", "TREATMENT", 43, 70], ["PCR", "TEST", 90, 93], ["Illumina HiSeqTM", "TREATMENT", 115, 131], ["rRNA reads", "TEST", 303, 313], ["Transcripts reconstruction", "TREATMENT", 443, 469], ["The reconstruction of transcripts", "TREATMENT", 469, 502], ["Cufflinks", "TEST", 525, 534]]], ["The program reference annotation-based transcripts (RABT) was preferred.", [["RABT", "PROTEIN", 52, 56]]], ["Cufflinks constructed faux reads according to reference to make up for the influence of low coverage sequencing.", [["low coverage sequencing", "TREATMENT", 88, 111]]], ["During the last step of assembly, all of the reassembled fragments were aligned with reference genes and then similar fragments were removed.", [["fragments", "ANATOMY", 57, 66], ["fragments", "ANATOMY", 118, 127], ["reassembled fragments", "DNA", 45, 66], ["reference genes", "DNA", 85, 100], ["the reassembled fragments", "PROBLEM", 41, 66], ["similar fragments", "PROBLEM", 110, 127], ["fragments", "OBSERVATION", 57, 66], ["fragments", "OBSERVATION", 118, 127]]], ["Then we used Cuffmerge to merge transcripts from different replicates of a group into a comprehensive set of transcripts, and then merged the transcripts from multiple groups into a finally comprehensive set of transcripts for further downstream differential expression analysis.Identification and annotations for novel transcriptsTo identify the new transcripts, all of the reconstructed transcripts were aligned with reference genome and divided into twelve categories using Cuffcompare (V2.2.1).", [["reference genome", "DNA", 419, 435], ["Cuffmerge", "TREATMENT", 13, 22], ["further downstream differential expression analysis", "TEST", 227, 278], ["new", "OBSERVATION_MODIFIER", 347, 350], ["transcripts", "OBSERVATION", 351, 362]]], ["We used the following parameters to identify reliable novel transcripts: the length of transcript was longer than 200 bp and the exon number was more than 2.", [["novel transcripts", "RNA", 54, 71]]], ["The novel transcripts were then searched against KEGG database for annotations (http://www.genome.jp/kegg/).Quantification of transcript abundanceTranscripts abundance was quantified by RSEM (V1.2.8) and normalized to FPKM (Fragments Per Kilobase of transcript per Million mapped reads).", [["FPKM", "DNA", 218, 222], ["KEGG database", "TEST", 49, 62], ["transcript abundanceTranscripts abundance", "PROBLEM", 126, 167]]], ["The formula is shown as follow:Quantification of transcript abundanceC, the number of fragments that are mapped to transcripts; N, the total number of fragments that are mapped to reference genes; L, the number of base pairs of transcript.Identification and statistics of circRNAsThe Anchors reads were mapped to Sus scrofa reference genome, then subjected to find_circ (V1.0) to identify circRNAs.", [["abundanceC", "GENE_OR_GENE_PRODUCT", 60, 70], ["circRNAs", "GENE_OR_GENE_PRODUCT", 272, 280], ["Sus scrofa", "ORGANISM", 313, 323], ["circRNAs", "GENE_OR_GENE_PRODUCT", 389, 397], ["transcript abundanceC", "RNA", 49, 70], ["reference genes", "DNA", 180, 195], ["circRNAs", "DNA", 272, 280], ["Anchors reads", "DNA", 284, 297], ["Sus scrofa reference genome", "DNA", 313, 340], ["find_circ", "DNA", 360, 369], ["V1.0", "DNA", 371, 375], ["circRNAs", "DNA", 389, 397], ["Sus scrofa", "SPECIES", 313, 323], ["Sus scrofa", "SPECIES", 313, 323], ["transcript abundanceC", "PROBLEM", 49, 70], ["fragments", "OBSERVATION", 86, 95], ["total", "OBSERVATION_MODIFIER", 135, 140], ["fragments", "OBSERVATION", 151, 160], ["circRNAs", "OBSERVATION", 389, 397]]], ["The identified circRNAs were subjected to statistical analysis of type, chromosome distribution, and length distribution.Quantification of circRNA abundanceTo quantify circRNAs, back-spliced junction reads were scaled to RPKM (Reads per kilobase of transcript per Million mapped reads).", [["chromosome", "ANATOMY", 72, 82], ["circRNAs", "GENE_OR_GENE_PRODUCT", 15, 23], ["chromosome", "CELLULAR_COMPONENT", 72, 82], ["circRNA", "GENE_OR_GENE_PRODUCT", 139, 146], ["circRNAs", "GENE_OR_GENE_PRODUCT", 168, 176], ["circRNAs", "DNA", 15, 23], ["circRNA abundanceTo", "RNA", 139, 158], ["circRNAs", "RNA", 168, 176], ["RPKM", "DNA", 221, 225], ["type, chromosome distribution, and length distribution", "PROBLEM", 66, 120], ["circRNA abundanceTo quantify circRNAs", "PROBLEM", 139, 176], ["back-spliced junction reads", "TREATMENT", 178, 205], ["circRNAs", "OBSERVATION", 15, 23], ["chromosome distribution", "OBSERVATION", 72, 95], ["length", "OBSERVATION_MODIFIER", 101, 107], ["distribution", "OBSERVATION_MODIFIER", 108, 120], ["circRNA", "OBSERVATION", 139, 146]]], ["The formula is shown below:Quantification of circRNA abundanceC,the number of reads that were mapped to transcripts; N, the total number of reads that were mapped to reference genes; L, the number of base pairs of transcripts.Library construction and sequencing of miRNAsAfter total RNA was extracted using TRIzol, the RNA molecules in a size range of 18~30 nt were enriched by polyacrylamide gel electrophoresis (PAGE).", [["polyacrylamide", "CHEMICAL", 378, 392], ["circRNA", "GENE_OR_GENE_PRODUCT", 45, 52], ["miRNAsAfter", "GENE_OR_GENE_PRODUCT", 265, 276], ["circRNA abundanceC", "RNA", 45, 63], ["reference genes", "DNA", 166, 181], ["miRNAsAfter total RNA", "RNA", 265, 286], ["RNA molecules", "PROTEIN", 319, 332], ["circRNA abundanceC", "PROBLEM", 45, 63], ["Library construction", "TREATMENT", 226, 246], ["sequencing of miRNAsAfter total RNA", "TREATMENT", 251, 286], ["TRIzol", "TREATMENT", 307, 313], ["the RNA molecules", "TEST", 315, 332], ["polyacrylamide gel electrophoresis", "TREATMENT", 378, 412], ["circRNA", "OBSERVATION", 45, 52], ["size", "OBSERVATION_MODIFIER", 338, 342]]], ["Then the 3\u2032 adapters were added.", [["3\u2032 adapters", "DNA", 9, 20], ["the 3\u2032 adapters", "TREATMENT", 5, 20]]], ["The 36~44-nt RNAs were enriched.", [["36~44-nt RNAs", "RNA", 4, 17], ["The 36~44-nt RNAs", "TREATMENT", 0, 17]]], ["The 5\u2032 adapters were then ligated to the RNAs as well.", [["5\u2032 adapters", "DNA", 4, 15], ["The 5\u2032 adapters", "TREATMENT", 0, 15]]], ["The ligation products were reversely transcribed by PCR amplification.", [["The ligation products", "TREATMENT", 0, 21], ["PCR amplification", "TEST", 52, 69], ["ligation", "OBSERVATION", 4, 12]]], ["The 140~160-bp PCR products were enriched to generate a cDNA library and sequenced using Illumina HiSeqTM 2500 by Gene Denovo Biotechnology Co. (Guangzhou, China).Alignment of miRNAsTo get clean tags, we removed low quality reads.", [["140~160-bp PCR products", "DNA", 4, 27], ["cDNA library", "DNA", 56, 68], ["Illumina HiSeqTM 2500", "DNA", 89, 110], ["miRNAs", "DNA", 176, 182], ["bp PCR products", "TREATMENT", 12, 27], ["a cDNA library", "TREATMENT", 54, 68], ["Illumina HiSeqTM", "TREATMENT", 89, 105], ["miRNAs", "ANATOMY", 176, 182]]], ["All of the clean tags were aligned with small RNAs in GeneBank database (Release 209.0) and Rfam database (11.0) to identify and remove rRNA, scRNA, snoRNA, snRNA, and tRNA.", [["scRNA", "GENE_OR_GENE_PRODUCT", 142, 147], ["tRNA", "CELLULAR_COMPONENT", 168, 172], ["small RNAs", "RNA", 40, 50], ["rRNA, scRNA, snoRNA,", "RNA", 136, 156], ["snRNA", "RNA", 157, 162], ["tRNA", "DNA", 168, 172], ["Rfam database", "TEST", 92, 105], ["rRNA", "PROBLEM", 136, 140], ["scRNA", "TREATMENT", 142, 147], ["snoRNA", "TREATMENT", 149, 155], ["snRNA", "TREATMENT", 157, 162], ["tRNA", "TREATMENT", 168, 172], ["clean", "OBSERVATION", 11, 16], ["small RNAs", "OBSERVATION", 40, 50]]], ["Then, the rest of clean tags was aligned with Sus scrofa reference genome and searched against miRBase database (Release 21) to identify existed miRNAs.", [["Sus scrofa reference genome", "DNA", 46, 73], ["Sus scrofa", "SPECIES", 46, 56], ["Sus scrofa", "SPECIES", 46, 56]]], ["Unmapped miRNAs were aligned with other species.", [["other species", "PROBLEM", 34, 47], ["species", "OBSERVATION_MODIFIER", 40, 47]]], ["All of the unannotated tags were aligned with Sus scrofa reference genome.", [["Sus scrofa", "ORGANISM", 46, 56], ["Sus scrofa reference genome", "DNA", 46, 73], ["Sus scrofa", "SPECIES", 46, 56], ["Sus scrofa", "SPECIES", 46, 56]]], ["According to the genome positions and hairpin structures predicted by software Mireap (v0.2), the novel miRNA candidates were obaineds.Quantification of miRNA abundanceThe miRNA level was calculated and normalized to transcripts per million (TPM).", [["genome positions", "DNA", 17, 33], ["miRNA candidates", "DNA", 104, 120], ["miRNA abundance", "PROBLEM", 153, 168], ["The miRNA level", "TEST", 168, 183], ["miRNA abundance", "OBSERVATION", 153, 168]]], ["The formula is show below: TPM \u00bc Actual miRNA counts=Total counts of clean tags \u00c3 10 6Prediction of miRNAs targetsRNAhybrid (v2.1.2) + svm_light (v6.01), Miranda (v3.3a), and TargetScan (v7.0) were used to predict targets of miRNAs.", [["Actual miRNA counts", "TEST", 33, 52], ["Total counts", "TEST", 53, 65], ["clean tags", "TEST", 69, 79], ["miRNAs targets", "TEST", 100, 114], ["RNAhybrid", "TEST", 114, 123], ["v", "TEST", 125, 126], ["svm_light", "TEST", 135, 144], ["Miranda (v", "TEST", 154, 164], ["TargetScan (v", "TEST", 175, 188], ["miRNAs", "ANATOMY", 225, 231]]], ["The intersection of the targets was chosen as candidate targets of miRNAs.Significance analysis of miRNAs, mRNAs, and circRNAsThe edgeR package (http://www.r-project.org/) was used to identify differentially expressed miRNAs, mRNAs, and cir-cRNAs.", [["circRNAs", "GENE_OR_GENE_PRODUCT", 118, 126], ["cir-cRNAs", "GENE_OR_GENE_PRODUCT", 237, 246], ["miRNAs", "DNA", 67, 73], ["miRNAs", "RNA", 99, 105], ["mRNAs", "RNA", 107, 112], ["circRNAs", "RNA", 118, 126], ["edgeR package", "DNA", 130, 143], ["miRNAs", "RNA", 218, 224], ["mRNAs", "RNA", 226, 231], ["cir-cRNAs", "DNA", 237, 246], ["Significance analysis", "TEST", 74, 95], ["miRNAs", "PROBLEM", 99, 105], ["mRNAs", "TEST", 107, 112], ["The edgeR package", "TREATMENT", 126, 143], ["miRNAs", "ANATOMY", 99, 105]]], ["A fold change \u22652 and \u2264 0.5, plus a P value < 0.05 were set as thresholds for significant differentially expressed miR-NAs and circRNAs. mRNAs with a fold change \u22652 and \u2264 0.5, plus a false discovery rate (FDR) < 0.05, were identified as significant differentially mRNAs.Significance analysis of miRNAs, mRNAs, and circRNAsKEGG and interaction analysis of differentially expressed mRNAs, miRNAs, and circRNAs KEGG database (http://www.genome.jp/kegg/) was used to annotate the pathways.", [["miR-NAs", "GENE_OR_GENE_PRODUCT", 114, 121], ["circRNAs", "GENE_OR_GENE_PRODUCT", 126, 134], ["circRNAsKEGG", "GENE_OR_GENE_PRODUCT", 313, 325], ["miR", "PROTEIN", 114, 117], ["circRNAs", "DNA", 126, 134], ["mRNAs", "RNA", 136, 141], ["differentially mRNAs", "RNA", 248, 268], ["miRNAs", "RNA", 294, 300], ["mRNAs", "RNA", 302, 307], ["circRNAsKEGG", "DNA", 313, 325], ["mRNAs", "RNA", 379, 384], ["miRNAs", "RNA", 386, 392], ["A fold change", "PROBLEM", 0, 13], ["a P value", "TEST", 33, 42], ["a fold change", "TEST", 147, 160], ["a false discovery rate", "TEST", 180, 202], ["significant differentially mRNAs", "PROBLEM", 236, 268], ["Significance analysis", "TEST", 269, 290], ["miRNAs", "TEST", 294, 300], ["mRNAs", "TEST", 302, 307], ["interaction analysis", "TEST", 330, 350], ["miRNAs", "TEST", 386, 392], ["circRNAs KEGG database", "TEST", 398, 420], ["fold", "OBSERVATION_MODIFIER", 2, 6], ["change", "OBSERVATION", 7, 13], ["significant", "OBSERVATION_MODIFIER", 236, 247], ["differentially mRNAs", "OBSERVATION", 248, 268], ["miRNAs", "ANATOMY", 294, 300]]], ["The formula for P-value is shown below:Significance analysis of miRNAs, mRNAs, and circRNAsN,the number of all genes with KEGG annotation; N, the number of target genes (differentially expressed mRNAs, target genes of differentially expressed miR-NAs, or source genes of differentially expressed cir-cRNAs); M, the number of all genes in specific pathways. m; the number of target genes in specific pathways.Significance analysis of miRNAs, mRNAs, and circRNAsp-value \u22640.05 is set as a threshold.", [["circRNAsN", "GENE_OR_GENE_PRODUCT", 83, 92], ["miR-NAs", "GENE_OR_GENE_PRODUCT", 243, 250], ["cir-cRNAs", "GENE_OR_GENE_PRODUCT", 296, 305], ["P", "DNA", 16, 17], ["miRNAs", "RNA", 64, 70], ["mRNAs", "RNA", 72, 77], ["circRNAsN", "RNA", 83, 92], ["target genes", "DNA", 156, 168], ["mRNAs", "RNA", 195, 200], ["target genes", "DNA", 202, 214], ["miR", "DNA", 243, 246], ["NAs", "DNA", 247, 250], ["source genes", "DNA", 255, 267], ["cir-cRNAs", "DNA", 296, 305], ["target genes", "DNA", 374, 386], ["miRNAs", "RNA", 433, 439], ["mRNAs", "RNA", 441, 446], ["circRNAsp", "DNA", 452, 461], ["P-value", "TEST", 16, 23], ["miRNAs", "TEST", 64, 70], ["mRNAs", "TEST", 72, 77], ["circRNAsN", "TEST", 83, 92], ["KEGG annotation", "TEST", 122, 137], ["Significance analysis", "TEST", 408, 429], ["miRNAs", "TEST", 433, 439], ["mRNAs", "TEST", 441, 446], ["circRNAsp", "TEST", 452, 461], ["miRNAs", "ANATOMY", 433, 439]]], ["The interaction networks among miRNAs, circRNAs, and mRNAs were built and visualized using Cytoscape (v3.5.1) (http:// www.cytoscape.org/).circRNA identificationBoth divergent primers and convergent primers were designed to identify the circular form.", [["circRNAs", "GENE_OR_GENE_PRODUCT", 39, 47], ["miRNAs", "RNA", 31, 37], ["circRNAs", "RNA", 39, 47], ["mRNAs", "RNA", 53, 58], ["Cytoscape", "TEST", 91, 100], ["v", "TEST", 102, 103], ["convergent primers", "TEST", 188, 206]]], ["Head-to-tail splicing was validated by PCR and sequencing after reverse transcription.Quantification of miRNAs, circRNAs, and mRNAs using qRT-PCRThe total RNA of IPEC-J2 cells were isolated using TRIzol reagent and reversely transcribed using M-MLV reverse transcriptase (Invitrogen, US) according to the manufacturer \u2032 s instructions.", [["IPEC-J2 cells", "ANATOMY", 162, 175], ["circRNAs", "GENE_OR_GENE_PRODUCT", 112, 120], ["IPEC-J2 cells", "CELL", 162, 175], ["miRNAs", "RNA", 104, 110], ["circRNAs", "RNA", 112, 120], ["mRNAs", "RNA", 126, 131], ["qRT-PCRThe total RNA", "RNA", 138, 158], ["IPEC-J2 cells", "CELL_LINE", 162, 175], ["MLV reverse transcriptase", "PROTEIN", 245, 270], ["PCR", "TEST", 39, 42], ["miRNAs", "PROBLEM", 104, 110], ["circRNAs", "TEST", 112, 120], ["mRNAs", "TEST", 126, 131], ["qRT", "TEST", 138, 141], ["IPEC", "TEST", 162, 166], ["J2 cells", "PROBLEM", 167, 175], ["TRIzol reagent", "TREATMENT", 196, 210], ["tail", "ANATOMY", 8, 12], ["miRNAs", "ANATOMY", 104, 110]]], ["For reverse transcription of circRNAs, the total RNA was treated with RNase R (Epicentre, US) to remove linear RNA and then was subjected to reverse transcription. qRT-PCR was performed on iQ5 real-time PCR System (Bio-Rad, US) [16] .", [["circRNAs", "GENE_OR_GENE_PRODUCT", 29, 37], ["RNase R", "GENE_OR_GENE_PRODUCT", 70, 77], ["circRNAs", "PROTEIN", 29, 37], ["RNase R", "PROTEIN", 70, 77], ["linear RNA", "RNA", 104, 114], ["the total RNA", "TREATMENT", 39, 52], ["RNase R (Epicentre, US", "TREATMENT", 70, 92], ["linear RNA", "PROBLEM", 104, 114], ["PCR", "TEST", 168, 171], ["circRNAs", "OBSERVATION", 29, 37]]], ["Relative quantification of miRNAs was normalized to U6 using 2 -\u0394\u0394Ct method.", [["miRNAs", "RNA", 27, 33], ["U6", "DNA", 52, 54], ["Relative quantification of miRNAs", "PROBLEM", 0, 33], ["2 -\u0394\u0394Ct method", "TREATMENT", 61, 75], ["miRNAs", "OBSERVATION", 27, 33]]], ["The relative quantification of mRNAs and circRNAs were normalized to GAPDH using the 2 -\u0394\u0394Ct method.Dual-luciferase assayThe sequences of circRNAs and 3 \u2032 UTR of mRNAs were respectively amplified by PCR and cloned into vector psiCHECK-2 (Promega, US) (Primers are shown in Additional file 1: Table S9 ).", [["circRNAs", "GENE_OR_GENE_PRODUCT", 41, 49], ["GAPDH", "GENE_OR_GENE_PRODUCT", 69, 74], ["luciferase", "GENE_OR_GENE_PRODUCT", 105, 115], ["circRNAs", "GENE_OR_GENE_PRODUCT", 138, 146], ["mRNAs", "RNA", 31, 36], ["circRNAs", "PROTEIN", 41, 49], ["GAPDH", "PROTEIN", 69, 74], ["luciferase", "PROTEIN", 105, 115], ["circRNAs and 3 \u2032 UTR", "DNA", 138, 158], ["mRNAs", "RNA", 162, 167], ["vector psiCHECK-2", "DNA", 219, 236], ["mRNAs and circRNAs", "PROBLEM", 31, 49], ["GAPDH", "TEST", 69, 74], ["the 2 -\u0394\u0394Ct method", "TREATMENT", 81, 99], ["Dual-luciferase assay", "TEST", 100, 121], ["circRNAs", "TEST", 138, 146], ["mRNAs", "TEST", 162, 167], ["PCR", "TEST", 199, 202]]], ["The binding sites of miR-22 in targets and circRNA were mutated [16] (Additional file 1: Table S9 ).", [["miR-22", "GENE_OR_GENE_PRODUCT", 21, 27], ["circRNA", "GENE_OR_GENE_PRODUCT", 43, 50], ["binding sites", "DNA", 4, 17], ["miR-22", "DNA", 21, 27], ["circRNA", "DNA", 43, 50]]], ["IPEC-J2 cells were co-transfected with 100 ng of plasmid and 100 nM of miR-22 mimics (or miRNA mimics control, miR-22 inhibitors, miRNA inhibitors control) using Lipofectamine 3000 (Invitrogen, US).", [["IPEC-J2 cells", "ANATOMY", 0, 13], ["plasmid", "ANATOMY", 49, 56], ["IPEC-J2 cells", "CELL", 0, 13], ["miR-22", "GENE_OR_GENE_PRODUCT", 71, 77], ["miR-22", "GENE_OR_GENE_PRODUCT", 111, 117], ["IPEC-J2 cells", "CELL_LINE", 0, 13], ["miR-22 mimics", "DNA", 71, 84], ["IPEC", "TEST", 0, 4], ["J2 cells", "PROBLEM", 5, 13], ["plasmid", "TREATMENT", 49, 56], ["miR", "TEST", 71, 74], ["miRNA mimics control", "TREATMENT", 89, 109], ["miR-22 inhibitors", "TREATMENT", 111, 128], ["miRNA inhibitors control", "TREATMENT", 130, 154], ["Lipofectamine", "TREATMENT", 162, 175], ["J2 cells", "OBSERVATION", 5, 13]]], ["At 48 h post transfection (hpt), the luciferase activities were tested using Dual-Glo Luciferase Assay System (Promega, US) following the manufacturer\u2032s manual.Western blot analysisCells were treated with RIPA lysis buffer containing phenylmethyl sulfonylfluoride (PMSF).", [["Cells", "ANATOMY", 181, 186], ["phenylmethyl sulfonylfluoride", "CHEMICAL", 234, 263], ["phenylmethyl sulfonylfluoride", "CHEMICAL", 234, 263], ["PMSF", "CHEMICAL", 265, 269], ["luciferase", "GENE_OR_GENE_PRODUCT", 37, 47], ["Cells", "CELL", 181, 186], ["phenylmethyl sulfonylfluoride", "SIMPLE_CHEMICAL", 234, 263], ["PMSF", "SIMPLE_CHEMICAL", 265, 269], ["luciferase", "PROTEIN", 37, 47], ["the luciferase activities", "TEST", 33, 58], ["Dual-Glo Luciferase", "TREATMENT", 77, 96], ["the manufacturer\u2032s manual", "TREATMENT", 134, 159], ["blot analysis", "TEST", 168, 181], ["RIPA lysis buffer", "TREATMENT", 205, 222], ["phenylmethyl sulfonylfluoride (PMSF", "TREATMENT", 234, 269]]], ["Protein concentration was measured using BCA Protein Assay Reagent (Pierce, US).", [["Protein concentration", "TEST", 0, 21]]], ["Proteins were separated on a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently transferred onto a polyvinylidene difluoride (PVDF) membranes (Millipore, US).", [["sodium dodecyl sulfate", "CHEMICAL", 33, 55], ["SDS-PAGE", "CHEMICAL", 92, 100], ["sodium dodecyl sulfate", "CHEMICAL", 33, 55], ["polyacrylamide", "CHEMICAL", 56, 70], ["polyvinylidene difluoride", "CHEMICAL", 138, 163], ["PVDF", "CHEMICAL", 165, 169], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 33, 55], ["a 12% sodium dodecyl sulfate", "TREATMENT", 27, 55], ["polyacrylamide gel electrophoresis", "TREATMENT", 56, 90], ["a polyvinylidene difluoride (PVDF) membranes", "TREATMENT", 136, 180]]], ["The PVDF membrane was blocked with 5% non-fat milk for 2 h at room temperature and then subsequently incubated with primary antibodies overnight at 4\u00b0C and HRP-conjugated secondary antibody at room temperature for 1 h.", [["PVDF membrane", "ANATOMY", 4, 17], ["fat milk", "ANATOMY", 42, 50], ["PVDF", "CHEMICAL", 4, 8], ["membrane", "CELLULAR_COMPONENT", 9, 17], ["fat milk", "ORGANISM_SUBSTANCE", 42, 50], ["HRP", "SIMPLE_CHEMICAL", 156, 159], ["primary antibodies", "PROTEIN", 116, 134], ["HRP", "PROTEIN", 156, 159], ["The PVDF membrane", "TREATMENT", 0, 17], ["5% non-fat milk", "TREATMENT", 35, 50], ["primary antibodies", "TEST", 116, 134], ["HRP", "TEST", 156, 159]]], ["Finally, the membrane was developed with enhanced chemiluminescence (ECL) (Promega, US).Statistical analysisThe data are presented as the means \u00b1 SEM.", [["membrane", "ANATOMY", 13, 21], ["membrane", "CELLULAR_COMPONENT", 13, 21], ["enhanced chemiluminescence", "PROBLEM", 41, 67], ["Statistical analysis", "TEST", 88, 108]]], ["Statistical significance were analyzed by unpaired Student \u2032 s t-test. p < 0.05 was defined as statistical significance.Additional fileAdditional file 1: Table S1 .", [["S1", "ANATOMY", 160, 162]]], ["The detailed information of differentially expressed mRNAs.", [["differentially expressed mRNAs", "RNA", 28, 58]]], ["Table S2 .", [["S2", "ANATOMY", 6, 8]]], ["The detailed information of differentially expressed circRNAs.", [["circRNAs", "GENE_OR_GENE_PRODUCT", 53, 61], ["circRNAs", "PROTEIN", 53, 61], ["circRNAs", "OBSERVATION", 53, 61]]], ["The target genes of differentially expressed miRNAs.", [["target genes", "DNA", 4, 16], ["differentially", "OBSERVATION_MODIFIER", 20, 34], ["expressed miRNAs", "OBSERVATION", 35, 51]]], ["Source genes of differentially expressed circRNAs.", [["circRNAs", "GENE_OR_GENE_PRODUCT", 41, 49], ["Source genes", "DNA", 0, 12], ["circRNAs", "PROTEIN", 41, 49], ["differentially expressed circRNAs", "OBSERVATION", 16, 49]]], ["Table S6 .", [["S6", "PROTEIN", 6, 8]]], ["The interactions between miRNAs and mRNAs.", [["miRNAs", "RNA", 25, 31], ["mRNAs", "RNA", 36, 41]]], ["The circRNA-miRNA-mRNA regulation network.", [["circRNA-miRNA-mRNA", "GENE_OR_GENE_PRODUCT", 4, 22], ["-miRNA", "PROTEIN", 11, 17], ["circRNA", "OBSERVATION", 4, 11]]], ["The sequences of miR-22 mimics and inhibitors.", [["miR-22", "GENE_OR_GENE_PRODUCT", 17, 23], ["miR", "TEST", 17, 20], ["inhibitors", "TREATMENT", 35, 45]]]]}